reference_id,authors,title,journal,year,volume,citation_footer,citation_type,citation,urls,pubmed_id,doi,header,reference_type,study_id,exclusion_reason,PUBMED_ID_TITLE_AUTHORS,PUBMED_ID_TITLE,PUBMED_ID_S2,N_CITATIONS,S2_PDF_LINK,CORE_PDF_LINK,PUBMED_ID
CD014384-bib-0001,"Branchey MH, Branchey LB, Richardson MA. ",Effects of gradual decrease and discontinuation of neuroleptics on clinical condition and tardive dyskinesia, Psychopharmacology Bulletin ,1981,17,    ,['citation-journal']," Branchey MH, Branchey LB, Richardson MA. Effects of gradual decrease and discontinuation of neuroleptics on clinical condition and tardive dyskinesia.  Psychopharmacology Bulletin 1981;17(1):118-20. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/7232639', 'https://scholar.google.com/scholar_lookup?title=Effects+of+gradual+decrease+and+discontinuation+of+neuroleptics+on+clinical+condition+and+tardive+dyskinesia+&author=MH+Branchey&author=LB+Branchey&author=MA+Richardson&publication_year=1981&hl=en']",7232639,, Branchey 1981 {published data only}  ,included,CD014384-bbs2-0001,,7015884,,,,,,7232639
CD014384-bib-0002,"Branchey MH, Branchey LB, Richardson MA. ",Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia  in schizophrenic patients, American Journal of Psychiatry ,1981,138,    ,['citation-journal']," Branchey MH, Branchey LB, Richardson MA. Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia  in schizophrenic patients.  American Journal of Psychiatry 1981;138(5):608-12. CENTRAL [DOI: 10.1176/ajp.138.5.608]    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/7015884', 'https://scholar.google.com/scholar_lookup?title=Effects+of+neuroleptic+adjustment+on+clinical+condition+and+tardive+dyskinesia+\xa0in+schizophrenic+patients+&author=MH+Branchey&author=LB+Branchey&author=MA+Richardson&publication_year=1981&hl=en']",7015884,, Branchey 1981 {published data only}  ,included,CD014384-bbs2-0001,,7015884,,,,,,7015884
CD014384-bib-0003,"Caffey EM, Forrest IS, Frank TV, Klett CJ. ",Phenothiazine excretion in chronic schizophrenics, American Journal of Psychiatry ,1963,120,    ,['citation-journal']," Caffey EM, Forrest IS, Frank TV, Klett CJ. Phenothiazine excretion in chronic schizophrenics.  American Journal of Psychiatry 1963;120:578-82. CENTRAL [DOI: 10.1176/ajp.120.6.578]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1176/ajp.120.6.578', 'https://www.ncbi.nlm.nih.gov/pubmed/14086436', 'https://scholar.google.com/scholar_lookup?title=Phenothiazine+excretion+in+chronic+schizophrenics&author=EM+Caffey&author=IS+Forrest&author=TV+Frank&author=CJ+Klett&publication_year=1963&hl=en']",14086436,https://doi.org/10.1176/ajp.120.6.578, Caffey 1964 {published data only}  ,included,CD014384-bbs2-0002,,14086436,,14086436,13,,,14086436
CD014384-bib-0004,"Caffey EM Jr, Diamond LS, Frank TV, Grasberger JC, Herman L, Klett CJ, et al. ",Discontinuation or reduction of chemotherapy in chronic schizophrenics, Journal of Chronic Diseases ,1964,17,    ,['citation-journal']," Caffey EM Jr, Diamond LS, Frank TV, Grasberger JC, Herman L, Klett CJ, et al. Discontinuation or reduction of chemotherapy in chronic schizophrenics.  Journal of Chronic Diseases 1964;17(4):347-58. CENTRAL [DOI: 10.1016/0021-9681(64)90075-x]    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/14141840', 'https://scholar.google.com/scholar_lookup?title=Discontinuation+or+reduction+of+chemotherapy+in+chronic+schizophrenics&author=LS+Diamond&author=TV+Frank&author=JC+Grasberger&author=L+Herman&author=CJ+Klett&publication_year=1964&hl=en']",14141840,, Caffey 1964 {published data only}  ,included,CD014384-bbs2-0002,,,,,,,,14141840
CD014384-bib-0005,"Carpenter WT Jr, Buchanan RW, Kirkpatrick B, Lann HD, Breier AF, Summerfelt AT. ",Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks, American Journal of Psychiatry ,1999,156,    ,['citation-journal']," Carpenter WT Jr, Buchanan RW, Kirkpatrick B, Lann HD, Breier AF, Summerfelt AT. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks.  American Journal of Psychiatry 1999;156(3):412-8. CENTRAL [DOI: 10.1176/ajp.156.3.412]    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/10080557', 'https://scholar.google.com/scholar_lookup?title=Comparative+effectiveness+of+fluphenazine+decanoate+injections+every+2+weeks+versus+every+6+weeks+&author=RW+Buchanan&author=B+Kirkpatrick&author=HD+Lann&author=AF+Breier&author=AT+Summerfelt&publication_year=1999&hl=en']",10080557,, Carpenter 1999 {published data only}  ,included,CD014384-bbs2-0003,,10080557,10080557,,,,,10080557
CD014384-bib-0006,Cookson IB. ,The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime, International Clinical Psychopharmacology ,1987,2,    ,['citation-journal'], Cookson IB. The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime.  International Clinical Psychopharmacology 1987;2(2):141-9. CENTRAL [DOI: 10.1097/00004850-198704000-00008]    Link to article     PubMed     Google Scholar     ,"['', 'https://doi.org/10.1097/00004850-198704000-00008', 'https://www.ncbi.nlm.nih.gov/pubmed/3298419', 'https://scholar.google.com/scholar_lookup?title=The+effects+of+a+50%+reduction+of+cis(z)-flupenthixol+decanoate+in+chronic+schizophrenic+patients+maintained+on+a+high+dose+regime+&author=IB+Cookson&publication_year=1987&hl=en']",3298419,https://doi.org/10.1097/00004850-198704000-00008, Cookson 1987 {published data only}  ,included,CD014384-bbs2-0004,,3298419,3298419,,32,,,3298419
CD014384-bib-0007,"Faraone SV, Green AI, Brown W, Yin P, Tsuang, MT. ",Neuroleptic dose reduction in persistently psychotic patients, Hospital and Community Psychiatry ,1989,40,    ,['citation-journal']," Faraone SV, Green AI, Brown W, Yin P, Tsuang, MT. Neuroleptic dose reduction in persistently psychotic patients.  Hospital and Community Psychiatry 1989;40(11):1193-5. CENTRAL [DOI: 10.1176/ps.40.11.1193]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1176/ps.40.11.1193', 'https://www.ncbi.nlm.nih.gov/pubmed/2572532', 'https://scholar.google.com/scholar_lookup?title=Neuroleptic+dose+reduction+in+persistently+psychotic+patients&author=SV+Faraone&author=AI+Green&author=W+Brown&author=P+Yin&publication_year=1989&hl=en']",2572532,https://doi.org/10.1176/ps.40.11.1193, Faraone 1989 {published data only}  ,included,CD014384-bbs2-0005,,2572532,,2572532,12,,,2572532
CD014384-bib-0008,"Baker RA, Eramo A, Nylander AG, Tsai LF, Peters-Strickland TS, Kostic D, et al. ",The effect of previous dose or oral aripiprazole (10 or 30 mg/day) on the efficacy and tolerability of aripiprazole once-monthly: results from post-hoc analyses from two double-blind randomized controlled trials, Schizophrenia Research ,2014,153,    ,['citation-journal']," Baker RA, Eramo A, Nylander AG, Tsai LF, Peters-Strickland TS, Kostic D, et al. The effect of previous dose or oral aripiprazole (10 or 30 mg/day) on the efficacy and tolerability of aripiprazole once-monthly: results from post-hoc analyses from two double-blind randomized controlled trials.  Schizophrenia Research 2014;153(S1):S293. CENTRAL [DOI: 10.1016/S0920-9964(14)70830-8]    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/S0920-9964(14)70830-8', 'https://scholar.google.com/scholar_lookup?title=The+effect+of+previous+dose+or+oral+aripiprazole+(10+or+30+mg/day)+on+the+efficacy+and+tolerability+of+aripiprazole+once-monthly:+results+from+post-hoc+analyses+from+two+double-blind+randomized+controlled+trials+&author=RA+Baker&author=A+Eramo&author=AG+Nylander&author=LF+Tsai&author=TS+Peters-Strickland&author=D+Kostic&publication_year=2014&hl=en']",,https://doi.org/10.1016/S0920-9964(14)70830-8, Fleischhacker 2014 {published and unpublished data}  ,included,CD014384-bbs2-0006,,,,,3,,,
CD014384-bib-0009,"Baker RA, Eramo A, Tsai LF, Peters-Strickland T, Sanchez R. ",P.3.d.033 The effects of aripiprazole once-monthly on the PANSS Marder factors in the treatment of patients with schizophrenia, European Neuropsychopharmacology ,2014,24,    ,['citation-journal']," Baker RA, Eramo A, Tsai LF, Peters-Strickland T, Sanchez R. P.3.d.033 The effects of aripiprazole once-monthly on the PANSS Marder factors in the treatment of patients with schizophrenia.  European Neuropsychopharmacology 2014;24:S541. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/S0924-977X(14)70866-1', 'https://scholar.google.com/scholar_lookup?title=P.3.d.033+The+effects+of+aripiprazole+once-monthly+on+the+PANSS+Marder+factors+in+the+treatment+of+patients+with+schizophrenia+&author=RA+Baker&author=A+Eramo&author=LF+Tsai&author=T+Peters-Strickland&author=R+Sanchez&publication_year=2014&hl=en']",,https://doi.org/10.1016/S0924-977X(14)70866-1, Fleischhacker 2014 {published and unpublished data}  ,included,CD014384-bbs2-0006,,,,,1,,,
CD014384-bib-0010,"De Hert M, Eramo A, Landsberg W, Kostic D, Tsai LF, Baker RA. ",Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis, Neuropsychiatric Disease and Treatment ,2015,11,    ,['citation-journal']," De Hert M, Eramo A, Landsberg W, Kostic D, Tsai LF, Baker RA. Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis.  Neuropsychiatric Disease and Treatment 2015;11:1299-306. CENTRAL [DOI: 10.2147/NDT.S80479]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2147/NDT.S80479', 'https://www.ncbi.nlm.nih.gov/pubmed/26064048', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+aripiprazole+once-monthly+in+obese+and+nonobese+patients+with+schizophrenia:+a+post+hoc+analysis+&author=M+DeHert&author=A+Eramo&author=W+Landsberg&author=D+Kostic&author=LF+Tsai&author=RA+Baker&publication_year=2015&hl=en']",26064048,https://doi.org/10.2147/NDT.S80479, Fleischhacker 2014 {published and unpublished data}  ,included,CD014384-bbs2-0006,,26064048,26064048,26064048,9,https://www.dovepress.com/getfile.php?fileID=25241,,26064048
CD014384-bib-0011,"Eramo A, De Hert M, Landsberg W, Tsai LF, Baker RA. ",The efficacy and safety of aripiprazole once-monthly in obese and non-obese patients with schizophrenia; a post-hoc analysis, International Journal of Neuropsychopharmacology ,2014,17,    ,['citation-journal']," Eramo A, De Hert M, Landsberg W, Tsai LF, Baker RA. The efficacy and safety of aripiprazole once-monthly in obese and non-obese patients with schizophrenia; a post-hoc analysis.  International Journal of Neuropsychopharmacology 2014;17:69. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=The+efficacy+and+safety+of+aripiprazole+once-monthly+in+obese+and+non-obese+patients+with+schizophrenia;+a+post-hoc+analysis+&author=A+Eramo&author=M+DeHert&author=W+Landsberg&author=LF+Tsai&author=RA+Baker&publication_year=2014&hl=en']",,, Fleischhacker 2014 {published and unpublished data}  ,included,CD014384-bbs2-0006,,,,,,,,
CD014384-bib-0012,"Eramo A, Fleischhacker WW, Sanchez R, Tsai LF, Peters-Strickland TS, Baker RA, et al. ","All-cause discontinuation and safety of aripiprazole once-monthly for the treatment of schizophrenia: a pooled analysis of two double-blind, randomized, controlled trials", European Psychiatry ,2014,29,    ,['citation-journal']," Eramo A, Fleischhacker WW, Sanchez R, Tsai LF, Peters-Strickland TS, Baker RA, et al. All-cause discontinuation and safety of aripiprazole once-monthly for the treatment of schizophrenia: a pooled analysis of two double-blind, randomized, controlled trials.  European Psychiatry 2014;29:S174. CENTRAL [DOI: 10.1016/S0924-9338(14)78135-0]    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=All-cause+discontinuation+and+safety+of+aripiprazole+once-monthly+for+the+treatment+of+schizophrenia:+a+pooled+analysis+of+two+double-blind,+randomized,+controlled+trials+&author=A+Eramo&author=WW+Fleischhacker&author=R+Sanchez&author=LF+Tsai&author=TS+Peters-Strickland&author=RA+Baker&publication_year=2014&hl=en']",,, Fleischhacker 2014 {published and unpublished data}  ,included,CD014384-bbs2-0006,,,,,,,,
CD014384-bib-0013,"Fleischhacker WW, Baker RA, Eramo A, Sanchez R, Tsai LF, Peters-Strickland T, et al. ","Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies", Schizophrenia Research ,2014,159,    ,['citation-journal']," Fleischhacker WW, Baker RA, Eramo A, Sanchez R, Tsai LF, Peters-Strickland T, et al. Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies.  Schizophrenia Research 2014;159(2-3):415-20. CENTRAL [DOI: 10.1016/j.schres.2014.09.019]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.schres.2014.09.019', 'https://www.ncbi.nlm.nih.gov/pubmed/25281992', 'https://scholar.google.com/scholar_lookup?title=Effects+of+aripiprazole+once-monthly+on+domains+of+personal+and+social+performance:+results+from+2+multicenter,+randomized,+double-blind+studies+&author=WW+Fleischhacker&author=RA+Baker&author=A+Eramo&author=R+Sanchez&author=LF+Tsai&author=T+Peters-Strickland&publication_year=2014&hl=en']",25281992,https://doi.org/10.1016/j.schres.2014.09.019, Fleischhacker 2014 {published and unpublished data}  ,included,CD014384-bbs2-0006,,,25281992,25281992,25,https://doi.org/10.1016/j.schres.2014.09.019,,25281992
CD014384-bib-0014,"Fleischhacker WW, Sanchez R, Jin N, Peters-Strickland T, Johnson BR, Eramo A, et al. ","P.3.d.028 Personal and social performance in schizophrenia: double-blind, non-inferiority study of once-monthly vs oral aripiprazole", European Neuropsychopharmacology ,2013,23,    ,['citation-journal']," Fleischhacker WW, Sanchez R, Jin N, Peters-Strickland T, Johnson BR, Eramo A, et al. P.3.d.028 Personal and social performance in schizophrenia: double-blind, non-inferiority study of once-monthly vs oral aripiprazole.  European Neuropsychopharmacology 2013;23:S474-5. CENTRAL [DOI: 10.1016/S0924-977X(13)70751-X]    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/S0924-977X(13)70751-X', 'https://scholar.google.com/scholar_lookup?title=P.3.d.028+Personal+and+social+performance+in+schizophrenia:+double-blind,+non-inferiority+study+of+once-monthly+vs+oral+aripiprazole+&author=WW+Fleischhacker&author=R+Sanchez&author=N+Jin&author=T+Peters-Strickland&author=BR+Johnson&author=A+Eramo&publication_year=2013&hl=en']",,https://doi.org/10.1016/S0924-977X(13)70751-X, Fleischhacker 2014 {published and unpublished data}  ,included,CD014384-bbs2-0006,,,,,2,,,
CD014384-bib-0015,"Fleischhacker WW, Sanchez R, Lan-Feng T, Peters-Strickland T, Baker RA, Eramo A, et al. ","Safety and effectiveness of aripiprazole once-monthly for the treatment of schizophrenia: a pooled analysis of two double-blind, randomized, controlled trials (246 and 247)", Neuropsychopharmacology ,2013,38,    ,['citation-journal']," Fleischhacker WW, Sanchez R, Lan-Feng T, Peters-Strickland T, Baker RA, Eramo A, et al. Safety and effectiveness of aripiprazole once-monthly for the treatment of schizophrenia: a pooled analysis of two double-blind, randomized, controlled trials (246 and 247).  Neuropsychopharmacology 2013;38(Poster Session II-Tuesday):S394-5. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Safety+and+effectiveness+of+aripiprazole+once-monthly+for+the+treatment+of+schizophrenia:+a+pooled+analysis+of+two+double-blind,+randomized,+controlled+trials+(246+and+247)+&author=WW+Fleischhacker&author=R+Sanchez&author=T+Lan-Feng&author=T+Peters-Strickland&author=RA+Baker&author=A+Eramo&publication_year=2013&hl=en']",,, Fleischhacker 2014 {published and unpublished data}  ,included,CD014384-bbs2-0006,,,,,,,,
CD014384-bib-0016,"Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, et al. ","Aripiprazole once-monthly for the treatment of schizophrenia: a double-blind, randomized, non-inferiority study vs. oral aripiprazole", Neuropsychopharmacology ,2012,38,    ,['citation-journal']," Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, et al. Aripiprazole once-monthly for the treatment of schizophrenia: a double-blind, randomized, non-inferiority study vs. oral aripiprazole.  Neuropsychopharmacology 2012;38:S339. CENTRAL [DOI: 10.1038/npp.2012.221]    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Aripiprazole+once-monthly+for+the+treatment+of+schizophrenia:+a+double-blind,+randomized,+non-inferiority+study+vs.+oral+aripiprazole+&author=WW+Fleischhacker&author=R+Sanchez&author=PP+Perry&author=N+Jin&author=T+Peters-Strickland&author=BR+Johnson&publication_year=2012&hl=en']",,, Fleischhacker 2014 {published and unpublished data}  ,included,CD014384-bbs2-0006,,,,,,,,
CD014384-bib-0017,"Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, et al. ","Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study", British Journal of Psychiatry ,2014,205,    ,['citation-journal']," Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study.  British Journal of Psychiatry 2014;205(2):135-44. CENTRAL [DOI: 10.1192/bjp.bp.113.134213]    Link to article     Google Scholar     ","['', 'https://doi.org/10.1192/bjp.bp.113.134213', 'https://scholar.google.com/scholar_lookup?title=Aripiprazole+once-monthly+for+treatment+of+schizophrenia:+double-blind,+randomised,+non-inferiority+study+&author=WW+Fleischhacker&author=R+Sanchez&author=PP+Perry&author=N+Jin&author=T+Peters-Strickland&author=BR+Johnson&publication_year=2014&hl=en']",,https://doi.org/10.1192/bjp.bp.113.134213, Fleischhacker 2014 {published and unpublished data}  ,included,CD014384-bbs2-0006,,,,24925984,155,https://www.cambridge.org/core/services/aop-cambridge-core/content/view/C0552CEDAD997CBE22B2DF2B95D42717/S0007125000277271a.pdf/div-class-title-aripiprazole-once-monthly-for-treatment-of-schizophrenia-double-blind-randomised-non-inferiority-study-div.pdf,,24925984
CD014384-bib-0018,Holtzhausen A. ,"A 38 ­week, multicenter, randomized, double­blind, active­ controlled study to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole (OPC­ 14597) as maintenance treatment in patients with schizophrenia “ASPIRE EU” (Aripiprazole Intramuscular Depot Program in Schizophrenia)",,2008,,    ,['citation-other']," Holtzhausen A. A 38 ­week, multicenter, randomized, double­blind, active­ controlled study to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole (OPC­ 14597) as maintenance treatment in patients with schizophrenia “ASPIRE EU” (Aripiprazole Intramuscular Depot Program in Schizophrenia). South African National Clinical Trial Register2008. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=A+38+\xadweek,+multicenter,+randomized,+double\xadblind,+active\xad+controlled+study+to+evaluate+the+efficacy,+safety,+and+tolerability+of+an+intramuscular+depot+formulation+of+aripiprazole+(OPC\xad+14597)+as+maintenance+treatment+in+patients+with+schizophrenia+“ASPIRE+EU”+(Aripiprazole+Intramuscular+Depot+Program+in+Schizophrenia)+&author=A+Holtzhausen&publication_year=2008&hl=en']",,, Fleischhacker 2014 {published and unpublished data}  ,included,CD014384-bbs2-0006,,,,,,,,
CD014384-bib-0019,"Kane JM, Sanchez R, Baker RA, Eramo A, Peters-Strickland T, Perry PP, et al. ","Patient-centered outcomes with aripiprazole once-monthly for maintenance treatment in patients with schizophrenia: results from two multicenter, randomized, double-blind studies", Clinical Schizophrenia & Related Psychoses ,2015,9,    ,['citation-journal']," Kane JM, Sanchez R, Baker RA, Eramo A, Peters-Strickland T, Perry PP, et al. Patient-centered outcomes with aripiprazole once-monthly for maintenance treatment in patients with schizophrenia: results from two multicenter, randomized, double-blind studies.  Clinical Schizophrenia & Related Psychoses 2015;9(2):79-87. CENTRAL [DOI: 10.3371/CSRP.KASA.022015]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.3371/CSRP.KASA.022015', 'https://www.ncbi.nlm.nih.gov/pubmed/25711509', 'https://scholar.google.com/scholar_lookup?title=Patient-centered+outcomes+with+aripiprazole+once-monthly+for+maintenance+treatment+in+patients+with+schizophrenia:+results+from+two+multicenter,+randomized,+double-blind+studies+&author=JM+Kane&author=R+Sanchez&author=RA+Baker&author=A+Eramo&author=T+Peters-Strickland&author=PP+Perry&publication_year=2015&hl=en']",25711509,https://doi.org/10.3371/CSRP.KASA.022015, Fleischhacker 2014 {published and unpublished data}  ,included,CD014384-bbs2-0006,,,25711509,25711509,14,,,25711509
CD014384-bib-0020,NCT00706654. ,Intramuscular depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia (ASPIRE),,,,   ,['citation-other'], NCT00706654. Intramuscular depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia (ASPIRE). clinicaltrials.gov/ct2/show/NCT00706654 (first received 27 June 2008). CENTRAL    ,[''],,, Fleischhacker 2014 {published and unpublished data}  ,included,CD014384-bbs2-0006,,,,,,,,
CD014384-bib-0021,"Nylander AG, Eramo A, Baker R, Tsai LF, Peters-Strickland T, Sanchez R. ","The effect of previous dose of oral aripiprazole (10 or 30 mg/day) on the efficacy and tolerability of aripiprazoleonce-monthly: post-hoc analysis of two double-blind, randomized, controlled trials", International Journal of Neuropsychopharmacology ,2014,17,    ,['citation-journal']," Nylander AG, Eramo A, Baker R, Tsai LF, Peters-Strickland T, Sanchez R. The effect of previous dose of oral aripiprazole (10 or 30 mg/day) on the efficacy and tolerability of aripiprazoleonce-monthly: post-hoc analysis of two double-blind, randomized, controlled trials.  International Journal of Neuropsychopharmacology 2014;17:149-50. CENTRAL [DOI: 10.1017/S1461145714000741]    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/24074141', 'https://scholar.google.com/scholar_lookup?title=The+effect+of+previous+dose+of+oral+aripiprazole+(10+or+30+mg/day)+on+the+efficacy+and+tolerability+of+aripiprazoleonce-monthly:+post-hoc+analysis+of+two+double-blind,+randomized,+controlled+trials+&author=AG+Nylander&author=A+Eramo&author=R+Baker&author=LF+Tsai&author=T+Peters-Strickland&author=R+Sanchez&publication_year=2014&hl=en']",24074141,, Fleischhacker 2014 {published and unpublished data}  ,included,CD014384-bbs2-0006,,,,,,,,24074141
CD014384-bib-0022,Otsuka Pharmaceutical Development & Commercialization Inc. ,Clinical Summary for Protocol 31-07-247NCT No. 00706654,,,,   ,['citation-other'], Otsuka Pharmaceutical Development & Commercialization Inc. Clinical Summary for Protocol 31-07-247NCT No. 00706654. clinical-trials.otsuka.com/sites/g/files/qhldwo4256/files/2020-05/31-07-247%20Clinical%20Summary.pdf. CENTRAL    ,[''],,, Fleischhacker 2014 {published and unpublished data}  ,included,CD014384-bbs2-0006,,,,,,,,
CD014384-bib-0023,"Peters-Strickland T, Fleischhacker WW, Sanchez R, Jin N, Baker RA, Johnson B, et al. ","P.3.d.027 Aripiprazole once-monthly for schizophrenia: a double-blind, randomised, non-inferiority study versus oral aripiprazole", European Neuropsychopharmacology ,2013,23,    ,['citation-journal']," Peters-Strickland T, Fleischhacker WW, Sanchez R, Jin N, Baker RA, Johnson B, et al. P.3.d.027 Aripiprazole once-monthly for schizophrenia: a double-blind, randomised, non-inferiority study versus oral aripiprazole.  European Neuropsychopharmacology 2013;23:S473-4. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/S0924-977X(13)70750-8', 'https://scholar.google.com/scholar_lookup?title=P.3.d.027+Aripiprazole+once-monthly+for+schizophrenia:+a+double-blind,+randomised,+non-inferiority+study+versus+oral+aripiprazole+&author=T+Peters-Strickland&author=WW+Fleischhacker&author=R+Sanchez&author=N+Jin&author=RA+Baker&author=B+Johnson&publication_year=2013&hl=en']",,https://doi.org/10.1016/S0924-977X(13)70750-8, Fleischhacker 2014 {published and unpublished data}  ,included,CD014384-bbs2-0006,,,,,1,,,
CD014384-bib-0024,"Hirschowitz J, Hitzemann R, Curtis C, Piscani K. ",Dose reduction in schizophrenia,,1995,,    ,['citation-other']," Hirschowitz J, Hitzemann R, Curtis C, Piscani K. Dose reduction in schizophrenia. In: 34th Annual Meeting of the American College of Neuropsychopharmacology; 1995 Dec 11-15; San Juan, Puerto Rico. 1995:166. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Dose+reduction+in+schizophrenia&author=J+Hirschowitz&author=R+Hitzemann&author=C+Curtis&author=K+Piscani&publication_year=1995&hl=en']",,, Hirschowitz 1995 {published data only}  ,included,CD014384-bbs2-0007,,9050126,,,,,,9050126
CD014384-bib-0025,"Hogarty GE, McEvoy JP, Munetz M, DiBarry AL, Bartone P, Cather R, et al. ","Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study", Archives of General Psychiatry ,1988,45,    ,['citation-journal']," Hogarty GE, McEvoy JP, Munetz M, DiBarry AL, Bartone P, Cather R, et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study.  Archives of General Psychiatry 1988;45(9):797-805. CENTRAL [DOI: 10.1001/archpsyc.1988.01800330021002]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1001/archpsyc.1988.01800330021002', 'https://www.ncbi.nlm.nih.gov/pubmed/3415422', 'https://scholar.google.com/scholar_lookup?title=Dose+of+fluphenazine,+familial+expressed+emotion,+and+outcome+in+schizophrenia.+Results+of+a+two-year+controlled+study+&author=GE+Hogarty&author=JP+McEvoy&author=M+Munetz&author=AL+DiBarry&author=P+Bartone&author=R+Cather&publication_year=1988&hl=en']",3415422,https://doi.org/10.1001/archpsyc.1988.01800330021002, Hogarty 1988 {published data only}  ,included,CD014384-bbs2-0008,,,3415422,3415422,218,,,3415422
CD014384-bib-0026,"Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL, Bartone P, Coole S, et al. ",Pharmacotherapy of impaired affect in recovering schizophrenic patients, Archives of General Psychiatry ,1995,52,    ,['citation-journal']," Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL, Bartone P, Coole S, et al. Pharmacotherapy of impaired affect in recovering schizophrenic patients.  Archives of General Psychiatry 1995;52(1):29-41. CENTRAL [DOI: 10.1001/archpsyc.1995.03950130029004]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1001/archpsyc.1995.03950130029004', 'https://www.ncbi.nlm.nih.gov/pubmed/7811160', 'https://scholar.google.com/scholar_lookup?title=Pharmacotherapy+of+impaired+affect+in+recovering+schizophrenic+patients&author=GE+Hogarty&author=JP+McEvoy&author=RF+Ulrich&author=AL+DiBarry&author=P+Bartone&author=S+Coole&publication_year=1995&hl=en']",7811160,https://doi.org/10.1001/archpsyc.1995.03950130029004, Hogarty 1995 {published data only}  ,included,CD014384-bbs2-0009,,,7811160,7811160,79,,,7811160
CD014384-bib-0027,EUCTR2013-000338-37-DE. ,"Evaluation of the necessity of a pharmacological treatment with antipsychotics for the prevention of relapse in long-term stabilized schizophrenic patients: a randomized, single-blind, longitudinal trial",,,,   ,['citation-other']," EUCTR2013-000338-37-DE. Evaluation of the necessity of a pharmacological treatment with antipsychotics for the prevention of relapse in long-term stabilized schizophrenic patients: a randomized, single-blind, longitudinal trial. www.clinicaltrialsregister.eu/ctr-search/trial/2013-000338-37/DE (first received 23 September 2014). CENTRAL    ",[''],,, Huhn 2020 {published and unpublished data}  ,included,CD014384-bbs2-0010,,,,,,,,
CD014384-bib-0028,"Huhn M, Leucht C, Rothe P, Dold M, Heres S, Bornschein S, et al. ",Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial, European Archives of Psychiatry and Clinical Neuroscience ,2020,271,    ,['citation-journal']," Huhn M, Leucht C, Rothe P, Dold M, Heres S, Bornschein S, et al. Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial.  European Archives of Psychiatry and Clinical Neuroscience 2020;271(2):293-302. CENTRAL [DOI: 10.1007/s00406-020-01109-y]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1007/s00406-020-01109-y', 'https://www.ncbi.nlm.nih.gov/pubmed/32062728', 'https://scholar.google.com/scholar_lookup?title=Reducing+antipsychotic+drugs+in+stable+patients+with+chronic+schizophrenia+or+schizoaffective+disorder:+a+randomized+controlled+pilot+trial+&author=M+Huhn&author=C+Leucht&author=P+Rothe&author=M+Dold&author=S+Heres&author=S+Bornschein&publication_year=2020&hl=en']",32062728,https://doi.org/10.1007/s00406-020-01109-y, Huhn 2020 {published and unpublished data}  ,included,CD014384-bbs2-0010,,,,32062728,34,https://link.springer.com/content/pdf/10.1007/s00406-020-01109-y.pdf,,32062728
CD014384-bib-0029,NCT02307396. ,Evaluation of the necessity of long-term pharmacological treatment with antipsychotics in schizophrenic patients,,,,   ,['citation-other'], NCT02307396. Evaluation of the necessity of long-term pharmacological treatment with antipsychotics in schizophrenic patients. clinicaltrials.gov/ct2/show/NCT02307396 (first received 4 December 2014). CENTRAL    ,[''],,, Huhn 2020 {published and unpublished data}  ,included,CD014384-bbs2-0010,,,,,,,,
CD014384-bib-0030,"Johnson DA, Ludlow JM, Street K, Taylor RD. ",Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia, British Journal of Psychiatry ,1987,151,    ,['citation-journal']," Johnson DA, Ludlow JM, Street K, Taylor RD. Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia.  British Journal of Psychiatry 1987;151:634-8. CENTRAL [DOI: 10.1192/bjp.151.5.634]    Link to article     Google Scholar     ","['', 'https://doi.org/10.1192/bjp.151.5.634', 'https://scholar.google.com/scholar_lookup?title=Double-blind+comparison+of+half-dose+and+standard-dose+flupenthixol+decanoate+in+the+maintenance+treatment+of+stabilised+out-patients+with+schizophrenia+&author=DA+Johnson&author=JM+Ludlow&author=K+Street&author=RD+Taylor&publication_year=1987&hl=en']",,https://doi.org/10.1192/bjp.151.5.634, Johnson 1987 {published data only}  ,included,CD014384-bbs2-0011,,3446307,3446307,3446307,106,,,3446307
CD014384-bib-0031,"Kane JM, Rifkin A, Woerner M, Reardon G, Kreisman D, Blumenthal R, et al. ",High-dose versus low-dose strategies in the treatment of schizophrenia, Psychopharmacology Bulletin ,1985,21,    ,['citation-journal']," Kane JM, Rifkin A, Woerner M, Reardon G, Kreisman D, Blumenthal R, et al. High-dose versus low-dose strategies in the treatment of schizophrenia.  Psychopharmacology Bulletin 1985;21(3):533-7. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/2863848', 'https://scholar.google.com/scholar_lookup?title=High-dose+versus+low-dose+strategies+in+the+treatment+of+schizophrenia&author=JM+Kane&author=A+Rifkin&author=M+Woerner&author=G+Reardon&author=D+Kreisman&author=R+Blumenthal&publication_year=1985&hl=en']",2863848,, Kane 1983 {published data only}  ,included,CD014384-bbs2-0012,,,2863848,,,,,2863848
CD014384-bib-0032,"Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, et al. ",Low-dose neuroleptic treatment of outpatient schizophrenics: i. Preliminary results for relapse rates, Archives of General Psychiatry ,1983,40,    ,['citation-journal']," Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, et al. Low-dose neuroleptic treatment of outpatient schizophrenics: i. Preliminary results for relapse rates.  Archives of General Psychiatry 1983;40(8):893-6. CENTRAL [DOI: 10.1001/archpsyc.1983.01790070083010]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1001/archpsyc.1983.01790070083010', 'https://www.ncbi.nlm.nih.gov/pubmed/6347119', 'https://scholar.google.com/scholar_lookup?title=Low-dose+neuroleptic+treatment+of+outpatient+schizophrenics:+i.+Preliminary+results+for+relapse+rates+&author=JM+Kane&author=A+Rifkin&author=M+Woerner&author=G+Reardon&author=S+Sarantakos&author=D+Schiebel&publication_year=1983&hl=en']",6347119,https://doi.org/10.1001/archpsyc.1983.01790070083010, Kane 1983 {published data only}  ,included,CD014384-bbs2-0012,,,6347119,6347119,233,,,6347119
CD014384-bib-0033,"Kane JM, Rifkin A, Woerner M, Reardon G. ",Low-dose neuroleptics in outpatient schizophrenics, Psychopharmacology Bulletin ,1982,18,    ,['citation-journal']," Kane JM, Rifkin A, Woerner M, Reardon G. Low-dose neuroleptics in outpatient schizophrenics.  Psychopharmacology Bulletin 1982;18(1):20-1. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Low-dose+neuroleptics+in+outpatient+schizophrenics&author=JM+Kane&author=A+Rifkin&author=M+Woerner&author=G+Reardon&publication_year=1982&hl=en']",,, Kane 1983 {published data only}  ,included,CD014384-bbs2-0012,,6347119,,,,,,6347119
CD014384-bib-0034,"Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, et al. ","Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia", American Journal of Psychiatry ,2010,167,    ,['citation-journal']," Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.  American Journal of Psychiatry 2010;167(2):181-9. CENTRAL [DOI: 10.1176/appi.ajp.2009.07081221]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1176/appi.ajp.2009.07081221', 'https://www.ncbi.nlm.nih.gov/pubmed/20008947', 'https://scholar.google.com/scholar_lookup?title=Olanzapine+long-acting+injection:+a+24-week,+randomized,+double-blind+trial+of+maintenance+treatment+in+patients+with+schizophrenia+&author=JM+Kane&author=HC+Detke&author=D+Naber&author=G+Sethuraman&author=DY+Lin&author=RF+Bergstrom&publication_year=2010&hl=en']",20008947,https://doi.org/10.1176/appi.ajp.2009.07081221, Kane 2010 {published and unpublished data}  ,included,CD014384-bbs2-0013,,,,20008947,208,,,20008947
CD014384-bib-0035,NCT00088491. ,"A double-blind, randomized study comparing intramuscular olanzapine depot to oral olanzapine and low-dose depot in the maintenance therapy of patients with schizophrenia",,,,   ,['citation-other']," NCT00088491. A double-blind, randomized study comparing intramuscular olanzapine depot to oral olanzapine and low-dose depot in the maintenance therapy of patients with schizophrenia. clinicaltrials.gov/ct2/show/NCT00088491 (first received 28 July 2004). CENTRAL    ",[''],,, Kane 2010 {published and unpublished data}  ,included,CD014384-bbs2-0013,,,,,,,,
CD014384-bib-0036,NCT00088491. ,Comparison of intramuscular olanzapine depot to oral olanzapine and low dose depot in patients with schizophrenia,,,,   ,['citation-other'], NCT00088491. Comparison of intramuscular olanzapine depot to oral olanzapine and low dose depot in patients with schizophrenia. clinicaltrials.gov/ct2/show/NCT00088491 (first received 28 July 2004). CENTRAL    ,[''],,, Kane 2010 {published and unpublished data}  ,included,CD014384-bbs2-0013,,,,,,,,
CD014384-bib-0037,"Kinion ES, Campbell JM, Linc LG, Paradise N. ",Decreasing neuroleptic doses in older adults with schizophrenia, Journal of Clinical Geropsychology ,2000,6,    ,['citation-journal']," Kinion ES, Campbell JM, Linc LG, Paradise N. Decreasing neuroleptic doses in older adults with schizophrenia.  Journal of Clinical Geropsychology 2000;6(1):15-23. CENTRAL [DOI: 10.1023/A:1009520106119]    Link to article     Google Scholar     ","['', 'https://doi.org/10.1023/A:1009520106119', 'https://scholar.google.com/scholar_lookup?title=Decreasing+neuroleptic+doses+in+older+adults+with+schizophrenia&author=ES+Kinion&author=JM+Campbell&author=LG+Linc&author=N+Paradise&publication_year=2000&hl=en']",,https://doi.org/10.1023/A:1009520106119, Kinion 2000 {published data only}  ,included,CD014384-bbs2-0014,,,,,2,,,
CD014384-bib-0038,"Lonowski DJ, Sterling FE, Kennedy JC. ",Gradual reduction of neuroleptic drugs among chronic schizophrenics. A double-blind controlled study, Acta Psychiatrica Scandinavica ,1978,57,    ,['citation-journal']," Lonowski DJ, Sterling FE, Kennedy JC. Gradual reduction of neuroleptic drugs among chronic schizophrenics. A double-blind controlled study.  Acta Psychiatrica Scandinavica 1978;57(2):97-102. CENTRAL [DOI: 10.1111/j.1600-0447.1978.tb06877.x]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1111/j.1600-0447.1978.tb06877.x', 'https://www.ncbi.nlm.nih.gov/pubmed/345749', 'https://scholar.google.com/scholar_lookup?title=Gradual+reduction+of+neuroleptic+drugs+among+chronic+schizophrenics.+A+double-blind+controlled+study+&author=DJ+Lonowski&author=FE+Sterling&author=JC+Kennedy&publication_year=1978&hl=en']",345749,https://doi.org/10.1111/j.1600-0447.1978.tb06877.x, Lonowski 1978 {published data only}  ,included,CD014384-bbs2-0015,,345749,,345749,13,,,345749
CD014384-bib-0039,"Newcomer JW, Riney SJ, Vinogradov S, Csernansky JG. ",Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease, Psychopharmacology Bulletin ,1992,28,    ,['citation-journal']," Newcomer JW, Riney SJ, Vinogradov S, Csernansky JG. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease.  Psychopharmacology Bulletin 1992;28(1):101-7. CENTRAL [DOI: 10.1016/0165-1781(92)90001-J]    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/1609034', 'https://scholar.google.com/scholar_lookup?title=Plasma+prolactin+and+homovanillic+acid+as+markers+for+psychopathology+and+abnormal+movements+after+neuroleptic+dose+decrease+&author=JW+Newcomer&author=SJ+Riney&author=S+Vinogradov&author=JG+Csernansky&publication_year=1992&hl=en']",1609034,, Newcomer 1992 {published data only}  ,included,CD014384-bbs2-0016,,1609034,1609034,,,,,1609034
CD014384-bib-0040,"Ozawa C, Bies RR, Pillai N, Suzuki T, Mimura M, Uchida H. ","Model-guided antipsychotic dose reduction in schizophrenia: a pilot, single-blind randomized controlled trial", Journal of Clinical Psychopharmacology ,2019,39,    ,['citation-journal']," Ozawa C, Bies RR, Pillai N, Suzuki T, Mimura M, Uchida H. Model-guided antipsychotic dose reduction in schizophrenia: a pilot, single-blind randomized controlled trial.  Journal of Clinical Psychopharmacology 2019;39(4):329-35. CENTRAL [DOI: 10.1097/jcp.0000000000001046]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/JCP.0000000000001046', 'https://www.ncbi.nlm.nih.gov/pubmed/31188232', 'https://scholar.google.com/scholar_lookup?title=Model-guided+antipsychotic+dose+reduction+in+schizophrenia:+a+pilot,+single-blind+randomized+controlled+trial+&author=C+Ozawa&author=RR+Bies&author=N+Pillai&author=T+Suzuki&author=M+Mimura&author=H+Uchida&publication_year=2019&hl=en']",31188232,https://doi.org/10.1097/JCP.0000000000001046, Ozawa 2019 {published and unpublished data}  ,included,CD014384-bbs2-0017,,31188232,31188232,31188232,13,,,31188232
CD014384-bib-0041,UMIN000014976. ,Model-guided antipsychotic dose reduction in schizophrenia: a single-blind randomized controlled trial,,,,   ,['citation-other'], UMIN000014976. Model-guided antipsychotic dose reduction in schizophrenia: a single-blind randomized controlled trial. rctportal.niph.go.jp/en/detail?trial_id=UMIN000014976 (first received 28 August 2014). CENTRAL    ,[''],,, Ozawa 2019 {published and unpublished data}  ,included,CD014384-bbs2-0017,,,,,,,,
CD014384-bib-0042,NCT00431574. ,Antipsychotic medication extended dosing study,,,,   ,['citation-other'], NCT00431574. Antipsychotic medication extended dosing study. clinicaltrials.gov/ct2/show/NCT00431574 (first received 6 February 2007). CENTRAL    ,[''],,, Remington 2011 {published data only}  ,included,CD014384-bbs2-0018,,20868639,,,,,,20868639
CD014384-bib-0043,"Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S, et al. ","""Extended"" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial", Journal of Clinical Psychiatry ,2011,72,    ,['citation-journal']," Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S, et al. ""Extended"" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial.  Journal of Clinical Psychiatry 2011;72(8):1042-8. CENTRAL [DOI: 10.4088/jcp.09m05866yel]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4088/JCP.09m05866yel', 'https://www.ncbi.nlm.nih.gov/pubmed/20868639', 'https://scholar.google.com/scholar_lookup?title=']",20868639,https://doi.org/10.4088/JCP.09m05866yel, Remington 2011 {published data only}  ,included,CD014384-bbs2-0018,,,,20868639,65,,,20868639
CD014384-bib-0044,"Rouillon F, Chartier F, Gasquet I. ",Strategies of treatment with olanzapine in schizophrenic patients during stable phase: results of a pilot study, European Neuropsychopharmacology ,2008,18,    ,['citation-journal']," Rouillon F, Chartier F, Gasquet I. Strategies of treatment with olanzapine in schizophrenic patients during stable phase: results of a pilot study.  European Neuropsychopharmacology 2008;18(9):646-52. CENTRAL [DOI: 10.1016/j.euroneuro.2008.04.012]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.euroneuro.2008.04.012', 'https://www.ncbi.nlm.nih.gov/pubmed/18550345', 'https://scholar.google.com/scholar_lookup?title=Strategies+of+treatment+with+olanzapine+in+schizophrenic+patients+during+stable+phase:+results+of+a+pilot+study+&author=F+Rouillon&author=F+Chartier&author=I+Gasquet&publication_year=2008&hl=en']",18550345,https://doi.org/10.1016/j.euroneuro.2008.04.012, Rouillon 2008 {published data only}  ,included,CD014384-bbs2-0019,,18550345,18550345,18550345,20,,,18550345
CD014384-bib-0045,"Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, et al. ",Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment, Archives of General Psychiatry ,1997,54,    ,['citation-journal']," Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment.  Archives of General Psychiatry 1997;54(5):453-63. CENTRAL [DOI: 10.1001/archpsyc.1997.01830170079011]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1001/archpsyc.1997.01830170079011', 'https://www.ncbi.nlm.nih.gov/pubmed/9152099', 'https://scholar.google.com/scholar_lookup?title=Relapse+and+rehospitalization+during+maintenance+treatment+of+schizophrenia.+The+effects+of+dose+reduction+and+family+treatment+&author=NR+Schooler&author=SJ+Keith&author=JB+Severe&author=SM+Matthews&author=AS+Bellack&author=ID+Glick&publication_year=1997&hl=en']",9152099,https://doi.org/10.1001/archpsyc.1997.01830170079011, Schooler 1997 {published data only}  ,included,CD014384-bbs2-0020,,,9152099,9152099,315,,,9152099
CD014384-bib-0046,"Takeuchi H, Suzuki T, Bies RR, Remington G, Watanabe K, Mimura M, et al. ","Dose reduction of risperidone and olanzapine and estimated dopamine D(2) receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study", Journal of Clinical Psychiatry ,2014,75,    ,['citation-journal']," Takeuchi H, Suzuki T, Bies RR, Remington G, Watanabe K, Mimura M, et al. Dose reduction of risperidone and olanzapine and estimated dopamine D(2) receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study.  Journal of Clinical Psychiatry 2014;75(11):1209-14. CENTRAL [DOI: 10.4088/jcp.13m08841]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4088/JCP.13m08841', 'https://www.ncbi.nlm.nih.gov/pubmed/25099201', 'https://scholar.google.com/scholar_lookup?title=Dose+reduction+of+risperidone+and+olanzapine+and+estimated+dopamine+D(2)+receptor+occupancy+in+stable+patients+with+schizophrenia:+findings+from+an+open-label,+randomized,+controlled+study+&author=H+Takeuchi&author=T+Suzuki&author=RR+Bies&author=G+Remington&author=K+Watanabe&author=M+Mimura&publication_year=2014&hl=en']",25099201,https://doi.org/10.4088/JCP.13m08841, Takeuchi 2014 {published and unpublished data}  ,included,CD014384-bbs2-0021,,,,25099201,14,,,25099201
CD014384-bib-0047,"Takeuchi H, Suzuki T, Remington G, Bies R, Watanabe K, Mimura M, et al. ",Impact of atypical antipsychotic dose reduction on cognitive function and subjective experiences, Neuropsychopharmacology ,2014,39,    ,['citation-journal']," Takeuchi H, Suzuki T, Remington G, Bies R, Watanabe K, Mimura M, et al. Impact of atypical antipsychotic dose reduction on cognitive function and subjective experiences.  Neuropsychopharmacology 2014;39:S385. CENTRAL [DOI: 10.1002/central/CN-01040905/]    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Impact+of+atypical+antipsychotic+dose+reduction+on+cognitive+function+and+subjective+experiences+&author=H+Takeuchi&author=T+Suzuki&author=G+Remington&author=R+Bies&author=K+Watanabe&author=M+Mimura&publication_year=2014&hl=en']",,, Takeuchi 2014 {published and unpublished data}  ,included,CD014384-bbs2-0021,,,,,,,,
CD014384-bib-0048,"Takeuchi H, Suzuki T, Remington G, Bies RR, Abe T, Graff-Guerrero A, et al. ","Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study", Schizophrenia Bulletin ,2013,39,    ,['citation-journal']," Takeuchi H, Suzuki T, Remington G, Bies RR, Abe T, Graff-Guerrero A, et al. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study.  Schizophrenia Bulletin 2013;39(5):993-8. CENTRAL [DOI: 10.1093/schbul/sbt090]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1093/schbul/sbt090', 'https://www.ncbi.nlm.nih.gov/pubmed/23821768', 'https://scholar.google.com/scholar_lookup?title=Effects+of+risperidone+and+olanzapine+dose+reduction+on+cognitive+function+in+stable+patients+with+schizophrenia:+an+open-label,+randomized,+controlled,+pilot+study+&author=H+Takeuchi&author=T+Suzuki&author=G+Remington&author=RR+Bies&author=T+Abe&author=A+Graff-Guerrero&publication_year=2013&hl=en']",23821768,https://doi.org/10.1093/schbul/sbt090, Takeuchi 2014 {published and unpublished data}  ,included,CD014384-bbs2-0021,,,23821768,23821768,109,https://academic.oup.com/schizophreniabulletin/article-pdf/39/5/993/5430580/sbt090.pdf,,23821768
CD014384-bib-0049,"Takeuchi H, Suzuki T, Remington G, Watanabe K, Mimura M, Uchida H, et al. ","Lack of effect of risperidone or olanzapine dose reduction on metabolic parameters, prolactin, and corrected QT interval in stable patients with schizophrenia", Journal of Clinical Psychopharmacology ,2014,34,    ,['citation-journal']," Takeuchi H, Suzuki T, Remington G, Watanabe K, Mimura M, Uchida H, et al. Lack of effect of risperidone or olanzapine dose reduction on metabolic parameters, prolactin, and corrected QT interval in stable patients with schizophrenia.  Journal of Clinical Psychopharmacology 2014;34(4):517-20. CENTRAL [DOI: 0.1097/JCP.0000000000000142]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/JCP.0000000000000142', 'https://www.ncbi.nlm.nih.gov/pubmed/24911439', 'https://scholar.google.com/scholar_lookup?title=Lack+of+effect+of+risperidone+or+olanzapine+dose+reduction+on+metabolic+parameters,+prolactin,+and+corrected+QT+interval+in+stable+patients+with+schizophrenia+&author=H+Takeuchi&author=T+Suzuki&author=G+Remington&author=K+Watanabe&author=M+Mimura&author=H+Uchida&publication_year=2014&hl=en']",24911439,https://doi.org/10.1097/JCP.0000000000000142, Takeuchi 2014 {published and unpublished data}  ,included,CD014384-bbs2-0021,,,,24911439,6,,,24911439
CD014384-bib-0050,"Takeuchi H, Suzuki T, Remington G, Watanabe K, Mimura M, Uchida H. ",Lack of effect of risperidone or olanzapine dose reduction on subjective experiences in stable patients with schizophrenia, Psychiatry Research ,2014,218,    ,['citation-journal']," Takeuchi H, Suzuki T, Remington G, Watanabe K, Mimura M, Uchida H. Lack of effect of risperidone or olanzapine dose reduction on subjective experiences in stable patients with schizophrenia.  Psychiatry Research 2014;218(1-2):244-6. CENTRAL [DOI: 10.1016/j.psychres.2014.04.019]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.psychres.2014.04.019', 'https://www.ncbi.nlm.nih.gov/pubmed/24768247', 'https://scholar.google.com/scholar_lookup?title=Lack+of+effect+of+risperidone+or+olanzapine+dose+reduction+on+subjective+experiences+in+stable+patients+with+schizophrenia+&author=H+Takeuchi&author=T+Suzuki&author=G+Remington&author=K+Watanabe&author=M+Mimura&author=H+Uchida&publication_year=2014&hl=en']",24768247,https://doi.org/10.1016/j.psychres.2014.04.019, Takeuchi 2014 {published and unpublished data}  ,included,CD014384-bbs2-0021,,24911439,,24768247,2,,,24768247
CD014384-bib-0051,"Takeuchi H, Uchida H, Suzuki T, Bies RR, Watanabe K, Remington G,  et al. ",Effects of atypical antipsychotic dose reduction on cognitive function in stable patients with schizophrenia: a randomized controlled trial, Schizophrenia Bulletin ,2013,39,    ,['citation-journal']," Takeuchi H, Uchida H, Suzuki T, Bies RR, Watanabe K, Remington G,  et al. Effects of atypical antipsychotic dose reduction on cognitive function in stable patients with schizophrenia: a randomized controlled trial.  Schizophrenia Bulletin 2013;39:S354. CENTRAL [DOI: 10.1093/schbul/sbt011]    Link to article     Google Scholar     ","['', 'https://doi.org/10.1093/schbul/sbt090', 'https://scholar.google.com/scholar_lookup?title=Effects+of+atypical+antipsychotic+dose+reduction+on+cognitive+function+in+stable+patients+with+schizophrenia:+a+randomized+controlled+trial+&author=H+Takeuchi&author=H+Uchida&author=T+Suzuki&author=RR+Bies&author=K+Watanabe&author=G+Remington&publication_year=2013&hl=en']",,https://doi.org/10.1093/schbul/sbt090, Takeuchi 2014 {published and unpublished data}  ,included,CD014384-bbs2-0021,,,,23821768,109,https://academic.oup.com/schizophreniabulletin/article-pdf/39/5/993/5430580/sbt090.pdf,,23821768
CD014384-bib-0052,Takeuchi H. ,Optimal antipsychotic dose and dosing interval in the treatment of schizophrenia, Psychiatria et neurologia Japonica ,2015,117,    ,['citation-journal'], Takeuchi H. Optimal antipsychotic dose and dosing interval in the treatment of schizophrenia.  Psychiatria et neurologia Japonica 2015;117(7):562-7. CENTRAL    PubMed     Google Scholar     ,"['', 'https://www.ncbi.nlm.nih.gov/pubmed/26552322', 'https://scholar.google.com/scholar_lookup?title=Optimal+antipsychotic+dose+and+dosing+interval+in+the+treatment+of+schizophrenia&author=H+Takeuchi&publication_year=2015&hl=en']",26552322,, Takeuchi 2014 {published and unpublished data}  ,included,CD014384-bbs2-0021,,31770770,,,,,,26552322
CD014384-bib-0053,UMIN000001834. ,Effects of antipsychotic reduction on negative subjective experience and cognitive function,,,, [center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002200]   ,['citation-other'], UMIN000001834. Effects of antipsychotic reduction on negative subjective experience and cognitive function. rctportal.niph.go.jp/en/detail?trial_id=UMIN000001834 (first received 31 March 2009). CENTRAL [center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002200]    ,[''],,, Takeuchi 2014 {published and unpublished data}  ,included,CD014384-bbs2-0021,,,,,,,,
CD014384-bib-0054,"Volavka J, Cooper TB, Czobor P, Lindenmayer JP, Citrome LL, Mohr P, et al. ",High dose treatment with haloperidol: the effect of dose reduction, Journal of Clinical Psychopharmacology ,2000,20,    ,['citation-journal']," Volavka J, Cooper TB, Czobor P, Lindenmayer JP, Citrome LL, Mohr P, et al. High dose treatment with haloperidol: the effect of dose reduction.  Journal of Clinical Psychopharmacology 2000;20(2):252-6. CENTRAL [DOI: 10.1097/00004714-200004000-00020]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/00004714-200004000-00020', 'https://www.ncbi.nlm.nih.gov/pubmed/10770466', 'https://scholar.google.com/scholar_lookup?title=High+dose+treatment+with+haloperidol:+the+effect+of+dose+reduction&author=J+Volavka&author=TB+Cooper&author=P+Czobor&author=JP+Lindenmayer&author=LL+Citrome&author=P+Mohr&publication_year=2000&hl=en']",10770466,https://doi.org/10.1097/00004714-200004000-00020, Volavka 2000 {published data only}  ,included,CD014384-bbs2-0022,,,,10770466,28,,,10770466
CD014384-bib-0055,"Volavka J, Cooper TB, Czobor P, Lindenmayer JP, Citrome LL, Mohr P. ",Haloperidol blood levels and effects in schizophrenia,,1997,,    ,['citation-other']," Volavka J, Cooper TB, Czobor P, Lindenmayer JP, Citrome LL, Mohr P. Haloperidol blood levels and effects in schizophrenia. In: 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, California, USA. 1997. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Haloperidol+blood+levels+and+effects+in+schizophrenia&author=J+Volavka&author=TB+Cooper&author=P+Czobor&author=JP+Lindenmayer&author=LL+Citrome&author=P+Mohr&publication_year=1997&hl=en']",,, Volavka 2000 {published data only}  ,included,CD014384-bbs2-0022,,10770466,,,,,,10770466
CD014384-bib-0056,"Bo Q, Dong F, Li X, Wang Z, Ma X, Wang C. ","Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia", BMC Psychiatry ,2016,16,    ,['citation-journal']," Bo Q, Dong F, Li X, Wang Z, Ma X, Wang C. Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia.  BMC Psychiatry 2016;16(1):386. CENTRAL [DOI: 10.1186/s12888-016-1103-3]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1186/s12888-016-1103-3', 'https://www.ncbi.nlm.nih.gov/pubmed/27829454', 'https://scholar.google.com/scholar_lookup?title=Prolactin+related+symptoms+during+risperidone+maintenance+treatment:+results+from+a+prospective,+multicenter+study+of+schizophrenia+&author=Q+Bo&author=F+Dong&author=X+Li&author=Z+Wang&author=X+Ma&author=C+Wang&publication_year=2016&hl=en']",27829454,https://doi.org/10.1186/s12888-016-1103-3, Wang 2010 {published data only}  ,included,CD014384-bbs2-0023,,,27829454,27829454,10,https://bmcpsychiatry.biomedcentral.com/track/pdf/10.1186/s12888-016-1103-3,,27829454
CD014384-bib-0057,"Bo QJ, Li XB, Wang ZM, Li AN, Ma X, Wang CY. ","Extrapyramidal symptoms during risperidone maintenance treatment in schizophrenia: a prospective, multicenter study", Journal of Clinical Psychopharmacology ,2016,36,    ,['citation-journal']," Bo QJ, Li XB, Wang ZM, Li AN, Ma X, Wang CY. Extrapyramidal symptoms during risperidone maintenance treatment in schizophrenia: a prospective, multicenter study.  Journal of Clinical Psychopharmacology 2016;36:125-9. CENTRAL [DOI: 10.1097/JCP.0000000000000464]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/JCP.0000000000000464', 'https://www.ncbi.nlm.nih.gov/pubmed/26848792', 'https://scholar.google.com/scholar_lookup?title=Extrapyramidal+symptoms+during+risperidone+maintenance+treatment+in+schizophrenia:+a+prospective,+multicenter+study+&author=QJ+Bo&author=XB+Li&author=ZM+Wang&author=AN+Li&author=X+Ma&author=CY+Wang&publication_year=2016&hl=en']",26848792,https://doi.org/10.1097/JCP.0000000000000464, Wang 2010 {published data only}  ,included,CD014384-bbs2-0023,,,26848792,26848792,6,,,26848792
CD014384-bib-0058,NCT00848432. ,Risperidone maintenance treatment in schizophrenia,,,,   ,['citation-other'], NCT00848432. Risperidone maintenance treatment in schizophrenia. clinicaltrials.gov/ct2/show/NCT00848432 (first received 20 February 2009). CENTRAL    ,[''],,, Wang 2010 {published data only}  ,included,CD014384-bbs2-0023,,33538534,,,,,,33538534
CD014384-bib-0059,"Wang CY, Xiang YT, Cai ZJ, Weng YZ, Bo QJ, Zhao JP, et al. ","Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial", American Journal of Psychiatry ,2010,167,    ,['citation-journal']," Wang CY, Xiang YT, Cai ZJ, Weng YZ, Bo QJ, Zhao JP, et al. Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial.  American Journal of Psychiatry 2010;167(6):676-85. CENTRAL [DOI: 10.1176/appi.ajp.2009.09030358]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1176/appi.ajp.2009.09030358', 'https://www.ncbi.nlm.nih.gov/pubmed/20231321', 'https://scholar.google.com/scholar_lookup?title=Risperidone+maintenance+treatment+in+schizophrenia:+a+randomized,+controlled+trial&author=CY+Wang&author=YT+Xiang&author=ZJ+Cai&author=YZ+Weng&author=QJ+Bo&author=JP+Zhao&publication_year=2010&hl=en']",20231321,https://doi.org/10.1176/appi.ajp.2009.09030358, Wang 2010 {published data only}  ,included,CD014384-bbs2-0023,,,,20231321,57,,,20231321
CD014384-bib-0060,"Wang CY, Xiang YT, Ungvari GS. ",Reply to Uchida et al, American Journal of Psychiatry ,2010,167,    ,['citation-journal']," Wang CY, Xiang YT, Ungvari GS. Reply to Uchida et al.  American Journal of Psychiatry 2010;167(8):994-5. CENTRAL [DOI: 10.1176/appi.ajp.2010.10030409r]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1176/appi.ajp.2010.10030409r', 'https://www.ncbi.nlm.nih.gov/pubmed/20693469', 'https://scholar.google.com/scholar_lookup?title=Reply+to+Uchida+et+al&author=CY+Wang&author=YT+Xiang&author=GS+Ungvari&publication_year=2010&hl=en']",20693469,https://doi.org/10.1176/appi.ajp.2010.10030409r, Wang 2010 {published data only}  ,included,CD014384-bbs2-0023,,,,,1,,,20693469
CD014384-bib-0061,"Xiang T, Wang CY,  Weng YZ, Bo QJ, Chiu HF, Chan SS, et al. ","Predictors of relapse in Chinese schizophrenia patients: a prospective, multi-center study", Social Psychiatry and Psychiatric Epidemiology ,2011,46,    ,['citation-journal']," Xiang T, Wang CY,  Weng YZ, Bo QJ, Chiu HF, Chan SS, et al. Predictors of relapse in Chinese schizophrenia patients: a prospective, multi-center study.  Social Psychiatry and Psychiatric Epidemiology 2011;46(12):1325-30. CENTRAL [DOI: 10.1007/s00127-010-0304-1]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1007/s00127-010-0304-1', 'https://www.ncbi.nlm.nih.gov/pubmed/21046070', 'https://scholar.google.com/scholar_lookup?title=Predictors+of+relapse+in+Chinese+schizophrenia+patients:+a+prospective,+multi-center+study+&author=T+Xiang&author=CY+Wang&author=YZ+\xa0Weng&author=QJ+Bo&author=HF+Chiu&author=SS+Chan&publication_year=2011&hl=en']",21046070,https://doi.org/10.1007/s00127-010-0304-1, Wang 2010 {published data only}  ,included,CD014384-bbs2-0023,,,21046070,21046070,24,,,21046070
CD014384-bib-0062,"Xiang YT, Wang CY, Chiu HF, Weng YZ, Bo QJ, Chan SS, et al. ","Socio-demographic and clinical profiles of paranoid and nonparanoid schizophrenia: a prospective, multicenter study in China", Perspectives in Psychiatric Care ,2011,47,    ,['citation-journal']," Xiang YT, Wang CY, Chiu HF, Weng YZ, Bo QJ, Chan SS, et al. Socio-demographic and clinical profiles of paranoid and nonparanoid schizophrenia: a prospective, multicenter study in China.  Perspectives in Psychiatric Care 2011;47(3):126-30. CENTRAL [DOI: 10.1111/j.1744-6163.2010.00281.x]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1111/j.1744-6163.2010.00281.x', 'https://www.ncbi.nlm.nih.gov/pubmed/21707627', 'https://scholar.google.com/scholar_lookup?title=Socio-demographic+and+clinical+profiles+of+paranoid+and+nonparanoid+schizophrenia:+a+prospective,+multicenter+study+in+China+&author=YT+Xiang&author=CY+Wang&author=HF+Chiu&author=YZ+Weng&author=QJ+Bo&author=SS+Chan&publication_year=2011&hl=en']",21707627,https://doi.org/10.1111/j.1744-6163.2010.00281.x, Wang 2010 {published data only}  ,included,CD014384-bbs2-0023,,,,21707627,7,https://doi.org/10.1111/j.1744-6163.2010.00281.x,,21707627
CD014384-bib-0063,"Xiang YT, Wang CY, Ungvari GS, Kreyenbuhl JA, Chiu HF, Lai KY, et al. ",Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia, Pharmacopsychiatry ,2011,44,    ,['citation-journal']," Xiang YT, Wang CY, Ungvari GS, Kreyenbuhl JA, Chiu HF, Lai KY, et al. Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia.  Pharmacopsychiatry 2011;44(4):135-41. CENTRAL [DOI: 10.1055/s-0031-1277178]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1055/s-0031-1277178', 'https://www.ncbi.nlm.nih.gov/pubmed/21710403', 'https://scholar.google.com/scholar_lookup?title=Weight+changes+and+their+associations+with+demographic+and+clinical+characteristics+in+risperidone+maintenance+treatment+for+schizophrenia+&author=YT+Xiang&author=CY+Wang&author=GS+Ungvari&author=JA+Kreyenbuhl&author=HF+Chiu&author=KY+Lai&publication_year=2011&hl=en']",21710403,https://doi.org/10.1055/s-0031-1277178, Wang 2010 {published data only}  ,included,CD014384-bbs2-0023,,,21710403,,0,,,21710403
CD014384-bib-0064,"Xiang YT, Wang CY, Weng YZ, Bo QJ, Chiu HF, Zhao JP, et al. ","Sex differences in patients with schizophrenia: a prospective, multi-center study", Psychiatry Research ,2010,177,    ,['citation-journal']," Xiang YT, Wang CY, Weng YZ, Bo QJ, Chiu HF, Zhao JP, et al. Sex differences in patients with schizophrenia: a prospective, multi-center study.  Psychiatry Research 2010;177(3):294-8. CENTRAL [DOI: 10.1016/j.psychres.2010.03.014]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.psychres.2010.03.014', 'https://www.ncbi.nlm.nih.gov/pubmed/20417572', 'https://scholar.google.com/scholar_lookup?title=Sex+differences+in+patients+with+schizophrenia:+a+prospective,+multi-center+study&author=YT+Xiang&author=CY+Wang&author=YZ+Weng&author=QJ+Bo&author=HF+Chiu&author=JP+Zhao&publication_year=2010&hl=en']",20417572,https://doi.org/10.1016/j.psychres.2010.03.014, Wang 2010 {published data only}  ,included,CD014384-bbs2-0023,,,,20417572,22,,,20417572
CD014384-bib-0065,"Faber G, Smid HG, Van Gool AR, Wunderink L, Van Den Bosch RJ, Wiersma D. ","Continued cannabis use and outcome in first-episode psychosis: data from a randomized, open-label, controlled trial", Journal of Clinical Psychiatry ,2012,73,    ,['citation-journal']," Faber G, Smid HG, Van Gool AR, Wunderink L, Van Den Bosch RJ, Wiersma D. Continued cannabis use and outcome in first-episode psychosis: data from a randomized, open-label, controlled trial.  Journal of Clinical Psychiatry 2012;73(5):632-8. CENTRAL [DOI: 10.4088/JCP.11m07069]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4088/JCP.11m07069', 'https://www.ncbi.nlm.nih.gov/pubmed/22394457', 'https://scholar.google.com/scholar_lookup?title=Continued+cannabis+use+and+outcome+in+first-episode+psychosis:+data+from+a+randomized,+open-label,+controlled+trial+&author=G+Faber&author=HG+Smid&author=AR+VanGool&author=L+Wunderink&author=RJ+VanDenBosch&author=D+Wiersma&publication_year=2012&hl=en']",22394457,https://doi.org/10.4088/JCP.11m07069, Wunderink 2007 {published data only}  ,included,CD014384-bbs2-0024,,22394457,22394457,22394457,43,,,22394457
CD014384-bib-0066,ISRCTN16228411. ,Medication strategies in first onset schizophrenia (Mesifos),,,,   ,['citation-other'], ISRCTN16228411. Medication strategies in first onset schizophrenia (Mesifos). www.isrctn.com/ISRCTN16228411 (first received 19 December 2005). CENTRAL    ,[''],,, Wunderink 2007 {published data only}  ,included,CD014384-bbs2-0024,,,,,,,,
CD014384-bib-0067,ISRCTN16228411. ,Medication strategies in first onset schizophrenia (MESIFOS),,,,   ,['citation-other'], ISRCTN16228411. Medication strategies in first onset schizophrenia (MESIFOS). www.isrctn.com/ISRCTN16228411 (first received 19 December 2005). CENTRAL    ,[''],,, Wunderink 2007 {published data only}  ,included,CD014384-bbs2-0024,,,,,,,,
CD014384-bib-0068,"Nienhuis F, Wunderink A, Wiersma D, Van den Bosch RJ, Bruggeman R, Faber G, et al. ",MESIFOS: Medication strategies in first onset schizophrenia effects of short versus sustained antipsychotic treatment on quality of life after first episode psychosis: a randomized trial, Schizophrenia Research ,2003,60,    ,['citation-journal']," Nienhuis F, Wunderink A, Wiersma D, Van den Bosch RJ, Bruggeman R, Faber G, et al. MESIFOS: Medication strategies in first onset schizophrenia effects of short versus sustained antipsychotic treatment on quality of life after first episode psychosis: a randomized trial.  Schizophrenia Research 2003;60:296-7. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/S0920-9964(03)80502-9', 'https://scholar.google.com/scholar_lookup?title=MESIFOS:+Medication+strategies+in+first+onset+schizophrenia+effects+of+short+versus+sustained+antipsychotic+treatment+on+quality+of+life+after+first+episode+psychosis:+a+randomized+trial+&author=F+Nienhuis&author=A+Wunderink&author=D+Wiersma&author=RJ+VandenBosch&author=R+Bruggeman&author=G+Faber&publication_year=2003&hl=en']",,https://doi.org/10.1016/S0920-9964(03)80502-9, Wunderink 2007 {published data only}  ,included,CD014384-bbs2-0024,,,,,2,,,
CD014384-bib-0069,"Nienhuis F, Wunderink A, Wiersma D. ",Feasibility of carrying out maintenance or targeted medication treatment in first onset schizophrenia: the MESIFOS RCT, Schizophrenia Bulletin ,2005,31,    ,['citation-journal']," Nienhuis F, Wunderink A, Wiersma D. Feasibility of carrying out maintenance or targeted medication treatment in first onset schizophrenia: the MESIFOS RCT.  Schizophrenia Bulletin 2005;31:498. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Feasibility+of+carrying+out+maintenance+or+targeted+medication+treatment+in+first+onset+schizophrenia:+the+MESIFOS+RCT+&author=F+Nienhuis&author=A+Wunderink&author=D+Wiersma&publication_year=2005&hl=en']",,, Wunderink 2007 {published data only}  ,included,CD014384-bbs2-0024,,,,,,,,
CD014384-bib-0070,"Nienhuis FJ, Wunderink A, Wiersma D. ",Feasibility of carrying out targeted and maintenance treatment in first episode psychosis, Schizophrenia Research ,2006,86,    ,['citation-journal']," Nienhuis FJ, Wunderink A, Wiersma D. Feasibility of carrying out targeted and maintenance treatment in first episode psychosis.  Schizophrenia Research 2006;86(Suppl 1):S50-1. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/S0920-9964(06)70151-7', 'https://scholar.google.com/scholar_lookup?title=Feasibility+of+carrying+out+targeted+and+maintenance+treatment+in+first+episode+psychosis&author=FJ+Nienhuis&author=A+Wunderink&author=D+Wiersma&publication_year=2006&hl=en']",,https://doi.org/10.1016/S0920-9964(06)70151-7, Wunderink 2007 {published data only}  ,included,CD014384-bbs2-0024,,,,,2,,,
CD014384-bib-0071,"Nienhuis FJ, Wunderink A, Wiersma D. ",Feasibility of targeted and maintenance treatment in remitted first episode psychosis, Schizophrenia Bulletin ,2007,33,    ,['citation-journal']," Nienhuis FJ, Wunderink A, Wiersma D. Feasibility of targeted and maintenance treatment in remitted first episode psychosis.  Schizophrenia Bulletin 2007;33(2):450. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Feasibility+of+targeted+and+maintenance+treatment+in+remitted+first+episode+psychosis&author=FJ+Nienhuis&author=A+Wunderink&author=D+Wiersma&publication_year=2007&hl=en']",,, Wunderink 2007 {published data only}  ,included,CD014384-bbs2-0024,,,,,,,,
CD014384-bib-0072,"Wunderink A, Nienhuis FJ, Sytema S, Wiersma D. ",Guided discontinuation versus maintenance treatment in remitted first episode psychosis: relapse rates and functional outcome, Schizophrenia Research ,2006,86,    ,['citation-journal']," Wunderink A, Nienhuis FJ, Sytema S, Wiersma D. Guided discontinuation versus maintenance treatment in remitted first episode psychosis: relapse rates and functional outcome.  Schizophrenia Research 2006;86(Suppl 1):S51. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/S0920-9964(06)70152-9', 'https://scholar.google.com/scholar_lookup?title=Guided+discontinuation+versus+maintenance+treatment+in+remitted+first+episode+psychosis:+relapse+rates+and+functional+outcome+&author=A+Wunderink&author=FJ+Nienhuis&author=S+Sytema&author=D+Wiersma&publication_year=2006&hl=en']",,https://doi.org/10.1016/S0920-9964(06)70152-9, Wunderink 2007 {published data only}  ,included,CD014384-bbs2-0024,,,17503973,,4,,,17503973
CD014384-bib-0073,"Wunderink A, Wiersma D, de Wit P. ",Outcome of two medication strategies in first-onset schizophrenia: the MESIFOS RCT,,2005,,    ,['citation-other']," Wunderink A, Wiersma D, de Wit P. Outcome of two medication strategies in first-onset schizophrenia: the MESIFOS RCT. In: 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, Georgia, USA. 2005:Nr214. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Outcome+of+two+medication+strategies+in+first-onset+schizophrenia:+the+MESIFOS+RCT&author=A+Wunderink&author=D+Wiersma&author=P+Wit&publication_year=2005&hl=en']",,, Wunderink 2007 {published data only}  ,included,CD014384-bbs2-0024,,,,,,,,
CD014384-bib-0074,"Wunderink L, Nieboer R, Wiersma D, Sytema S, Nienhuis F. ",Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy, Schizophrenia Research ,2014,153,    ,['citation-journal']," Wunderink L, Nieboer R, Wiersma D, Sytema S, Nienhuis F. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy.  Schizophrenia Research 2014;153:S67. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/S0920-9964(14)70215-4', 'https://scholar.google.com/scholar_lookup?title=Recovery+in+remitted+first-episode+psychosis+at+7+years+of+follow-up+of+an+early+dose+reduction/discontinuation+or+maintenance+treatment+strategy+&author=L+Wunderink&author=R+Nieboer&author=D+Wiersma&author=S+Sytema&author=F+Nienhuis&publication_year=2014&hl=en']",,https://doi.org/10.1016/S0920-9964(14)70215-4, Wunderink 2007 {published data only}  ,included,CD014384-bbs2-0024,,23824214,,,3,,,23824214
CD014384-bib-0075,"Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. ",Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial, JAMA Psychiatry ,2013,70,    ,['citation-journal']," Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial.  JAMA Psychiatry 2013;70(9):913-20. CENTRAL [DOI: 10.1001/jamapsychiatry.2013.19]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1001/jamapsychiatry.2013.19', 'https://www.ncbi.nlm.nih.gov/pubmed/23824214', 'https://scholar.google.com/scholar_lookup?title=Recovery+in+remitted+first-episode+psychosis+at+7+years+of+follow-up+of+an+early+dose+reduction/discontinuation+or+maintenance+treatment+strategy:+long-term+follow-up+of+a+2-year+randomized+clinical+trial+&author=L+Wunderink&author=RM+Nieboer&author=D+Wiersma&author=S+Sytema&author=FJ+Nienhuis&publication_year=2013&hl=en']",23824214,https://doi.org/10.1001/jamapsychiatry.2013.19, Wunderink 2007 {published data only}  ,included,CD014384-bbs2-0024,,23824214,,23824214,543,https://doi.org/10.1001/jamapsychiatry.2013.19,,23824214
CD014384-bib-0076,"Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. ",Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial, JAMA Psychiatry ,2013,70,    ,['citation-journal']," Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial.  JAMA Psychiatry 2013;70(9):913-20. CENTRAL [DOI: 10.1001/jamapsychiatry.2013.19.]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1001/jamapsychiatry.2013.19', 'https://www.ncbi.nlm.nih.gov/pubmed/23824214', 'https://scholar.google.com/scholar_lookup?title=Recovery+in+remitted+first-episode+psychosis+at+7+years+of+follow-up+of+an+early+dose+reduction/discontinuation+or+maintenance+treatment+strategy:+long-term+follow-up+of+a+2-year+randomized+clinical+trial+&author=L+Wunderink&author=RM+Nieboer&author=D+Wiersma&author=S+Sytema&author=FJ+Nienhuis&publication_year=2013&hl=en']",23824214,https://doi.org/10.1001/jamapsychiatry.2013.19, Wunderink 2007 {published data only}  ,included,CD014384-bbs2-0024,,23824214,,23824214,543,https://doi.org/10.1001/jamapsychiatry.2013.19,,23824214
CD014384-bib-0077,"Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. ",Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy, Schizophrenia Research ,2014,153,    ,['citation-journal']," Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy.  Schizophrenia Research 2014;153:S67. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/S0920-9964(14)70215-4', 'https://scholar.google.com/scholar_lookup?title=Recovery+in+remitted+first-episode+psychosis+at+7+years+of+follow-up+of+an+early+dose+reduction/discontinuation+or+maintenance+treatment+strategy+&author=L+Wunderink&author=RM+Nieboer&author=D+Wiersma&author=S+Sytema&author=FJ+Nienhuis&publication_year=2014&hl=en']",,https://doi.org/10.1016/S0920-9964(14)70215-4, Wunderink 2007 {published data only}  ,included,CD014384-bbs2-0024,,23824214,,,3,,,23824214
CD014384-bib-0078,"Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. ",Recovery in remitted first episode psychosis at 7 years of follow-up of early guided discontinuation or maintenance treatment, Schizophrenia Bulletin ,2013,39,    ,['citation-journal']," Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first episode psychosis at 7 years of follow-up of early guided discontinuation or maintenance treatment.  Schizophrenia Bulletin 2013;39:S358. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Recovery+in+remitted+first+episode+psychosis+at+7+years+of+follow-up+of+early+guided+discontinuation+or+maintenance+treatment+&author=L+Wunderink&author=RM+Nieboer&author=D+Wiersma&author=S+Sytema&author=FJ+Nienhuis&publication_year=2013&hl=en']",,, Wunderink 2007 {published data only}  ,included,CD014384-bbs2-0024,,23824214,,,,,,23824214
CD014384-bib-0079,"Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. ",Recovery in remitted first episode psychosis at 7 years of follow-up of early guided discontinuation or maintenance treatment, Schizophrenia Bulletin ,2013,39,    ,['citation-journal']," Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first episode psychosis at 7 years of follow-up of early guided discontinuation or maintenance treatment.  Schizophrenia Bulletin 2013;39:S358. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Recovery+in+remitted+first+episode+psychosis+at+7+years+of+follow-up+of+early+guided+discontinuation+or+maintenance+treatment+&author=L+Wunderink&author=RM+Nieboer&author=D+Wiersma&author=S+Sytema&author=FJ+Nienhuis&publication_year=2013&hl=en']",,, Wunderink 2007 {published data only}  ,included,CD014384-bbs2-0024,,23824214,,,,,,23824214
CD014384-bib-0080,"Wunderink L, Nienhuis F, Sytema S, Wiersma D. ",Guided discontinuation trial versus maintenance treatment in remitted first episode psychosis: relapse rates and functional outcome, Early Intervention in Psychiatry ,2008,2,    ,['citation-journal']," Wunderink L, Nienhuis F, Sytema S, Wiersma D. Guided discontinuation trial versus maintenance treatment in remitted first episode psychosis: relapse rates and functional outcome.  Early Intervention in Psychiatry 2008;2(Suppl 1):A57. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Guided+discontinuation+trial+versus+maintenance+treatment+in+remitted+first+episode+psychosis:+relapse+rates+and+functional+outcome+&author=L+Wunderink&author=F+Nienhuis&author=S+Sytema&author=D+Wiersma&publication_year=2008&hl=en']",,, Wunderink 2007 {published data only}  ,included,CD014384-bbs2-0024,,17503973,,,,,,17503973
CD014384-bib-0081,"Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering H, Wiersma D. ",Guided discontinuation versus maintenance treatment in remitted first episode psychosis: relapse rates and functional outcome, Schizophrenia Bulletin ,2007,33,    ,['citation-journal']," Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering H, Wiersma D. Guided discontinuation versus maintenance treatment in remitted first episode psychosis: relapse rates and functional outcome.  Schizophrenia Bulletin 2007;33(2):466. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Guided+discontinuation+versus+maintenance+treatment+in+remitted+first+episode+psychosis:+relapse+rates+and+functional+outcome+&author=L+Wunderink&author=FJ+Nienhuis&author=S+Sytema&author=CJ+Slooff&author=H+Knegtering&author=D+Wiersma&publication_year=2007&hl=en']",,, Wunderink 2007 {published data only}  ,included,CD014384-bbs2-0024,,,17503973,,,,,17503973
CD014384-bib-0082,"Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. ",Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome, Journal of Clinical Psychiatry ,2007,68,    ,['citation-journal']," Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome.  Journal of Clinical Psychiatry 2007;68(5):654-61. CENTRAL [DOI: 10.4088/jcp.v68n0502]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4088/JCP.v68n0502', 'https://www.ncbi.nlm.nih.gov/pubmed/17503973', 'https://scholar.google.com/scholar_lookup?title=Guided+discontinuation+versus+maintenance+treatment+in+remitted+first-episode+psychosis:+relapse+rates+and+functional+outcome+&author=L+Wunderink&author=FJ+Nienhuis&author=S+Sytema&author=CJ+Slooff&author=R+Knegtering&author=D+Wiersma&publication_year=2007&hl=en']",17503973,https://doi.org/10.4088/JCP.v68n0502, Wunderink 2007 {published data only}  ,included,CD014384-bbs2-0024,,17503973,17503973,,136,,,17503973
CD014384-bib-0083,"Wunderink L, Nienhuis FJ, Wiersma D, Van den Bosch RJ, Bruggeman R, Faber G, et al. ","Medication strategies in first onset schizophrenia: a randomized trial of effectiveness of short versus sustained antipsychotic treatment and quality of life in first episode psychosis preliminary findings: incidence, compliance and early course", Schizophrenia Research ,2003,60,    ,['citation-journal']," Wunderink L, Nienhuis FJ, Wiersma D, Van den Bosch RJ, Bruggeman R, Faber G, et al. Medication strategies in first onset schizophrenia: a randomized trial of effectiveness of short versus sustained antipsychotic treatment and quality of life in first episode psychosis preliminary findings: incidence, compliance and early course.  Schizophrenia Research 2003;60:307. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/S0920-9964(03)80238-4', 'https://scholar.google.com/scholar_lookup?title=Medication+strategies+in+first+onset+schizophrenia:+a+randomized+trial+of+effectiveness+of+short+versus+sustained+antipsychotic+treatment+and+quality+of+life+in+first+episode+psychosis+preliminary+findings:+incidence,+compliance+and+early+course+&author=L+Wunderink&author=FJ+Nienhuis&author=D+Wiersma&author=RJ+VandenBosch&author=R+Bruggeman&author=G+Faber&publication_year=2003&hl=en']",,https://doi.org/10.1016/S0920-9964(03)80238-4, Wunderink 2007 {published data only}  ,included,CD014384-bbs2-0024,,,,,3,,,
CD014384-bib-0084,"Wunderink L, Sytema S, Wiersma D. ",Discontinuation challenge in remitted first episode psychosis: relapse rates and functional outcome compared with maintenance treatment,,2009,,    ,['citation-other']," Wunderink L, Sytema S, Wiersma D. Discontinuation challenge in remitted first episode psychosis: relapse rates and functional outcome compared with maintenance treatment. In: 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15-18; Barcelona, Spain. 2009. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Discontinuation+challenge+in+remitted+first+episode+psychosis:+relapse+rates+and+functional+outcome+compared+with+maintenance+treatment+&author=L+Wunderink&author=S+Sytema&author=D+Wiersma&publication_year=2009&hl=en']",,, Wunderink 2007 {published data only}  ,included,CD014384-bbs2-0024,,,,,,,,
CD014384-bib-0085,"Wunderink L, van Bebber J, Sytema S, Boonstra N, Meijer RR, Wigman JTW. ","Negative symptoms predict high relapse rates and both predict less favorable functional outcome in first episode psychosis, independent of treatment strategy", Schizophrenia Research ,2020,216,    ,['citation-journal']," Wunderink L, van Bebber J, Sytema S, Boonstra N, Meijer RR, Wigman JTW. Negative symptoms predict high relapse rates and both predict less favorable functional outcome in first episode psychosis, independent of treatment strategy.  Schizophrenia Research 2020;216:192-9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.schres.2019.12.001', 'https://www.ncbi.nlm.nih.gov/pubmed/31866076', 'https://scholar.google.com/scholar_lookup?title=Negative+symptoms+predict+high+relapse+rates+and+both+predict+less+favorable+functional+outcome+in+first+episode+psychosis,+independent+of+treatment+strategy+&author=L+Wunderink&author=J+Bebber&author=S+Sytema&author=N+Boonstra&author=RR+Meijer&author=JTW+Wigman&publication_year=2020&hl=en']",31866076,https://doi.org/10.1016/j.schres.2019.12.001, Wunderink 2007 {published data only}  ,included,CD014384-bbs2-0024,,33279373,,31866076,21,https://pure.rug.nl/ws/files/112043808/Negative_symptoms_predict_high_relapse_rates_and_both_predict_less_favorable_functional_outcome_in_first_episode_psychosis_independent_of_treatment_strategy_Elsevier_Enhanced_Reader.pdf,,31866076
CD014384-bib-0086,ChiCTR-POC-15006642. ,Follow-up study of the risk of relapse and the function after reducing high doses risperidone maintenance treatment in patient with schizophrenia,,,,   ,['citation-other'], ChiCTR-POC-15006642. Follow-up study of the risk of relapse and the function after reducing high doses risperidone maintenance treatment in patient with schizophrenia. apps.who.int/trialsearch/Trial.aspx?TrialID=ChiCTR-POC-15006642 (first received 24 June 2015). CENTRAL    ,[''],,, Zhou 2018 {published data only}  ,included,CD014384-bbs2-0025,,,,,,,,
CD014384-bib-0087,"Zhou Y, Li G, Li D, Cui H, Ning Y. ","Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: a single-blinded, 52-week, randomized controlled study", Journal of Psychopharmacology ,2018,32,    ,['citation-journal']," Zhou Y, Li G, Li D, Cui H, Ning Y. Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: a single-blinded, 52-week, randomized controlled study.  Journal of Psychopharmacology 2018;32(5):524-32. CENTRAL [DOI: 10.1177/0269881118756062]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1177/0269881118756062', 'https://www.ncbi.nlm.nih.gov/pubmed/29493377', 'https://scholar.google.com/scholar_lookup?title=Dose+reduction+of+risperidone+and+olanzapine+can+improve+cognitive+function+and+negative+symptoms+in+stable+schizophrenic+patients:+a+single-blinded,+52-week,+randomized+controlled+study+&author=Y+Zhou&author=G+Li&author=D+Li&author=H+Cui&author=Y+Ning&publication_year=2018&hl=en']",29493377,https://doi.org/10.1177/0269881118756062, Zhou 2018 {published data only}  ,included,CD014384-bbs2-0025,,,29493377,29493377,43,https://journals.sagepub.com/doi/pdf/10.1177/0269881118756062,,29493377
CD014384-bib-0088,"Arato M, O'Connor R, Meltzer HY, ZEUS Study Group. ","A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study", International Clinical Psychopharmacology ,2002,17,    ,['citation-journal']," Arato M, O'Connor R, Meltzer HY, ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study.  International Clinical Psychopharmacology 2002;17(5):207-15. CENTRAL [DOI: 10.1097/00004850-200209000-00001]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/00004850-200209000-00001', 'https://www.ncbi.nlm.nih.gov/pubmed/12177583', ""https://scholar.google.com/scholar_lookup?title=A+1-year,+double-blind,+placebo-controlled+trial+of+ziprasidone+40,+80+and+160+mg/day+in+chronic+schizophrenia:+the+Ziprasidone+Extended+Use+in+Schizophrenia+(ZEUS)+study+&author=M+Arato&author=R+O'Connor&author=HY+Meltzer&publication_year=2002&hl=en""]",12177583,https://doi.org/10.1097/00004850-200209000-00001, Arato 2002 {published data only}  ,excluded,CD014384-bbs2-0026, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction ,,12177583,12177583,179,,,12177583
CD014384-bib-0089,AstraZeneca. ,"RAPID - an open-label, randomised, multicentre phase IIIb study to evaluate the efficacy and tolerability of quetiapine IR (immediate release), over 14 days, in acute schizophrenia / schizoaffective disorder (rapid versus conventional titration)",,,,   ,['citation-other']," AstraZeneca. RAPID - an open-label, randomised, multicentre phase IIIb study to evaluate the efficacy and tolerability of quetiapine IR (immediate release), over 14 days, in acute schizophrenia / schizoaffective disorder (rapid versus conventional titration). clinicaltrials.gov/ct2/show/NCT00803101 (first received 5 December 2008). CENTRAL    ",[''],,, AstraZeneca 2007 {published data only}  ,excluded,CD014384-bbs2-0027, Design: randomised Participants: not stable ,,,,,,,
CD014384-bib-0090,"Baker RW, Kinon BJ, Liu H, Richey A, Hill AL, Bergstrom RF, et al. ",Effectiveness of rapid initial dose escalation of oral olanzapine for acute agitation, Schizophrenia Research ,2002,53,    ,['citation-journal']," Baker RW, Kinon BJ, Liu H, Richey A, Hill AL, Bergstrom RF, et al. Effectiveness of rapid initial dose escalation of oral olanzapine for acute agitation.  Schizophrenia Research 2002;53(Suppl 1):193. CENTRAL [DOI: 10.1016/S0920-9964(01)00381-4]    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effectiveness+of+rapid+initial+dose+escalation+of+oral+olanzapine+for+acute+agitation&author=RW+Baker&author=BJ+Kinon&author=H+Liu&author=A+Richey&author=AL+Hill&author=RF+Bergstrom&publication_year=2002&hl=en']",,, Baker 2002 {published data only}  ,excluded,CD014384-bbs2-0028, Design: randomised Participants: not stable ,,,,,,,
CD014384-bib-0091,"Baker RW, Kinon BJ, Liu H, Richey A, Hill AL, Bergstrom RF, et al . ",Effectiveness of rapid initial dose escalation of oral olanzapine for acute agitation , Schizophrenia Research ,2003,60,    ,['citation-journal']," Baker RW, Kinon BJ, Liu H, Richey A, Hill AL, Bergstrom RF, et al . Effectiveness of rapid initial dose escalation of oral olanzapine for acute agitation .  Schizophrenia Research 2003;60(Suppl 1):272. CENTRAL [DOI: 10.1016/S0920-9964(03)80427-9]    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/S0920-9964(03)80427-9', 'https://scholar.google.com/scholar_lookup?title=Effectiveness+of+rapid+initial+dose+escalation+of+oral+olanzapine+for+acute+agitation\xa0&author=RW+Baker&author=BJ+Kinon&author=H+Liu&author=A+Richey&author=AL+Hill&author=RF+Bergstrom&publication_year=2003&hl=en']",,https://doi.org/10.1016/S0920-9964(03)80427-9, Baker 2002 {published data only}  ,excluded,CD014384-bbs2-0028, Design: randomised Participants: not stable ,,,,7,,,
CD014384-bib-0092,"Baker RW, Kinon BJ, Maguire GA, Liu H, Hill AL. ",Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation, Journal of Clinical Psychopharmacology ,2003,23,    ,['citation-journal']," Baker RW, Kinon BJ, Maguire GA, Liu H, Hill AL. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation.  Journal of Clinical Psychopharmacology 2003;23(4):342-8. CENTRAL [DOI: 10.1097/01.jcp.0000085406.08426.a8]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/01.jcp.0000085406.08426.a8', 'https://www.ncbi.nlm.nih.gov/pubmed/12920409', 'https://scholar.google.com/scholar_lookup?title=Effectiveness+of+rapid+initial+dose+escalation+of+up+to+forty+milligrams+per+day+of+oral+olanzapine+in+acute+agitation+&author=RW+Baker&author=BJ+Kinon&author=GA+Maguire&author=H+Liu&author=AL+Hill&publication_year=2003&hl=en']",12920409,https://doi.org/10.1097/01.jcp.0000085406.08426.a8, Baker 2002 {published data only}  ,excluded,CD014384-bbs2-0028, Design: randomised Participants: not stable ,12920409,12920409,12920409,90,,,12920409
CD014384-bib-0093,Bogers 2018. ,"A double blind study to compare the switch of long-stay stabilized patients with schizophrenia or schizoaffective disorder to ziprasidone with low-dose conventional antipsychotics; followed by an open, prospective study to compare ziprasidone to clozapine",,,,   ,['citation-other']," Bogers 2018. A double blind study to compare the switch of long-stay stabilized patients with schizophrenia or schizoaffective disorder to ziprasidone with low-dose conventional antipsychotics; followed by an open, prospective study to compare ziprasidone to clozapine. www.trialregister.nl/trial/5711. CENTRAL    ",[''],,, Bogers 2018 {published data only}  ,excluded,CD014384-bbs2-0029, Design: randomised Participants: not stable ,,,,,,,
CD014384-bib-0094,"Bogers J, Schulte R, Broekman TG, Moleman P, de Haan L. ",Dose reduction of high-dose ﬁrst-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: a 1-year double-blind randomized clinical trial, European Neuropsychopharmacology ,2018,28,    ,['citation-journal']," Bogers J, Schulte R, Broekman TG, Moleman P, de Haan L. Dose reduction of high-dose ﬁrst-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: a 1-year double-blind randomized clinical trial.  European Neuropsychopharmacology 2018;28(9):1024-34. CENTRAL [DOI: 10.1016/j.euroneuro.2018.06.005]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.euroneuro.2018.06.005', 'https://www.ncbi.nlm.nih.gov/pubmed/30025751', 'https://scholar.google.com/scholar_lookup?title=Dose+reduction+of+high-dose+ﬁrst-generation+antipsychotics+or+switch+to+ziprasidone+in+long-stay+patients+with+schizophrenia:+a+1-year+double-blind+randomized+clinical+trial+&author=J+Bogers&author=R+Schulte&author=TG+Broekman&author=P+Moleman&author=L+Haan&publication_year=2018&hl=en']",30025751,https://doi.org/10.1016/j.euroneuro.2018.06.005, Bogers 2018 {published data only}  ,excluded,CD014384-bbs2-0029, Design: randomised Participants: not stable ,,,30025751,11,,,30025751
CD014384-bib-0095,"Bogers J, Schulte R, Theo B, de Haan L. ",Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: a 1-year double-blind randomized clinical trial, Abstracts for the Sixth Biennial SIRS Conference ,2018,44 (S1),    ,['citation-journal']," Bogers J, Schulte R, Theo B, de Haan L. Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: a 1-year double-blind randomized clinical trial.  Abstracts for the Sixth Biennial SIRS Conference 2018;44 (S1):S239. CENTRAL [DOI: 10.1093/schbul/sby017.584]    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Dose+reduction+of+high-dose+first-generation+antipsychotics+or+switch+to+ziprasidone+in+long-stay+patients+with+schizophrenia:+a+1-year+double-blind+randomized+clinical+trial+&author=J+Bogers&author=R+Schulte&author=B+Theo&author=L+Haan&publication_year=2018&hl=en']",,, Bogers 2018 {published data only}  ,excluded,CD014384-bbs2-0029, Design: randomised Participants: not stable ,,,,,,,
CD014384-bib-0096,Caffey EM. ,An evaluation of the treatment of drug-induced extrapyramidal symptoms,,1971,,    ,['citation-other'], Caffey EM. An evaluation of the treatment of drug-induced extrapyramidal symptoms. In: 5th World Congress of Psychiatry; 1971 Nov 28-Dec 4; Mexico City. 1971:225-6. CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=An+evaluation+of+the+treatment+of+drug-induced+extrapyramidal+symptoms&author=EM+Caffey&publication_year=1971&hl=en']",,, Caffey 1971 {published data only}  ,excluded,CD014384-bbs2-0030, Design: randomised Participants: not stable Intervention: no dose reduction ,,,,,,,
CD014384-bib-0097,"Dellva MA, Tran P, Tollefson GD, Wentley AL, Beasley CM Jr. ",Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia, Psychiatric Services ,1997,48,    ,['citation-journal']," Dellva MA, Tran P, Tollefson GD, Wentley AL, Beasley CM Jr. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.  Psychiatric Services 1997;48(12):1571-7. CENTRAL [DOI: 10.1176/ps.48.12.1571]    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/9406266', 'https://scholar.google.com/scholar_lookup?title=Standard+olanzapine+versus+placebo+and+ineffective-dose+olanzapine+in+the+maintenance+treatment+of+schizophrenia+&author=MA+Dellva&author=P+Tran&author=GD+Tollefson&author=AL+Wentley&publication_year=1997&hl=en']",9406266,, Dellva 1997 {published data only}  ,excluded,CD014384-bbs2-0031, Design: randomised Participants: not stable Intervention: no dose reduction; study evaluated standard versus low dose ,9406266,9406266,,,,,9406266
CD014384-bib-0098,"Durgam S, Landbloom RP, Mackle M, Wu X, Mathews M, Nasrallah HA. ","Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study", Neuropsychiatric Disease and Treatment ,2017,13,    ,['citation-journal']," Durgam S, Landbloom RP, Mackle M, Wu X, Mathews M, Nasrallah HA. Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study.  Neuropsychiatric Disease and Treatment 2017;13:2021-35. CENTRAL [DOI: 10.2147/NDT.S130211]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2147/NDT.S130211', 'https://www.ncbi.nlm.nih.gov/pubmed/28814871', 'https://scholar.google.com/scholar_lookup?title=Exploring+the+long-term+safety+of+asenapine+in+adults+with+schizophrenia+in+a+double-blind,+fixed-dose,+extension+study+&author=S+Durgam&author=RP+Landbloom&author=M+Mackle&author=X+Wu&author=M+Mathews&author=HA+Nasrallah&publication_year=2017&hl=en']",28814871,https://doi.org/10.2147/NDT.S130211, Durgam 2017 {published data only}  ,excluded,CD014384-bbs2-0032, Design: randomised Participants: not stable Intervention: no dose reduction; study evaluated standard versus low dose ,,,28814871,9,https://www.dovepress.com/getfile.php?fileID=37718,,28814871
CD014384-bib-0099,Eli Lilly and Company. ,A fixed-dose range safety and efficacy study of olanzapine versus haloperidol in the treatment of schizophrenia,,,,   ,['citation-other'], Eli Lilly and Company. A fixed-dose range safety and efficacy study of olanzapine versus haloperidol in the treatment of schizophrenia. assets.ctfassets.net/hadumfdtzsru/1GdsS40cIYEEqyUOWKGmsi/a23a6fa3d5560dc1d34683661bcfe29a/Olanzapine-F1D-EW-E003.pdf. CENTRAL    ,[''],,, Eli‐Lilly F1D‐EW‐E003 1997 {unpublished data only}  ,excluded,CD014384-bbs2-0033, Design: randomised Participants: not stable Intervention: no dose reduction; study evaluated standard versus low dose ,,,,,,,
CD014384-bib-0100,Eli Lilly and Company. ,Olanzapine versus placebo and haloperidol in the treatment of schizophrenia,,,,   ,['citation-other'], Eli Lilly and Company. Olanzapine versus placebo and haloperidol in the treatment of schizophrenia. assets.ctfassets.net/hadumfdtzsru/1vEkFeR3isUCwQeMi2MyOi/7286a8a03eb6520dd610750d9ba92b66/Olanzapine-F1D-MC-HGAD.pdf. CENTRAL    ,[''],,, Eli‐Lilly F1D‐MC‐HGAD 1997 {unpublished data only}  ,excluded,CD014384-bbs2-0034, Design: randomised Participants: not stable Intervention: no dose reduction; study evaluated standard versus low dose ,24242360,,,,,,24242360
CD014384-bib-0101,European Medicines Agency. ,Abilify H-C-471; European Public Assessment Report; Scientific discussion,,,,   ,['citation-other'], European Medicines Agency. Abilify H-C-471; European Public Assessment Report; Scientific discussion. www.ema.europa.eu/en/documents/scientific-discussion/abilify-epar-scientific-discussion_en.pdf (accessed prior to 29 October 2022). CENTRAL    ,[''],,, European Medicines Agency 2007 {published data only}  ,excluded,CD014384-bbs2-0035, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction ,,,,,,,
CD014384-bib-0102,"Faber G, Smid HG, Van Gool AR, Wunderink L, Van Den Bosch RJ, Wiersma D. ","Continued cannabis use and outcome in first-episode psychosis: data from a randomized, open-label, controlled trial", Journal of Clinical Psychiatry ,2012,73,    ,['citation-journal']," Faber G, Smid HG, Van Gool AR, Wunderink L, Van Den Bosch RJ, Wiersma D. Continued cannabis use and outcome in first-episode psychosis: data from a randomized, open-label, controlled trial.  Journal of Clinical Psychiatry 2012;73(5):632-8. CENTRAL [DOI: 10.4088/JCP.11m07069]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4088/JCP.11m07069', 'https://www.ncbi.nlm.nih.gov/pubmed/22394457', 'https://scholar.google.com/scholar_lookup?title=Continued+cannabis+use+and+outcome+in+first-episode+psychosis:+data+from+a+randomized,+open-label,+controlled+trial+&author=G+Faber&author=HG+Smid&author=AR+VanGool&author=L+Wunderink&author=RJ+VanDenBosch&author=D+Wiersma&publication_year=2012&hl=en']",22394457,https://doi.org/10.4088/JCP.11m07069, Faber 2012 {published data only}  ,excluded,CD014384-bbs2-0036, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction ,22394457,22394457,22394457,43,,,22394457
CD014384-bib-0103,"Goldstein MJ, Rodnick EH, Evans JR, May PR, Steinberg MR. ",Drug and family therapy in the aftercare of acute schizophrenics, Archives of General Psychiatry ,1978,35,    ,['citation-journal']," Goldstein MJ, Rodnick EH, Evans JR, May PR, Steinberg MR. Drug and family therapy in the aftercare of acute schizophrenics.  Archives of General Psychiatry 1978;35(10):1169–77. CENTRAL [DOI: 10.1001/archpsyc.1978.01770340019001]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1001/archpsyc.1978.01770340019001', 'https://www.ncbi.nlm.nih.gov/pubmed/211983', 'https://scholar.google.com/scholar_lookup?title=Drug+and+family+therapy+in+the+aftercare+of+acute+schizophrenics&author=MJ+Goldstein&author=EH+Rodnick&author=JR+Evans&author=PR+May&author=MR+Steinberg&publication_year=1978&hl=en']",211983,https://doi.org/10.1001/archpsyc.1978.01770340019001, Goldstein 1978 {published data only}  ,excluded,CD014384-bbs2-0037, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction ,211983,,211983,485,,,211983
CD014384-bib-0104,"Harris MJ, Heaton RK, Schalz A, Bailey A, Patterson TL. ",Neuroleptic dose reduction in older psychotic patients, Schizophrenia Research ,1997,27,    ,['citation-journal']," Harris MJ, Heaton RK, Schalz A, Bailey A, Patterson TL. Neuroleptic dose reduction in older psychotic patients.  Schizophrenia Research 1997;27(2-3):241-8. CENTRAL [DOI: 10.1016/S0920-9964(97)00083-2]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0920-9964(97)00083-2', 'https://www.ncbi.nlm.nih.gov/pubmed/9416653', 'https://scholar.google.com/scholar_lookup?title=Neuroleptic+dose+reduction+in+older+psychotic+patients&author=MJ+Harris&author=RK+Heaton&author=A+Schalz&author=A+Bailey&author=TL+Patterson&publication_year=1997&hl=en']",9416653,https://doi.org/10.1016/S0920-9964(97)00083-2, Harris 1997 {published data only}  ,excluded,CD014384-bbs2-0038, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction ,9416653,,9416653,22,,,9416653
CD014384-bib-0105,"Harris MJ, Paulsen JS, Lacro JoP, Rockwell E, Jeste DV. ",Neuroleptic maintenance treatment in the elderly,,1997,,    ,['citation-other']," Harris MJ, Paulsen JS, Lacro JoP, Rockwell E, Jeste DV. Neuroleptic maintenance treatment in the elderly. In: 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, California, USA. 1997. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Neuroleptic+maintenance+treatment+in+the+elderly&author=MJ+Harris&author=JS+Paulsen&author=E+Rockwell&author=DV+Jeste&publication_year=1997&hl=en']",,, Harris 1997 {published data only}  ,excluded,CD014384-bbs2-0038, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction ,,,,,,,
CD014384-bib-0106,"Hirschowitz J, Hitzemann R, Piscani K, Burr G, Frecska E, Culliton D, et al. ",The dose reduction in schizophrenia (DORIS) study: a final report, Schizophrenia Research ,1997,23,    ,['citation-journal']," Hirschowitz J, Hitzemann R, Piscani K, Burr G, Frecska E, Culliton D, et al. The dose reduction in schizophrenia (DORIS) study: a final report.  Schizophrenia Research 1997;23(1):31-43. CENTRAL [DOI: 10.1016/S0920-9964(96)00074-6]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0920-9964(96)00074-6', 'https://www.ncbi.nlm.nih.gov/pubmed/9050126', 'https://scholar.google.com/scholar_lookup?title=The+dose+reduction+in+schizophrenia+(DORIS)+study:+a+final+report&author=J+Hirschowitz&author=R+Hitzemann&author=K+Piscani&author=G+Burr&author=E+Frecska&author=D+Culliton&publication_year=1997&hl=en']",9050126,https://doi.org/10.1016/S0920-9964(96)00074-6, Hirschowitz 1997 {published data only}  ,excluded,CD014384-bbs2-0039, Design: randomised Participants: stable individuals with schizophrenia Intervention: dose reduction Comparator: no dose maintenance ,,9050126,9050126,6,,,9050126
CD014384-bib-0107,"Hsiao CC, Chen KP, Tsai CJ, Wang LJ, Chen CK, Lin SK. ",Rapid initiation of quetiapine well tolerated as compared with the conventional initiation regimen in patients with schizophrenia or schizoaffective disorders, Kaohsiung Journal of Medical Sciences ,2011,27,    ,['citation-journal']," Hsiao CC, Chen KP, Tsai CJ, Wang LJ, Chen CK, Lin SK. Rapid initiation of quetiapine well tolerated as compared with the conventional initiation regimen in patients with schizophrenia or schizoaffective disorders.  Kaohsiung Journal of Medical Sciences 2011;27(11):508-13. CENTRAL [DOI: 10.1016/j.kjms.2011.06.014]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.kjms.2011.06.014', 'https://www.ncbi.nlm.nih.gov/pubmed/22005160', 'https://scholar.google.com/scholar_lookup?title=Rapid+initiation+of+quetiapine+well+tolerated+as+compared+with+the+conventional+initiation+regimen+in+patients+with+schizophrenia+or+schizoaffective+disorders+&author=CC+Hsiao&author=KP+Chen&author=CJ+Tsai&author=LJ+Wang&author=CK+Chen&author=SK+Lin&publication_year=2011&hl=en']",22005160,https://doi.org/10.1016/j.kjms.2011.06.014, Hsiao 2011 {published data only}  ,excluded,CD014384-bbs2-0040, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction ,22005160,,22005160,9,https://onlinelibrary.wiley.com/doi/pdfdirect/10.1016/j.kjms.2011.06.014,,22005160
CD014384-bib-0108,"Huttunen MO, Tuhkanen H, Haavisto E, Nyholm R, Pitkänen M, Raitasuo V, et al. ",Low- and standard-dose depot haloperidol combined with targeted oral neuroleptics, Psychiatric Services ,1996,47,    ,['citation-journal']," Huttunen MO, Tuhkanen H, Haavisto E, Nyholm R, Pitkänen M, Raitasuo V, et al. Low- and standard-dose depot haloperidol combined with targeted oral neuroleptics.  Psychiatric Services 1996;47(1):83-5. CENTRAL [DOI: 10.1176/ps.47.1.83]    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/8925352', 'https://scholar.google.com/scholar_lookup?title=Low-+and+standard-dose+depot+haloperidol+combined+with+targeted+oral+neuroleptics&author=MO+Huttunen&author=H+Tuhkanen&author=E+Haavisto&author=R+Nyholm&author=M+Pitkänen&author=V+Raitasuo&publication_year=1996&hl=en']",8925352,, Huttunen 1996 {published data only}  ,excluded,CD014384-bbs2-0041, Design: randomised Participants: stable individuals with schizophrenia Intervention: starting dose not clear; likely standard versus low dose ,,8925352,,,,,8925352
CD014384-bib-0109,"Inderbitzin LB, Lewine R, Scheller-Gilkey G. ",Most effective dose study (meds): a double-blind reduction trial of fluphenazine decanoate, Schizophrenia Research ,1993,9,    ,['citation-journal']," Inderbitzin LB, Lewine R, Scheller-Gilkey G. Most effective dose study (meds): a double-blind reduction trial of fluphenazine decanoate.  Schizophrenia Research 1993;9:238-9. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/0920-9964(93)90531-M', 'https://scholar.google.com/scholar_lookup?title=Most+effective+dose+study+(meds):+a+double-blind+reduction+trial+of+fluphenazine+decanoate&author=LB+Inderbitzin&author=R+Lewine&author=G+Scheller-Gilkey&publication_year=1993&hl=en']",,https://doi.org/10.1016/0920-9964(93)90531-M, Inderbitzin 1994 {published data only}  ,excluded,CD014384-bbs2-0042, Design: not randomised ,,,,2,,,
CD014384-bib-0110,"Inderbitzin LB, Lewine RR, Scheller-Gilkey G, Swofford CD, Egan GJ, Gloersen BA, et al. ","A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients", American Journal of Psychiatry ,1994,151,    ,['citation-journal']," Inderbitzin LB, Lewine RR, Scheller-Gilkey G, Swofford CD, Egan GJ, Gloersen BA, et al. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.  American Journal of Psychiatry 1994;151(12):1753-9. CENTRAL [DOI: 10.1176/ajp.151.12.1753]    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/7977881', 'https://scholar.google.com/scholar_lookup?title=A+double-blind+dose-reduction+trial+of+fluphenazine+decanoate+for+chronic,+unstable+schizophrenic+patients+&author=LB+Inderbitzin&author=RR+Lewine&author=G+Scheller-Gilkey&author=CD+Swofford&author=GJ+Egan&author=BA+Gloersen&publication_year=1994&hl=en']",7977881,, Inderbitzin 1994 {published data only}  ,excluded,CD014384-bbs2-0042, Design: not randomised ,,7977881,,,,,7977881
CD014384-bib-0111,"Kalachnik JE, Harder SR, Kidd-Nielsen P, Errickson E, Doebler M, Sprague RL. ","Persistent tardive dyskinesia in randomly assigned neuroleptic reduction, neuroleptic nonreduction, and no-neuroleptic history groups: preliminary results", Psychopharmacology Bulletin ,1984,20,    ,['citation-journal']," Kalachnik JE, Harder SR, Kidd-Nielsen P, Errickson E, Doebler M, Sprague RL. Persistent tardive dyskinesia in randomly assigned neuroleptic reduction, neuroleptic nonreduction, and no-neuroleptic history groups: preliminary results.  Psychopharmacology Bulletin 1984;20(1):27-32. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/6144132', 'https://scholar.google.com/scholar_lookup?title=Persistent+tardive+dyskinesia+in+randomly+assigned+neuroleptic+reduction,+neuroleptic+nonreduction,+and+no-neuroleptic+history+groups:+preliminary+results+&author=JE+Kalachnik&author=SR+Harder&author=P+Kidd-Nielsen&author=E+Errickson&author=M+Doebler&author=RL+Sprague&publication_year=1984&hl=en']",6144132,, Kalachnik 1984 {published data only}  ,excluded,CD014384-bbs2-0043, Design: randomised Participants: no schizophrenia ,6144132,6144132,,,,,6144132
CD014384-bib-0112,"Kane JM, Rifkin A, Quitkin F, Nayak D, Saraf K, Ramos-Lorenzi JR, et al. ",Low dose fluphenazine decanoate in maintenance treatment of schizophrenia, Psychiatry Research ,1979,1,    ,['citation-journal']," Kane JM, Rifkin A, Quitkin F, Nayak D, Saraf K, Ramos-Lorenzi JR, et al. Low dose fluphenazine decanoate in maintenance treatment of schizophrenia.  Psychiatry Research 1979;1(3):341–8. CENTRAL [DOI: 10.1016/0165-1781(79)90016-7]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/0165-1781(79)90016-7', 'https://www.ncbi.nlm.nih.gov/pubmed/233160', 'https://scholar.google.com/scholar_lookup?title=Low+dose+fluphenazine+decanoate+in+maintenance+treatment+of+schizophrenia&author=JM+Kane&author=A+Rifkin&author=F+Quitkin&author=D+Nayak&author=K+Saraf&author=JR+Ramos-Lorenzi&publication_year=1979&hl=en']",233160,https://doi.org/10.1016/0165-1781(79)90016-7, Kane 1979 {published data only}  ,excluded,CD014384-bbs2-0044, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction ,,,233160,46,,,233160
CD014384-bib-0113,"Kane JM, Davis JM, Schooler N, Marder S, Casey D, Brauzer B, et al. ",A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia, American Journal of Psychiatry ,2002,159,    ,['citation-journal']," Kane JM, Davis JM, Schooler N, Marder S, Casey D, Brauzer B, et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia.  American Journal of Psychiatry 2002;159(4):554-60. CENTRAL [DOI: 10.1176/appi.ajp.159.4.554]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1176/appi.ajp.159.4.554', 'https://www.ncbi.nlm.nih.gov/pubmed/11925292', 'https://scholar.google.com/scholar_lookup?title=A+multidose+study+of+haloperidol+decanoate+in+the+maintenance+treatment+of+schizophrenia&author=JM+Kane&author=JM+Davis&author=N+Schooler&author=S+Marder&author=D+Casey&author=B+Brauzer&publication_year=2002&hl=en']",11925292,https://doi.org/10.1176/appi.ajp.159.4.554, Kane 2002 {published data only}  ,excluded,CD014384-bbs2-0045, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction; study evaluated standard versus low dose ,,11925292,11925292,68,,,11925292
CD014384-bib-0114,"Khazaie H, Shakeri J. ",Comparative efficacy of every 2 weeks versus every 6 weeks injections of fluphenazine decanoate, Archives of Iranian Medicine ,2005,8,    ,['citation-journal']," Khazaie H, Shakeri J. Comparative efficacy of every 2 weeks versus every 6 weeks injections of fluphenazine decanoate.  Archives of Iranian Medicine 2005;8(2):109-14. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Comparative+efficacy+of+every+2+weeks+versus+every+6+weeks+injections+of+fluphenazine+decanoate+&author=H+Khazaie&author=J+Shakeri&publication_year=2005&hl=en']",,, Khazaie 2005 {published data only}  ,excluded,CD014384-bbs2-0046," Design: concerns related to the data. Study is almost identical to Carpenter 1999 (included), and we had serious concerns that it was a fraudulent trial (e.g. the calculated Chi2 from 2 x 2 table on gender in Khazaie 2005 is different from the reported one (1.59 vs 3.59). The reported one is similar to the Carpenter 1999 one (3.59 vs 3.57), and this issue applied to all reported data).  ",,,,,,,
CD014384-bib-0115,"Kinon B, Stauffer VL, Wang L, Thi KT, Kollack-Walker S. ",Olanzapine improves tardive dyskinesia in patients with schizophrenia in a controlled prospective study, International Journal of Neuropsychopharmacology ,2002,5,    ,['citation-journal']," Kinon B, Stauffer VL, Wang L, Thi KT, Kollack-Walker S. Olanzapine improves tardive dyskinesia in patients with schizophrenia in a controlled prospective study.  International Journal of Neuropsychopharmacology 2002;5(Suppl 1):S165. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/S0924-977X(02)80332-7', 'https://scholar.google.com/scholar_lookup?title=Olanzapine+improves+tardive+dyskinesia+in+patients+with+schizophrenia+in+a+controlled+prospective+study+&author=B+Kinon&author=VL+Stauffer&author=L+Wang&author=KT+Thi&author=S+Kollack-Walker&publication_year=2002&hl=en']",,https://doi.org/10.1016/S0924-977X(02)80332-7, Kinon 2004 {published data only}  ,excluded,CD014384-bbs2-0047, Design: randomised Participants: insufficient description of stability ,,,,4,,,
CD014384-bib-0116,"Kinon BJ, Jeste DV, Kollack-Walker S, Stauffer V, Liu-Seifert H. ",Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods, Progress in Neuro-Psychopharmacology and Biological Psychiatry ,2004,28,    ,['citation-journal']," Kinon BJ, Jeste DV, Kollack-Walker S, Stauffer V, Liu-Seifert H. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods.  Progress in Neuro-Psychopharmacology and Biological Psychiatry 2004;28(6):985-96. CENTRAL [DOI: 10.1016/j.pnpbp.2004.05.016]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.pnpbp.2004.05.016', 'https://www.ncbi.nlm.nih.gov/pubmed/15380859', 'https://scholar.google.com/scholar_lookup?title=Olanzapine+treatment+for+tardive+dyskinesia+in+schizophrenia+patients:+a+prospective+clinical+trial+with+patients+randomized+to+blinded+dose+reduction+periods+&author=BJ+Kinon&author=DV+Jeste&author=S+Kollack-Walker&author=V+Stauffer&author=H+Liu-Seifert&publication_year=2004&hl=en']",15380859,https://doi.org/10.1016/j.pnpbp.2004.05.016, Kinon 2004 {published data only}  ,excluded,CD014384-bbs2-0047, Design: randomised Participants: insufficient description of stability ,15380859,15380859,15380859,48,,,15380859
CD014384-bib-0117,"Kinon BJ, Stauffer VL, Wang L, Thi KT. ",Olanzapine improves tardive dyskinesia in patients with schizophrenia,,2002,,    ,['citation-other']," Kinon BJ, Stauffer VL, Wang L, Thi KT. Olanzapine improves tardive dyskinesia in patients with schizophrenia. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia. 2002. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Olanzapine+improves+tardive+dyskinesia+in+patients+with+schizophrenia&author=BJ+Kinon&author=VL+Stauffer&author=L+Wang&author=KT+Thi&publication_year=2002&hl=en']",,, Kinon 2004 {published data only}  ,excluded,CD014384-bbs2-0047, Design: randomised Participants: insufficient description of stability ,,,,,,,
CD014384-bib-0118,"Kinon BJ, Stauffer VL, Wang L, Thi KT. ",Olanzapine improves tardive dyskinesia in patients with schizophrenia, Schizophrenia Research ,2002,53,    ,['citation-journal']," Kinon BJ, Stauffer VL, Wang L, Thi KT. Olanzapine improves tardive dyskinesia in patients with schizophrenia.  Schizophrenia Research 2002;53(3 Suppl 1):191. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Olanzapine+improves+tardive+dyskinesia+in+patients+with+schizophrenia&author=BJ+Kinon&author=VL+Stauffer&author=L+Wang&author=KT+Thi&publication_year=2002&hl=en']",,, Kinon 2004 {published data only}  ,excluded,CD014384-bbs2-0047, Design: randomised Participants: insufficient description of stability ,,,,,,,
CD014384-bib-0119,"Kollack-Walker S, Kinon BJ, Stauffer VL, Wang L, Thi KT. ",Olanzapine improves tardive dyskinesia in patients with schizophrenia,,2003,,    ,['citation-other']," Kollack-Walker S, Kinon BJ, Stauffer VL, Wang L, Thi KT. Olanzapine improves tardive dyskinesia in patients with schizophrenia. In: Abstracts of the IXth International Congress on Schizophrenia Research; 2003 Mar 29-Apr 2; Colorado Springs, Colorado. 2003. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Olanzapine+improves+tardive+dyskinesia+in+patients+with+schizophrenia&author=S+Kollack-Walker&author=BJ+Kinon&author=VL+Stauffer&author=L+Wang&author=KT+Thi&publication_year=2003&hl=en']",,, Kinon 2004 {published data only}  ,excluded,CD014384-bbs2-0047, Design: randomised Participants: insufficient description of stability ,,,,,,,
CD014384-bib-0120,"Kollack-Walker S, Kinon BJ, Stauffer VL, Wang L, Thi KT. ",Olanzapine improves tardive dyskinesia in patients with schizophrenia, Schizophrenia Research ,2003,60,    ,['citation-journal']," Kollack-Walker S, Kinon BJ, Stauffer VL, Wang L, Thi KT. Olanzapine improves tardive dyskinesia in patients with schizophrenia.  Schizophrenia Research 2003;60(Suppl 1):S359. CENTRAL [DOI: 10.1016/S0920-9964(03)80175-5]    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/S0920-9964(03)80175-5', 'https://scholar.google.com/scholar_lookup?title=Olanzapine+improves+tardive+dyskinesia+in+patients+with+schizophrenia&author=S+Kollack-Walker&author=BJ+Kinon&author=VL+Stauffer&author=L+Wang&author=KT+Thi&publication_year=2003&hl=en']",,https://doi.org/10.1016/S0920-9964(03)80175-5, Kinon 2004 {published data only}  ,excluded,CD014384-bbs2-0047, Design: randomised Participants: insufficient description of stability ,,,,6,,,
CD014384-bib-0121,"Koshikawa H, Suzuki E, Kanba S, Nibuya M, Ishizuki T, Kohno H, et al. ","Plasma homovanillic acid, serum anti-D1 and anti-D2 receptor activity, and psychopathology in chronic schizophrenia", Yakubutsu Seishin Kodo [Japanese Journal of Psychopharmacology] ,1991,11,    ,['citation-journal']," Koshikawa H, Suzuki E, Kanba S, Nibuya M, Ishizuki T, Kohno H, et al. Plasma homovanillic acid, serum anti-D1 and anti-D2 receptor activity, and psychopathology in chronic schizophrenia.  Yakubutsu Seishin Kodo [Japanese Journal of Psychopharmacology] 1991;11(1):79-81. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/1679276', 'https://scholar.google.com/scholar_lookup?title=Plasma+homovanillic+acid,+serum+anti-D1+and+anti-D2+receptor+activity,+and+psychopathology+in+chronic+schizophrenia+&author=H+Koshikawa&author=E+Suzuki&author=S+Kanba&author=M+Nibuya&author=T+Ishizuki&author=H+Kohno&publication_year=1991&hl=en']",1679276,, Koshikawa 1991 {published data only}  ,excluded,CD014384-bbs2-0048, Design: randomised Participants: stable individuals with schizophrenia Intervention: dose reduction Comparator: no dose maintenance (dose increase) ,,1679276,,,,,1679276
CD014384-bib-0122,"Lecrubier Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S. ",The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial, Acta Psychiatrica Scandinavica ,2006 ,114,    ,['citation-journal']," Lecrubier Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.  Acta Psychiatrica Scandinavica 2006 ;114(5):319-27. CENTRAL [DOI: 10.1111/j.1600-0447.2006.00887.x]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1111/j.1600-0447.2006.00887.x', 'https://www.ncbi.nlm.nih.gov/pubmed/17022791', 'https://scholar.google.com/scholar_lookup?title=The+treatment+of+negative+symptoms+and+deficit+states+of+chronic+schizophrenia:+olanzapine+compared+to+amisulpride+and+placebo+in+a+6-month+double-blind+controlled+clinical+trial+&author=Y+Lecrubier&author=P+Quintin&author=M+Bouhassira&author=E+Perrin&author=S+Lancrenon&publication_year=2006\xa0&hl=en']",17022791,https://doi.org/10.1111/j.1600-0447.2006.00887.x, Lecrubier 2006 {published data only}  ,excluded,CD014384-bbs2-0049, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction; study evaluated standard versus low dose ,,,17022791,87,,,17022791
CD014384-bib-0123,"Lee HS, Kim CH, Kim YH, Yoon DJ, Lee MS, Suh HS, et al. ",Effective titration of risperidone in Korean patients with schizophrenia: open multicenter randomized comparative study, International Journal of Neuropsychopharmacology ,2000,3,    ,['citation-journal']," Lee HS, Kim CH, Kim YH, Yoon DJ, Lee MS, Suh HS, et al. Effective titration of risperidone in Korean patients with schizophrenia: open multicenter randomized comparative study.  International Journal of Neuropsychopharmacology 2000;3(Suppl 1):S162. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effective+titration+of+risperidone+in+Korean+patients+with+schizophrenia:+open+multicenter+randomized+comparative+study+&author=HS+Lee&author=CH+Kim&author=YH+Kim&author=DJ+Yoon&author=MS+Lee&author=HS+Suh&publication_year=2000&hl=en']",,, Lee 2002 {published data only}  ,excluded,CD014384-bbs2-0050, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction (dose increase) ,,,,,,,
CD014384-bib-0124,"Lee HS, Kim CH, Kim YH, Yoon DJ, Lee MS, Suh HS, et al. ",Effective titration of risperidone in patients with schizophrenia: open multicenter randomized comparative 8 weeks study, Korean Journal of Psychopharmacology ,2002,13,    ,['citation-journal']," Lee HS, Kim CH, Kim YH, Yoon DJ, Lee MS, Suh HS, et al. Effective titration of risperidone in patients with schizophrenia: open multicenter randomized comparative 8 weeks study.  Korean Journal of Psychopharmacology 2002;13(4):276-88. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Effective+titration+of+risperidone+in+patients+with+schizophrenia:+open+multicenter+randomized+comparative+8+weeks+study+&author=HS+Lee&author=CH+Kim&author=YH+Kim&author=DJ+Yoon&author=MS+Lee&author=HS+Suh&publication_year=2002&hl=en']",,, Lee 2002 {published data only}  ,excluded,CD014384-bbs2-0050, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction (dose increase) ,,,,,,,
CD014384-bib-0125,"Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, et al. ","Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia", European Neuropsychopharmacology ,1991,1,    ,['citation-journal']," Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, et al. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia.  European Neuropsychopharmacology 1991;1(4):541-8. CENTRAL [DOI: 10.1016/0924-977x(91)90008-i]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/0924-977X(91)90008-I', 'https://www.ncbi.nlm.nih.gov/pubmed/1822319', 'https://scholar.google.com/scholar_lookup?title=Zuclopenthixol,+a+combined+dopamine+D1/D2+antagonist,+versus+haloperidol,+a+dopamine+D2+antagonist,+in+tardive+dyskinesia+&author=H+Lublin&author=J+Gerlach&author=U+Hagert&author=B+Meidahl&author=C+Molbjerg&author=V+Pedersen&publication_year=1991&hl=en']",1822319,https://doi.org/10.1016/0924-977X(91)90008-I, Lublin 1991 {published data only}  ,excluded,CD014384-bbs2-0051, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction ,,1822319,1822319,22,,,1822319
CD014384-bib-0126,"Mallikaarjun S, Kane JM, Bricmont P, McQuade R, Carson W, Sanchez R, et al. ","Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study", Schizophrenia Research ,2013,150,    ,['citation-journal']," Mallikaarjun S, Kane JM, Bricmont P, McQuade R, Carson W, Sanchez R, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study.  Schizophrenia Research 2013;150(1):281–8. CENTRAL [DOI: 10.1016/j.schres.2013.06.041]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.schres.2013.06.041', 'https://www.ncbi.nlm.nih.gov/pubmed/23890595', 'https://scholar.google.com/scholar_lookup?title=Pharmacokinetics,+tolerability+and+safety+of+aripiprazole+once-monthly+in+adult+schizophrenia:+an+open-label,+parallel-arm,+multiple-dose+study+&author=S+Mallikaarjun&author=JM+Kane&author=P+Bricmont&author=R+McQuade&author=W+Carson&author=R+Sanchez&publication_year=2013&hl=en']",23890595,https://doi.org/10.1016/j.schres.2013.06.041, Mallikaarjun 2013 {published data only}  ,excluded,CD014384-bbs2-0052, Design: randomised Participants: stable individuals with schizophrenia Intervention: dose reduction Comparator: no dose maintenance ,,,23890595,108,https://doi.org/10.1016/j.schres.2013.06.041,,23890595
CD014384-bib-0127,"Marder SR, Van Putten T, Mintz J, McKenzie J, Lebell M, Faltico G, et al. ",Costs and benefits of two doses of fluphenazine, Archives of General Psychiatry ,1984,41,    ,['citation-journal']," Marder SR, Van Putten T, Mintz J, McKenzie J, Lebell M, Faltico G, et al. Costs and benefits of two doses of fluphenazine.  Archives of General Psychiatry 1984;41(11):1025-9. CENTRAL [DOI: 10.1001/archpsyc.1983.01790220015002]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1001/archpsyc.1983.01790220015002', 'https://www.ncbi.nlm.nih.gov/pubmed/6437365', 'https://scholar.google.com/scholar_lookup?title=Costs+and+benefits+of+two+doses+of+fluphenazine&author=SR+Marder&author=T+VanPutten&author=J+Mintz&author=J+McKenzie&author=M+Lebell&author=G+Faltico&publication_year=1984&hl=en']",6437365,https://doi.org/10.1001/archpsyc.1983.01790220015002, Marder 1984 {published data only}  ,excluded,CD014384-bbs2-0053, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction ,,6437365,6437365,165,,,6437365
CD014384-bib-0128,"Marken PA, McCrary KE, Lacombe S, Sommi RW, Hornstra RK, Pierce CA, et al. ",Preliminary comparison of predictive and empiric lithium dosing: impact on patient outcome, Annals of Pharmacotherapy ,1994,28,    ,['citation-journal']," Marken PA, McCrary KE, Lacombe S, Sommi RW, Hornstra RK, Pierce CA, et al. Preliminary comparison of predictive and empiric lithium dosing: impact on patient outcome.  Annals of Pharmacotherapy 1994;28(10):1148-52. CENTRAL [DOI: 10.1177/106002809402801002]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1177/106002809402801002', 'https://www.ncbi.nlm.nih.gov/pubmed/7841567', 'https://scholar.google.com/scholar_lookup?title=Preliminary+comparison+of+predictive+and+empiric+lithium+dosing:+impact+on+patient+outcome+&author=PA+Marken&author=KE+McCrary&author=S+Lacombe&author=RW+Sommi&author=RK+Hornstra&author=CA+Pierce&publication_year=1994&hl=en']",7841567,https://doi.org/10.1177/106002809402801002, Marken 1994 {published data only}  ,excluded,CD014384-bbs2-0054, Design: randomised Participants: no diagnosis of schizophrenia ,,7841567,7841567,10,,,7841567
CD014384-bib-0129,"Matkovits-Gupta T, Lasser R, Young F, Happy J, Gharabawi G, Cucchiaro J, et al. In: Managing psychotic disorders through balanced receptor blockade: the Zomaril™ clinical program; 11th World Congress of Psychiatry; ",,,1999,,   ,['citation-other']," Matkovits-Gupta T, Lasser R, Young F, Happy J, Gharabawi G, Cucchiaro J, et al. In: Managing psychotic disorders through balanced receptor blockade: the Zomaril™ clinical program; 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany. 1999. CENTRAL    ",[''],,, Matkovits Gupta 1999 {published data only}  ,excluded,CD014384-bbs2-0055, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction (dose increase) ,,,,,,,
CD014384-bib-0130,"Matkovits-Gupta T, Cucchiaro J, El-Bizri H, Fairweather D, Klonowski E, Lasser R, et al. ","Safety and efficacy of iloperidone in patients with psychotic disorders: a randomized, double-blind multicenter study", Schizophrenia Research ,2001,49,    ,['citation-journal']," Matkovits-Gupta T, Cucchiaro J, El-Bizri H, Fairweather D, Klonowski E, Lasser R, et al. Safety and efficacy of iloperidone in patients with psychotic disorders: a randomized, double-blind multicenter study.  Schizophrenia Research 2001;49(1-2 Suppl):238. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+iloperidone+in+patients+with+psychotic+disorders:+a+randomized,+double-blind+multicenter+study+&author=T+Matkovits-Gupta&author=J+Cucchiaro&author=H+El-Bizri&author=D+Fairweather&author=E+Klonowski&author=R+Lasser&publication_year=2001&hl=en']",,, Matkovits Gupta 2001 {published data only}  ,excluded,CD014384-bbs2-0056, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction (dose increase) ,,,,,,,
CD014384-bib-0131,"Miller MJ, Shettel R, Fiedler HT. ",Chronic toxicologic evaluation of hydroxyphenamate and possible synergism with phenothiazines, Psychosomatics ,1965,6,    ,['citation-journal']," Miller MJ, Shettel R, Fiedler HT. Chronic toxicologic evaluation of hydroxyphenamate and possible synergism with phenothiazines.  Psychosomatics 1965;6(5):340-2. CENTRAL [DOI: 10.1016/s0033-3182(65)72252-4]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0033-3182(65)72252-4', 'https://www.ncbi.nlm.nih.gov/pubmed/5319246', 'https://scholar.google.com/scholar_lookup?title=Chronic+toxicologic+evaluation+of+hydroxyphenamate+and+possible+synergism+with+phenothiazines&author=MJ+Miller&author=R+Shettel&author=HT+Fiedler&publication_year=1965&hl=en']",5319246,https://doi.org/10.1016/S0033-3182(65)72252-4, Miller 1965 {published data only}  ,excluded,CD014384-bbs2-0057, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction ,5319246,5319246,5319246,3,,,5319246
CD014384-bib-0132,NCT00254787. ,"Rapid dose escalation of quetiapine versus conventional escalation in the treatment of patients with acute schizophrenia a multicentre, double-blind, parallel group, randomized study",,,,   ,['citation-other']," NCT00254787. Rapid dose escalation of quetiapine versus conventional escalation in the treatment of patients with acute schizophrenia a multicentre, double-blind, parallel group, randomized study. clinicaltrials.gov/ct2/show/NCT00254787 (first received 17 November 2005). CENTRAL    ",[''],,, NCT00254787 {published data only}  ,excluded,CD014384-bbs2-0058, Design: randomised Participants: not stable  ,,,,,,,
CD014384-bib-0133,NCT00254813. ,"Fast titration of quetiapine versus currently approved titration: a randomised, multicentre, parallel group open trial in schizophrenia and schizoaffective disorder",,,,   ,['citation-other']," NCT00254813. Fast titration of quetiapine versus currently approved titration: a randomised, multicentre, parallel group open trial in schizophrenia and schizoaffective disorder. clinicaltrials.gov/ct2/show/NCT00254813 (first received 17 November 2005). CENTRAL    ",[''],,, NCT00254813 {published data only}  ,excluded,CD014384-bbs2-0059, Design: randomised Participants: not stable  ,,,,,,,
CD014384-bib-0134,NCT00304473. ,"Fast titration of quetiapine versus conventional titration in the treatment of schizophrenia/schizoaffective disorder - a randomised, parallel group open trial",,,,   ,['citation-other']," NCT00304473. Fast titration of quetiapine versus conventional titration in the treatment of schizophrenia/schizoaffective disorder - a randomised, parallel group open trial. clinicaltrials.gov/ct2/show/NCT00304473 (first received 20 March 2006). CENTRAL    ",[''],,, NCT00304473 {published data only}  ,excluded,CD014384-bbs2-0060, Design: randomised Participants: not stable  ,,,,,,,
CD014384-bib-0135,NCT00457899. ,"RAPID - an open-label randomized, multicenter phase iiib study to evaluate the efficacy and tolerability of quetiapine IR (immediate release), over 14 days, in acute schizophrenia/schizoaffective disorder (rapid versus conventional titration)",,,,   ,['citation-other']," NCT00457899. RAPID - an open-label randomized, multicenter phase iiib study to evaluate the efficacy and tolerability of quetiapine IR (immediate release), over 14 days, in acute schizophrenia/schizoaffective disorder (rapid versus conventional titration). clinicaltrials.gov/ct2/show/NCT00457899 (first received 9 April 2007). CENTRAL    ",[''],,, NCT00457899 {published data only}  ,excluded,CD014384-bbs2-0061, Design: randomised Participants: not stable  ,,,,,,,
CD014384-bib-0136,NCT00486798. ,FAST - a study to evaluate the efficacy and safety of quetiapine IR in patients with acute psychosis,,,,   ,['citation-other'], NCT00486798. FAST - a study to evaluate the efficacy and safety of quetiapine IR in patients with acute psychosis. clinicaltrials.gov/ct2/show/NCT00486798 (first received 15 June 2007). CENTRAL    ,[''],,, NCT00486798 {published data only}  ,excluded,CD014384-bbs2-0062, Design: randomised Participants: not stable  ,,,,,,,
CD014384-bib-0137,NCT00919607. ,Evaluate the pharmacokinetics of quetiapine fumarate in Chinese schizophrenic patients,,,,   ,['citation-other'], NCT00919607. Evaluate the pharmacokinetics of quetiapine fumarate in Chinese schizophrenic patients. clinicaltrials.gov/ct2/show/NCT00919607 (first received 12 June 2009). CENTRAL    ,[''],,, NCT00919607 {published data only}  ,excluded,CD014384-bbs2-0063, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction ,,,,,,,
CD014384-bib-0138,"Nishikawa T, Tsuda A, Tanaka M, Hoaki Y, Koga I, Uchida Y. ",Prophylactic effect of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of haloperidol and propericiazine, Psychopharmacology ,,82,    ,['citation-journal']," Nishikawa T, Tsuda A, Tanaka M, Hoaki Y, Koga I, Uchida Y. Prophylactic effect of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of haloperidol and propericiazine.  Psychopharmacology   1984;82(3):153-6. CENTRAL [DOI: 10.1007/BF00427763]    Link to article     PubMed     ","['', 'https://doi.org/10.1007/BF00427763', 'https://www.ncbi.nlm.nih.gov/pubmed/6144125']",6144125,https://doi.org/10.1007/BF00427763, Nishikawa 1984 {published data only}  ,excluded,CD014384-bbs2-0064, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction; study evaluated standard versus low dose ,6144125,,6144125,19,,,6144125
CD014384-bib-0139,"Nishikawa T, Tsuda A, Tanaka M, Koga I, Uchida Y. ",Prophylactic effects of neuroleptics in symptom-free schizophrenics: roles of dopaminergic and noradrenergic blockers, Biological Psychiatry ,1985,20,    ,['citation-journal']," Nishikawa T, Tsuda A, Tanaka M, Koga I, Uchida Y. Prophylactic effects of neuroleptics in symptom-free schizophrenics: roles of dopaminergic and noradrenergic blockers.  Biological Psychiatry 1985;20(11):1161-6. CENTRAL [DOI: 10.1016/0006-3223(85)90174-x]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/0006-3223(85)90174-X', 'https://www.ncbi.nlm.nih.gov/pubmed/3902105', 'https://scholar.google.com/scholar_lookup?title=Prophylactic+effects+of+neuroleptics+in+symptom-free+schizophrenics:+roles+of+dopaminergic+and+noradrenergic+blockers+&author=T+Nishikawa&author=A+Tsuda&author=M+Tanaka&author=I+Koga&author=Y+Uchida&publication_year=1985&hl=en']",3902105,https://doi.org/10.1016/0006-3223(85)90174-X, Nishikawa 1985 {published data only}  ,excluded,CD014384-bbs2-0065, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction; study evaluated standard versus low dose ,3902105,3902105,3902105,32,,,3902105
CD014384-bib-0140,"Nishikawa T, Tanaka M, Tsuda A, Koga I, Uchida Y. ",Prophylactic effects of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of timiperone and sulpiride, Biological Psychiatry ,1989,25,    ,['citation-journal']," Nishikawa T, Tanaka M, Tsuda A, Koga I, Uchida Y. Prophylactic effects of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of timiperone and sulpiride.  Biological Psychiatry 1989;25(7):861-6. CENTRAL [DOI: 10.1016/0006-3223(89)90265-5]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/0006-3223(89)90265-5', 'https://www.ncbi.nlm.nih.gov/pubmed/2655717', 'https://scholar.google.com/scholar_lookup?title=Prophylactic+effects+of+neuroleptics+in+symptom-free+schizophrenics:+a+comparative+dose-response+study+of+timiperone+and+sulpiride+&author=T+Nishikawa&author=M+Tanaka&author=A+Tsuda&author=I+Koga&author=Y+Uchida&publication_year=1989&hl=en']",2655717,https://doi.org/10.1016/0006-3223(89)90265-5, Nishikawa 1989 {published data only}  ,excluded,CD014384-bbs2-0066, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction; study evaluated standard versus low dose ,2655717,2655717,2655717,13,,,2655717
CD014384-bib-0141,"Pae CU, Kim JJ, Lee CU, Lee SJ, Lee C, Patkar AA, et al. ","Rapid versus conventional initiation of quetiapine in the treatment of schizophrenia: a randomized, parallel-group trial", Journal of Clinical Psychiatry ,2007,68,    ,['citation-journal']," Pae CU, Kim JJ, Lee CU, Lee SJ, Lee C, Patkar AA, et al. Rapid versus conventional initiation of quetiapine in the treatment of schizophrenia: a randomized, parallel-group trial.  Journal of Clinical Psychiatry 2007;68(3):399-405. CENTRAL [DOI: 10.4088/jcp.v68n0307]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4088/JCP.v68n0307', 'https://www.ncbi.nlm.nih.gov/pubmed/17388709', 'https://scholar.google.com/scholar_lookup?title=Rapid+versus+conventional+initiation+of+quetiapine+in+the+treatment+of+schizophrenia:+a+randomized,+parallel-group+trial+&author=CU+Pae&author=JJ+Kim&author=CU+Lee&author=SJ+Lee&author=C+Lee&author=AA+Patkar&publication_year=2007&hl=en']",17388709,https://doi.org/10.4088/JCP.v68n0307, Pae 2007 {published data only}  ,excluded,CD014384-bbs2-0067, Design: randomised Participants: not stable  ,,17388709,17388709,21,,,17388709
CD014384-bib-0142,"Pae CU, Kim TS, Kim JJ, Lee SJ, Lee CU, Lee C, et al. ",Rapid versus conventional titration of quetiapine in acute schizophrenia, European Neuropsychopharmacology ,2005,15,    ,['citation-journal']," Pae CU, Kim TS, Kim JJ, Lee SJ, Lee CU, Lee C, et al. Rapid versus conventional titration of quetiapine in acute schizophrenia.  European Neuropsychopharmacology 2005;15(Suppl 3):S505. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Rapid+versus+conventional+titration+of+quetiapine+in+acute+schizophrenia&author=CU+Pae&author=TS+Kim&author=JJ+Kim&author=SJ+Lee&author=CU+Lee&author=C+Lee&publication_year=2005&hl=en']",,, Pae 2007 {published data only}  ,excluded,CD014384-bbs2-0067, Design: randomised Participants: not stable  ,,,,,,,
CD014384-bib-0143,"Pae CU, Kim TS, Kim JJ, Lee SJ, Lee CU, Paik IH. ",Rapid versus conventional initiation of quetiapine in acute schizophrenia,,2006,,    ,['citation-other']," Pae CU, Kim TS, Kim JJ, Lee SJ, Lee CU, Paik IH. Rapid versus conventional initiation of quetiapine in acute schizophrenia. In: 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. 2006. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Rapid+versus+conventional+initiation+of+quetiapine+in+acute+schizophrenia&author=CU+Pae&author=TS+Kim&author=JJ+Kim&author=SJ+Lee&author=CU+Lee&author=IH+Paik&publication_year=2006&hl=en']",,, Pae 2007 {published data only}  ,excluded,CD014384-bbs2-0067, Design: randomised Participants: not stable  ,,,,,,,
CD014384-bib-0144,"Schultz CC, Gastpar MT, Kis B, Leweke FM, Novikov J, Volz HP, et al. ",Fast dosage of quetiapine in comparison to conventional dosage in the treatment of acute schizophrenic patients - a multi-central double-blind randomised study, Nervenarzt ,2007,78,    ,['citation-journal']," Schultz CC, Gastpar MT, Kis B, Leweke FM, Novikov J, Volz HP, et al. Fast dosage of quetiapine in comparison to conventional dosage in the treatment of acute schizophrenic patients - a multi-central double-blind randomised study.  Nervenarzt 2007;78:94. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Fast+dosage+of+quetiapine+in+comparison+to+conventional+dosage+in+the+treatment+of+acute+schizophrenic+patients+-+a+multi-central+double-blind+randomised+study+&author=CC+Schultz&author=MT+Gastpar&author=B+Kis&author=FM+Leweke&author=J+Novikov&author=HP+Volz&publication_year=2007&hl=en']",,, Schultz 2007 {published data only}  ,excluded,CD014384-bbs2-0068, Design: randomised Participants: not stable  ,,,,,,,
CD014384-bib-0145,"Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, et al. ",A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder, Journal of Clinical Psychiatry ,2006,67,    ,['citation-journal']," Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.  Journal of Clinical Psychiatry 2006;67(8):1194-203. CENTRAL [DOI: 10.4088/jcp.v67n0804]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4088/JCP.v67n0804', 'https://www.ncbi.nlm.nih.gov/pubmed/16965196', 'https://scholar.google.com/scholar_lookup?title=A+1-year+double-blind+study+of+2+doses+of+long-acting+risperidone+in+stable+patients+with+schizophrenia+or+schizoaffective+disorder+&author=GM+Simpson&author=RA+Mahmoud&author=RA+Lasser&author=M+Kujawa&author=CA+Bossie&author=I+Turkoz&publication_year=2006&hl=en']",16965196,https://doi.org/10.4088/JCP.v67n0804, Simpson 2007 {published data only}  ,excluded,CD014384-bbs2-0069, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction; study evaluated standard versus low dose ,,,16965196,92,,,16965196
CD014384-bib-0146,"Smith MA, McCoy R, Hamer J, Brecher M. In: Optimal titration for quetiapine: pilot trial; NCDEU Annual Meeting; ",,,2002,,   ,['citation-other']," Smith MA, McCoy R, Hamer J, Brecher M. In: Optimal titration for quetiapine: pilot trial; NCDEU Annual Meeting; 2002 Jun 10-13; Boca Raton, Florida. 2002. CENTRAL    ",[''],,, Smith 2002 {published data only}  ,excluded,CD014384-bbs2-0070, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction (dose increase) ,,,,,,,
CD014384-bib-0147,"Soria JM, Santiuste MA, Salorio P. ",The effect of neuroleptic medication on behaviour in chronic schizophrenia, Psiquis ,1994,15,    ,['citation-journal']," Soria JM, Santiuste MA, Salorio P. The effect of neuroleptic medication on behaviour in chronic schizophrenia [Efecto de la medicacion neuroleptica sobre la conducta en la esquizofrenia cronica].  Psiquis 1994;15(3):21-5. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=The+effect+of+neuroleptic+medication+on+behaviour+in+chronic+schizophrenia&author=JM+Soria&author=MA+Santiuste&author=P+Salorio&publication_year=1994&hl=en']",,, Soria 1994 {published data only}  ,excluded,CD014384-bbs2-0071, Design: not randomised ,,,,,,,
CD014384-bib-0148,"Sramek JJ, Mack RJ, Awni W, Hourani J, Jhee SS, Barto S, et al. ",Two rapid-dose titrations of sertindole in patients with schizophrenia, Journal of Clinical Psychopharmacology ,1997,17,    ,['citation-journal']," Sramek JJ, Mack RJ, Awni W, Hourani J, Jhee SS, Barto S, et al. Two rapid-dose titrations of sertindole in patients with schizophrenia.  Journal of Clinical Psychopharmacology 1997;17(5):419-22. CENTRAL [DOI: 10.1097/00004714-199710000-00011]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/00004714-199710000-00011', 'https://www.ncbi.nlm.nih.gov/pubmed/9315993', 'https://scholar.google.com/scholar_lookup?title=Two+rapid-dose+titrations+of+sertindole+in+patients+with+schizophrenia&author=JJ+Sramek&author=RJ+Mack&author=W+Awni&author=J+Hourani&author=SS+Jhee&author=S+Barto&publication_year=1997&hl=en']",9315993,https://doi.org/10.1097/00004714-199710000-00011, Sramek 1997 {published data only}  ,excluded,CD014384-bbs2-0072, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction (dose increase) ,,9315993,9315993,11,,,9315993
CD014384-bib-0149,"Sramek JJ, Kirkesseli S, Paccaly Moulin A, Davidson J, Jhee SS, Hourani J, et al. ",A bridging study of fananserin in schizophrenic patients, Psychopharmacology Bulletin ,1998,34,    ,['citation-journal']," Sramek JJ, Kirkesseli S, Paccaly Moulin A, Davidson J, Jhee SS, Hourani J, et al. A bridging study of fananserin in schizophrenic patients.  Psychopharmacology Bulletin 1998;34(4):811-8. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/10513457', 'https://scholar.google.com/scholar_lookup?title=A+bridging+study+of+fananserin+in+schizophrenic+patients&author=JJ+Sramek&author=S+Kirkesseli&author=A+PaccalyMoulin&author=J+Davidson&author=SS+Jhee&author=J+Hourani&publication_year=1998&hl=en']",10513457,, Sramek 1998 {published data only}  ,excluded,CD014384-bbs2-0073, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction (dose increase) ,,10513457,,,,,10513457
CD014384-bib-0150,"Sukegawa T, Ito T, Hasegawa M, Mizuno Y, Inagaki A, Sakamoto H, et al. ",A randomized controlled trial on the dose reduction and simplification for polypharmacy of antipsychotics, Tottori Journal of Clinical Research ,2008,1,    ,['citation-journal']," Sukegawa T, Ito T, Hasegawa M, Mizuno Y, Inagaki A, Sakamoto H, et al. A randomized controlled trial on the dose reduction and simplification for polypharmacy of antipsychotics.  Tottori Journal of Clinical Research 2008;1(1):169-81. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=A+randomized+controlled+trial+on+the+dose+reduction+and+simplification+for+polypharmacy+of+antipsychotics+&author=T+Sukegawa&author=T+Ito&author=M+Hasegawa&author=Y+Mizuno&author=A+Inagaki&author=H+Sakamoto&publication_year=2008&hl=en']",,, Sukegawa 2008 {published data only}  ,excluded,CD014384-bbs2-0074, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction (combined dose reduction and polypharmacy reduction) ,,,,,,,
CD014384-bib-0151,Sukegawa T. ,Implementation of appropriate administration of antipsychotics - measures to reduce high-dose multiple antipsychotics, Nihon Rinsho [Japanese Journal of Clinical Medicine] ,2013,71,    ,['citation-journal'], Sukegawa T. Implementation of appropriate administration of antipsychotics - measures to reduce high-dose multiple antipsychotics.  Nihon Rinsho [Japanese Journal of Clinical Medicine] 2013;71(4):712-7. CENTRAL    PubMed     Google Scholar     ,"['', 'https://www.ncbi.nlm.nih.gov/pubmed/23678605', 'https://scholar.google.com/scholar_lookup?title=Implementation+of+appropriate+administration+of+antipsychotics+-+measures+to+reduce+high-dose+multiple+antipsychotics+&author=T+Sukegawa&publication_year=2013&hl=en']",23678605,, Sukegawa 2013 {published data only}  ,excluded,CD014384-bbs2-0075, Design: not randomised ,23678605,23678605,,,,,23678605
CD014384-bib-0152,Sukegawa T. ,Measures to reduce high-dose multiple antipsychotics in Japan, Seishin Shinkeigaku Zasshi [Psychiatria et Neurologia Japonica] ,2012,114,    ,['citation-journal'], Sukegawa T. Measures to reduce high-dose multiple antipsychotics in Japan.  Seishin Shinkeigaku Zasshi [Psychiatria et Neurologia Japonica] 2012;114(6):696-701. CENTRAL    PubMed     Google Scholar     ,"['', 'https://www.ncbi.nlm.nih.gov/pubmed/22844821', 'https://scholar.google.com/scholar_lookup?title=Measures+to+reduce+high-dose+multiple+antipsychotics+in+Japan&author=T+Sukegawa&publication_year=2012&hl=en']",22844821,, Sukegawa 2013 {published data only}  ,excluded,CD014384-bbs2-0075, Design: not randomised ,23678605,,,,,,22844821
CD014384-bib-0153,"Suzuki E, Kanba S, Nibuya M, Koshikawa H, Nakaki T, Yagi G. ","Plasma homovanillic acid, plasma anti-D1 and -D2 dopamine-receptor activity, and negative symptoms in chronically medicated schizophrenia", Biological Psychiatry ,1992,31,    ,['citation-journal']," Suzuki E, Kanba S, Nibuya M, Koshikawa H, Nakaki T, Yagi G. Plasma homovanillic acid, plasma anti-D1 and -D2 dopamine-receptor activity, and negative symptoms in chronically medicated schizophrenia.  Biological Psychiatry 1992;31(4):357-64. CENTRAL [DOI: 10.1016/0006-3223(92)90229-S]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/0006-3223(92)90229-S', 'https://www.ncbi.nlm.nih.gov/pubmed/1348430', 'https://scholar.google.com/scholar_lookup?title=Plasma+homovanillic+acid,+plasma+anti-D1+and+-D2+dopamine-receptor+activity,+and+negative+symptoms+in+chronically+medicated+schizophrenia+&author=E+Suzuki&author=S+Kanba&author=M+Nibuya&author=H+Koshikawa&author=T+Nakaki&author=G+Yagi&publication_year=1992&hl=en']",1348430,https://doi.org/10.1016/0006-3223(92)90229-S, Suzuki 1992 {published data only}  ,excluded,CD014384-bbs2-0076, Design: randomised Participants: stable individuals with schizophrenia Intervention: dose reduction Comparator: no dose maintenance ,,,1348430,13,,,1348430
CD014384-bib-0154,"Townsend MH, Baier MB. ",Are high initial doses of olanzapine required to reduce agitation associated with schizophrenia?, Journal of Clinical Psychopharmacology ,2004,24,    ,['citation-journal']," Townsend MH, Baier MB. Are high initial doses of olanzapine required to reduce agitation associated with schizophrenia? Journal of Clinical Psychopharmacology 2004;24(1):95-7. CENTRAL [DOI: 10.1097/01.jcp.0000106226.36344.83]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/01.jcp.0000106226.36344.83', 'https://www.ncbi.nlm.nih.gov/pubmed/14709956', 'https://scholar.google.com/scholar_lookup?title=Are+high+initial+doses+of+olanzapine+required+to+reduce+agitation+associated+with+schizophrenia?+&author=MH+Townsend&author=MB+Baier&publication_year=2004&hl=en']",14709956,https://doi.org/10.1097/01.jcp.0000106226.36344.83, Townsend 2004 {published data only}  ,excluded,CD014384-bbs2-0077, Design: randomised Participants: not stable  ,14709956,14709956,14709956,2,,,14709956
CD014384-bib-0155,"Uchida H, Suzuki T, Yamazawa R, Tomita M, Nemoto T, Kimura Y, et al. ",Reducing the dose of antipsychotic agents ameliorates visual hypersensitivity attack: an ideal treatment option in terms of the adverse effect, Journal of Clinical Psychopharmacology ,2006,26,    ,['citation-journal']," Uchida H, Suzuki T, Yamazawa R, Tomita M, Nemoto T, Kimura Y, et al. Reducing the dose of antipsychotic agents ameliorates visual hypersensitivity attack: an ideal treatment option in terms of the adverse effect.  Journal of Clinical Psychopharmacology 2006;26(1):50-5. CENTRAL [DOI: 10.1097/01.jcp.0000195384.04008.25]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/01.jcp.0000195384.04008.25', 'https://www.ncbi.nlm.nih.gov/pubmed/16415706', 'https://scholar.google.com/scholar_lookup?title=Reducing+the+dose+of+antipsychotic+agents+ameliorates+visual+hypersensitivity+attack:+an+ideal+treatment+option+in+terms+of+the+adverse+effect+&author=H+Uchida&author=T+Suzuki&author=R+Yamazawa&author=M+Tomita&author=T+Nemoto&author=Y+Kimura&publication_year=2006&hl=en']",16415706,https://doi.org/10.1097/01.jcp.0000195384.04008.25, Uchida 2006 {published data only}  ,excluded,CD014384-bbs2-0078, Design: randomised Participants: insufficient description of stability ,,16415706,16415706,16,,,16415706
CD014384-bib-0156,"Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin R, et al. ",Does cognitive function improve with quetiapine in comparison to haloperidol?, Schizophrenia Research ,2002,53,    ,['citation-journal']," Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin R, et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophrenia Research 2002;53(3):239-48. CENTRAL [DOI: 10.1016/s0920-9964(01)00268-7]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0920-9964(01)00268-7', 'https://www.ncbi.nlm.nih.gov/pubmed/11738537', 'https://scholar.google.com/scholar_lookup?title=Does+cognitive+function+improve+with+quetiapine+in+comparison+to+haloperidol?&author=DI+Velligan&author=J+Newcomer&author=J+Pultz&author=J+Csernansky&author=AL+Hoff&author=R+Mahurin&publication_year=2002&hl=en']",11738537,https://doi.org/10.1016/S0920-9964(01)00268-7, Velligan 2002 {published data only}  ,excluded,CD014384-bbs2-0079, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction; study evaluated standard versus low dose ,,,11738537,193,,,11738537
CD014384-bib-0157,JPRN-UMIN000004511. ,The clinical study to correct multiple and large amount of administering to antipsychotic safely and effectively,,,,   ,['citation-other'], JPRN-UMIN000004511. The clinical study to correct multiple and large amount of administering to antipsychotic safely and effectively. center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005391 (first received 10 November 2010). CENTRAL    ,[''],,, Yamanouchi 2015 {published data only}  ,excluded,CD014384-bbs2-0080, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction (combined dose reduction and polypharmacy reduction) ,,,,,,,
CD014384-bib-0158,"Sukegawa T, Inagaki A, Yamanouchi Y, Inada T, Yoshio T, Yoshimura R, et al. ",Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan, BMC Psychiatry ,2014,14,    ,['citation-journal']," Sukegawa T, Inagaki A, Yamanouchi Y, Inada T, Yoshio T, Yoshimura R, et al. Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan.  BMC Psychiatry 2014;14(1):103. CENTRAL [DOI: 10.1186/1471-244X-14-103]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1186/1471-244X-14-103', 'https://www.ncbi.nlm.nih.gov/pubmed/24708857', 'https://scholar.google.com/scholar_lookup?title=Study+protocol:+safety+correction+of+high+dose+antipsychotic+polypharmacy+in+Japan&author=T+Sukegawa&author=A+Inagaki&author=Y+Yamanouchi&author=T+Inada&author=T+Yoshio&author=R+Yoshimura&publication_year=2014&hl=en']",24708857,https://doi.org/10.1186/1471-244X-14-103, Yamanouchi 2015 {published data only}  ,excluded,CD014384-bbs2-0080, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction (combined dose reduction and polypharmacy reduction) ,,24708857,24708857,18,https://bmcpsychiatry.biomedcentral.com/counter/pdf/10.1186/1471-244X-14-103,,24708857
CD014384-bib-0159,"Yamanouchi Y, Sukegawa T, Inagaki A, Inada T, Yoshio T, Yoshimura R, et al. ",Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method, International Journal of Neuropsychopharmacology ,2015,18,    ,['citation-journal']," Yamanouchi Y, Sukegawa T, Inagaki A, Inada T, Yoshio T, Yoshimura R, et al. Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method.  International Journal of Neuropsychopharmacology 2015;18:5. CENTRAL [DOI: 10.1093/ijnp/pyu016]    Link to article     Google Scholar     ","['', 'https://doi.org/10.1093/ijnp/pyu016', 'https://scholar.google.com/scholar_lookup?title=Evaluation+of+the+individual+safe+correction+of+antipsychotic+agent+polypharmacy+in+Japanese+patients+with+chronic+schizophrenia:+validation+of+safe+corrections+for+antipsychotic+polypharmacy+and+the+high-dose+method+&author=Y+Yamanouchi&author=T+Sukegawa&author=A+Inagaki&author=T+Inada&author=T+Yoshio&author=R+Yoshimura&publication_year=2015&hl=en']",,https://doi.org/10.1093/ijnp/pyu016, Yamanouchi 2015 {published data only}  ,excluded,CD014384-bbs2-0080, Design: randomised Participants: stable individuals with schizophrenia Intervention: no dose reduction (combined dose reduction and polypharmacy reduction) ,,25522380,25522380,23,https://academic.oup.com/ijnp/article-pdf/18/5/pyu016/7692283/pyu016.pdf,,25522380
CD014384-bib-0160,"Yoon HW, Lee JS, Park SJ, Lee SK, Choi WJ, Kim TY, et al. ","Comparing the effectiveness and safety of the addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia: a multicenter, open-label, prospective study", Clinical Neuropharmacology ,2016,39,    ,['citation-journal']," Yoon HW, Lee JS, Park SJ, Lee SK, Choi WJ, Kim TY, et al. Comparing the effectiveness and safety of the addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia: a multicenter, open-label, prospective study.  Clinical Neuropharmacology 2016;39(6):288–94. CENTRAL [DOI: 10.1097/WNF.0000000000000175]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/WNF.0000000000000175', 'https://www.ncbi.nlm.nih.gov/pubmed/27438182', 'https://scholar.google.com/scholar_lookup?title=Comparing+the+effectiveness+and+safety+of+the+addition+of+and+switching+to+aripiprazole+for+resolving+antipsychotic-induced+hyperprolactinemia:+a+multicenter,+open-label,+prospective+study+&author=HW+Yoon&author=JS+Lee&author=SJ+Park&author=SK+Lee&author=WJ+Choi&author=TY+Kim&publication_year=2016&hl=en']",27438182,https://doi.org/10.1097/WNF.0000000000000175, Yoon 2016 {published data only}  ,excluded,CD014384-bbs2-0081, Design: randomised Participants: stable individuals with schizophrenia Intervention: dose reduction Comparator: no dose maintenance ,,27438182,27438182,31,,,27438182
CD014384-bib-0172,"Achtyes E, Simmons A, Skabeev A, Levy N, Jiang Y, Marcy P, et al. ",Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia, BMC Psychiatry ,2018,18,    ,['citation-journal']," Achtyes E, Simmons A, Skabeev A, Levy N, Jiang Y, Marcy P, et al. Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia.  BMC Psychiatry 2018;18(1):292. [PMID: 30223804]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1186/s12888-018-1856-y', 'https://www.ncbi.nlm.nih.gov/pubmed/30223804', 'https://scholar.google.com/scholar_lookup?title=Patient+preferences+concerning+the+efficacy+and+side-effect+profile+of+schizophrenia+medications:+a+survey+of+patients+living+with+schizophrenia+&author=E+Achtyes&author=A+Simmons&author=A+Skabeev&author=N+Levy&author=Y+Jiang&author=P+Marcy&publication_year=2018&hl=en']",30223804,https://doi.org/10.1186/s12888-018-1856-y, Achtyes 2018 ,additional,CD014384-bbs2-0088,,,30223804,30223804,47,https://bmcpsychiatry.biomedcentral.com/track/pdf/10.1186/s12888-018-1856-y,,30223804
CD014384-bib-0173,"Addington D, Addington J, Maticka-Tyndale E. ",Assessing depression in schizophrenia: the Calgary Depression Scale, British Journal of Psychiatry ,1993,163,    ,['citation-journal']," Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale.  British Journal of Psychiatry 1993;163(S22):39-44.    Link to article     Google Scholar     ","['https://doi.org/10.1192/S0007125000292581', 'https://scholar.google.com/scholar_lookup?title=Assessing+depression+in+schizophrenia:+the+Calgary+Depression+Scale&author=D+Addington&author=J+Addington&author=E+Maticka-Tyndale&publication_year=1993&hl=en']",,https://doi.org/10.1192/S0007125000292581, Addington 1993 ,additional,CD014384-bbs2-0089,,8193062,,8110442,1148,,,8110442
CD014384-bib-0174,"Alphs LD, Summerfelt A, Lann H, Muller RJ. ",The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia, Psychopharmacology Bulletin ,1989,25,    ,['citation-journal']," Alphs LD, Summerfelt A, Lann H, Muller RJ. The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia.  Psychopharmacology Bulletin 1989;25(2):159-63.    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/2602512', 'https://scholar.google.com/scholar_lookup?title=The+negative+symptom+assessment:+a+new+instrument+to+assess+negative+symptoms+of+schizophrenia&author=LD+Alphs&author=A+Summerfelt&author=H+Lann&author=RJ+Muller&publication_year=1989&hl=en']",2602512,, Alphs 1989 ,additional,CD014384-bbs2-0090,,2602512,,,,,,2602512
CD014384-bib-0175,"Altamura AC, Cavallaro R, Regazzetti MG. ",Prevalence and risk factors for tardive dyskinesia: a study in an Italian population of chronic schizophrenics, European Archives of Psychiatry and Clinical Neuroscience ,1990,240,    ,['citation-journal']," Altamura AC, Cavallaro R, Regazzetti MG. Prevalence and risk factors for tardive dyskinesia: a study in an Italian population of chronic schizophrenics.  European Archives of Psychiatry and Clinical Neuroscience 1990;240(1):9-12. [DOI: 10.1007/BF02190085]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1007/BF02190085', 'https://www.ncbi.nlm.nih.gov/pubmed/1979540', 'https://scholar.google.com/scholar_lookup?title=Prevalence+and+risk+factors+for+tardive+dyskinesia:+a+study+in+an+Italian+population+of+chronic+schizophrenics+&author=AC+Altamura&author=R+Cavallaro&author=MG+Regazzetti&publication_year=1990&hl=en']",1979540,https://doi.org/10.1007/BF02190085, Altamura 1990 ,additional,CD014384-bbs2-0091,,,,1979540,7,,,1979540
CD014384-bib-0176,"Altman DG, Bland JM. ",Detecting skewness from summary information, BMJ ,1996,313,    ,['citation-journal']," Altman DG, Bland JM. Detecting skewness from summary information.  BMJ 1996;313(7066):1200. [PMID: 8916759]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.313.7066.1200', 'https://www.ncbi.nlm.nih.gov/pubmed/8916759', 'https://scholar.google.com/scholar_lookup?title=Detecting+skewness+from+summary+information&author=DG+Altman&author=JM+Bland&publication_year=1996&hl=en']",8916759,https://doi.org/10.1136/bmj.313.7066.1200, Altman 1996 ,additional,CD014384-bbs2-0092,,8916759,,8916759,866,https://www.bmj.com/content/bmj/313/7066/1200.1.full.pdf,,8916759
CD014384-bib-0177,"Andreasen N, Carpenter W, Kane J, Lasser R, Marder S, Weinberger D. ",Remission in schizophrenia: proposed criteria and rationale for consensus, American Journal of Psychiatry ,2005,62,    ,['citation-journal']," Andreasen N, Carpenter W, Kane J, Lasser R, Marder S, Weinberger D. Remission in schizophrenia: proposed criteria and rationale for consensus.  American Journal of Psychiatry 2005;62:441-9. [PMID: 15741458]    Link to article     Google Scholar     ","['https://doi.org/10.1176/appi.ajp.162.3.441', 'https://scholar.google.com/scholar_lookup?title=Remission+in+schizophrenia:+proposed+criteria+and+rationale+for+consensus&author=N+Andreasen&author=W+Carpenter&author=J+Kane&author=R+Lasser&author=S+Marder&author=D+Weinberger&publication_year=2005&hl=en']",,https://doi.org/10.1176/appi.ajp.162.3.441, Andreasen 2005 ,additional,CD014384-bbs2-0093,,15741458,,15741458,2314,,,15741458
CD014384-bib-0178,"Andreasen NC, Liu D, Ziebell S, Vora A, Ho BC. ","Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study", American Journal of Psychiatry ,2013,170,    ,['citation-journal']," Andreasen NC, Liu D, Ziebell S, Vora A, Ho BC. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study.  American Journal of Psychiatry 2013;170:609-15. [PMID: 23558429]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1176/appi.ajp.2013.12050674', 'https://www.ncbi.nlm.nih.gov/pubmed/23558429', 'https://scholar.google.com/scholar_lookup?title=Relapse+duration,+treatment+intensity,+and+brain+tissue+loss+in+schizophrenia:+a+prospective+longitudinal+MRI+study+&author=NC+Andreasen&author=D+Liu&author=S+Ziebell&author=A+Vora&author=BC+Ho&publication_year=2013&hl=en']",23558429,https://doi.org/10.1176/appi.ajp.2013.12050674, Andreasen 2013 ,additional,CD014384-bbs2-0094,,23558429,23558429,23558429,323,https://europepmc.org/articles/pmc3835590?pdf=render,,23558429
CD014384-bib-0179,American Psychiatric Association. ,,Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R),1987,,.   ,['citation-book']," American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R). Washington, DC : American Psychiatric Press, 1987.    ",[],,, APA 1987 ,additional,CD014384-bbs2-0095,,41699920,,,,,,41699920
CD014384-bib-0180,"Auquier P, Simeoni MC, Sapin C, Reine G, Aghababian V, Cramer J, et al. ",Development and validation of a patient-based health-related quality of life questionnaire in schizophrenia: the S-QoL, Schizophrenia Research ,2003,63,    ,['citation-journal']," Auquier P, Simeoni MC, Sapin C, Reine G, Aghababian V, Cramer J, et al. Development and validation of a patient-based health-related quality of life questionnaire in schizophrenia: the S-QoL.  Schizophrenia Research 2003;63(1-2):137-49.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0920-9964(02)00355-9', 'https://www.ncbi.nlm.nih.gov/pubmed/12892868', 'https://scholar.google.com/scholar_lookup?title=Development+and+validation+of+a+patient-based+health-related+quality+of+life+questionnaire+in+schizophrenia:+the+S-QoL+&author=P+Auquier&author=MC+Simeoni&author=C+Sapin&author=G+Reine&author=V+Aghababian&author=J+Cramer&publication_year=2003&hl=en']",12892868,https://doi.org/10.1016/S0920-9964(02)00355-9, Auquier 2003 ,additional,CD014384-bbs2-0096,,,12892868,12892868,147,,,12892868
CD014384-bib-0181,Awad AG. ,Subjective response to neuroleptics in schizophrenia, Schizophrenia Bulletin ,1993,19,    ,['citation-journal'], Awad AG. Subjective response to neuroleptics in schizophrenia.  Schizophrenia Bulletin 1993;19(3):609-18.    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.1093/schbul/19.3.609', 'https://www.ncbi.nlm.nih.gov/pubmed/7901897', 'https://scholar.google.com/scholar_lookup?title=Subjective+response+to+neuroleptics+in+schizophrenia&author=AG+Awad&publication_year=1993&hl=en']",7901897,https://doi.org/10.1093/schbul/19.3.609, Awad 1993 ,additional,CD014384-bbs2-0097,,30511350,,,240,,,7901897
CD014384-bib-0182,"Barbui C, Bighelli I, Carrà G, Castellazzi M, Lucii C, Martinotti M, et al,  STAR Network Investigators. ",Antipsychotic dose mediates the association between polypharmacy and corrected QT interval, PLOS ONE ,2016,11,    ,['citation-journal']," Barbui C, Bighelli I, Carrà G, Castellazzi M, Lucii C, Martinotti M, et al,  STAR Network Investigators. Antipsychotic dose mediates the association between polypharmacy and corrected QT interval.  PLOS ONE 2016;11(2):e0148212. [PMID: 26840602]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1371/journal.pone.0148212', 'https://www.ncbi.nlm.nih.gov/pubmed/26840602', 'https://scholar.google.com/scholar_lookup?title=Antipsychotic+dose+mediates+the+association+between+polypharmacy+and+corrected+QT+interval+&author=C+Barbui&author=I+Bighelli&author=G+Carrà&author=M+Castellazzi&author=C+Lucii&author=M+Martinotti&publication_year=2016&hl=en']",26840602,https://doi.org/10.1371/journal.pone.0148212, Barbui 2016 ,additional,CD014384-bbs2-0098,,,,26840602,53,https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0148212&type=printable,,26840602
CD014384-bib-0183,Barnes TRE. ,A rating scale for drug-induced akathisia, British Journal of Psychiatry ,1989,154,    ,['citation-journal'], Barnes TRE. A rating scale for drug-induced akathisia.  British Journal of Psychiatry 1989;154(5):672-6.    Link to article     Google Scholar     ,"['https://doi.org/10.1192/bjp.154.5.672', 'https://scholar.google.com/scholar_lookup?title=A+rating+scale+for+drug-induced+akathisia&author=TRE+Barnes&publication_year=1989&hl=en']",,https://doi.org/10.1192/bjp.154.5.672, Barnes 1989 ,additional,CD014384-bbs2-0099,,14870947,,2574607,2210,,,2574607
CD014384-bib-0184,"Bergman H, Rathbone J, Agarwal V, Soares-Weiser K. ",Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia, Cochrane Database of Systematic Reviews ,2018,,    ,['citation-journal']," Bergman H, Rathbone J, Agarwal V, Soares-Weiser K. Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.  Cochrane Database of Systematic Reviews 2018, Issue 2. Art. No: CD000459. [DOI: 10.1002/14651858.CD000459.pub3]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD000459.pub3', 'https://scholar.google.com/scholar_lookup?title=Antipsychotic+reduction+and/or+cessation+and+antipsychotics+as+specific+treatments+for+tardive+dyskinesia+&author=H+Bergman&author=J+Rathbone&author=V+Agarwal&author=K+Soares-Weiser&publication_year=2018&hl=en']",,https://doi.org/10.1002/14651858.CD000459.pub3, Bergman 2018 ,additional,CD014384-bbs2-0100,,29409162,,29409162,40,https://europepmc.org/articles/pmc6491084?pdf=render,,29409162
CD014384-bib-0185,"Bighelli I, Rodolico A, Siafis S, Samara MT, Hansen WP, Salomone S, et al. ",Antipsychotic polypharmacy reduction compared to polypharmacy continuation for people with schizophrenia, Cochrane Database of Systematic Reviews ,2022,,    ,['citation-journal']," Bighelli I, Rodolico A, Siafis S, Samara MT, Hansen WP, Salomone S, et al. Antipsychotic polypharmacy reduction compared to polypharmacy continuation for people with schizophrenia.  Cochrane Database of Systematic Reviews 2022, Issue 8. Art. No: CD014383. [DOI: 10.1002/14651858.CD014383.pub2]    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Antipsychotic+polypharmacy+reduction+compared+to+polypharmacy+continuation+for+people+with+schizophrenia+&author=I+Bighelli&author=A+Rodolico&author=S+Siafis&author=MT+Samara&author=WP+Hansen&author=S+Salomone&publication_year=2022&hl=en'],,, Bighelli 2022 ,additional,CD014384-bbs2-0101,,,,,,,,
CD014384-bib-0186,Bland JM. ,Statistics notes. Trials randomised in clusters, BMJ ,1997,315,    ,['citation-journal'], Bland JM. Statistics notes. Trials randomised in clusters.  BMJ 1997;315(7108):600. [PMID: 9302962]    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.1136/bmj.315.7108.600', 'https://www.ncbi.nlm.nih.gov/pubmed/9302962', 'https://scholar.google.com/scholar_lookup?title=Statistics+notes.+Trials+randomised+in+clusters&author=JM+Bland&publication_year=1997&hl=en']",9302962,https://doi.org/10.1136/bmj.315.7108.600, Bland 1997 ,additional,CD014384-bbs2-0102,,26037412,,9302962,548,https://www.bmj.com/content/bmj/315/7108/600.full.pdf,,9302962
CD014384-bib-0187,"Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. ",The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use, Therapie ,1999,54,    ,['citation-journal']," Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Aperçu sur la problématique des indices d'efficacité thérapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite].  Therapie 1999;54(4):405-11. [PMID: 10667106]    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/10667106', 'https://scholar.google.com/scholar_lookup?title=The+problem+of+therapeutic+efficacy+indices.+3.+Comparison+of+the+indices+and+their+use+&author=JP+Boissel&author=M+Cucherat&author=W+Li&author=G+Chatellier&author=F+Gueyffier&author=M+Buyse&publication_year=1999&hl=en']",10667106,, Boissel 1999 ,additional,CD014384-bbs2-0103,,,,,,,,10667106
CD014384-bib-0188,"Bouwmans C, de Sonneville C, Mulder CL, Hakkaart-van Roijen L. ",Employment and the associated impact on quality of life in people diagnosed with schizophrenia, Neuropsychiatric Disease and Treatment ,2015,11,    ,['citation-journal']," Bouwmans C, de Sonneville C, Mulder CL, Hakkaart-van Roijen L. Employment and the associated impact on quality of life in people diagnosed with schizophrenia.  Neuropsychiatric Disease and Treatment 2015;11:2125-42. [PMID: 26316759]    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/26316759', 'https://scholar.google.com/scholar_lookup?title=Employment+and+the+associated+impact+on+quality+of+life+in+people+diagnosed+with+schizophrenia&author=C+Bouwmans&author=C+Sonneville&author=CL+Mulder&author=L+Hakkaart-vanRoijen&publication_year=2015&hl=en']",26316759,, Bouwmans 2015 ,additional,CD014384-bbs2-0104,,26316759,,,,,,26316759
CD014384-bib-0189,"Busner J, Targum SD. ",The clinical global impressions scale: applying a research tool in clinical practice, Psychiatry (Edgmont) ,,4,    ,['citation-journal']," Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice.  Psychiatry (Edgmont)  2007/07;4(7):28-37.    PubMed     ",['https://www.ncbi.nlm.nih.gov/pubmed/20526405'],20526405,, Busner 2007/07 ,additional,CD014384-bbs2-0105,,20526405,,,,,,20526405
CD014384-bib-0190,"Caroff SN, Mu F, Ayyagari R, Schilling T, Abler V, Carroll B. ",Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia, BMC Psychiatry ,2018,18,    ,['citation-journal']," Caroff SN, Mu F, Ayyagari R, Schilling T, Abler V, Carroll B. Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia.  BMC Psychiatry 2018;18(1):306. [PMID: 30249218]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1186/s12888-018-1889-2', 'https://www.ncbi.nlm.nih.gov/pubmed/30249218', 'https://scholar.google.com/scholar_lookup?title=Hospital+utilization+rates+following+antipsychotic+dose+reductions:+implications+for+tardive+dyskinesia+&author=SN+Caroff&author=F+Mu&author=R+Ayyagari&author=T+Schilling&author=V+Abler&author=B+Carroll&publication_year=2018&hl=en']",30249218,https://doi.org/10.1186/s12888-018-1889-2, Caroff 2018 ,additional,CD014384-bbs2-0106,,32652964,,30249218,21,https://bmcpsychiatry.biomedcentral.com/track/pdf/10.1186/s12888-018-1889-2,,30249218
CD014384-bib-0191,"Carpenter WT Jr, Buchanan RW. ",Schizophrenia, New England Journal of Medicine ,1994,330,    ,['citation-journal']," Carpenter WT Jr, Buchanan RW. Schizophrenia.  New England Journal of Medicine 1994;330:681-90. [PMID: 8107719]    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/8107719', 'https://scholar.google.com/scholar_lookup?title=Schizophrenia&author=RW+Buchanan&publication_year=1994&hl=en']",8107719,, Carpenter 1994 ,additional,CD014384-bbs2-0107,,32332475,,,,,,8107719
CD014384-bib-0192,"Cassady SL, Thaker GK, Summerfelt A, Tamminga CA. ",The Maryland Psychiatric Research Center scale and the characterization of involuntary movements, Psychiatry Research ,1997,70,    ,['citation-journal']," Cassady SL, Thaker GK, Summerfelt A, Tamminga CA. The Maryland Psychiatric Research Center scale and the characterization of involuntary movements.  Psychiatry Research 1997;70(1):21-37.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0165-1781(97)03031-X', 'https://www.ncbi.nlm.nih.gov/pubmed/9172274', 'https://scholar.google.com/scholar_lookup?title=The+Maryland+Psychiatric+Research+Center+scale+and+the+characterization+of+involuntary+movements+&author=SL+Cassady&author=GK+Thaker&author=A+Summerfelt&author=CA+Tamminga&publication_year=1997&hl=en']",9172274,https://doi.org/10.1016/S0165-1781(97)03031-X, Cassady 1997 ,additional,CD014384-bbs2-0108,,9172274,,9172274,49,,,9172274
CD014384-bib-0193,"Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy M, Komossa K, et al. ",Maintenance treatment with antipsychotic drugs for schizophrenia, Cochrane Database of Systematic Reviews ,2020,,    ,['citation-journal']," Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy M, Komossa K, et al. Maintenance treatment with antipsychotic drugs for schizophrenia.  Cochrane Database of Systematic Reviews 2020, Issue 8. Art. No: CD008016. [DOI: 10.1002/14651858.CD008016.pub3]    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/32840872', 'https://scholar.google.com/scholar_lookup?title=Maintenance+treatment+with+antipsychotic+drugs+for+schizophrenia&author=A+Ceraso&author=JJ+Lin&author=J+Schneider-Thoma&author=S+Siafis&author=M+Tardy&author=K+Komossa&publication_year=2020&hl=en']",32840872,, Ceraso 2020 ,additional,CD014384-bbs2-0109,,,,,,,,32840872
CD014384-bib-0194,"Citrome L, Stauffer VL, Chen L, Kinon BJ, Kurtz DL, Jacobson JG, et al. ","Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration", Journal of Clinical Psychopharmacology ,2009,29,    ,['citation-journal']," Citrome L, Stauffer VL, Chen L, Kinon BJ, Kurtz DL, Jacobson JG, et al. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration.  Journal of Clinical Psychopharmacology 2009;29(3):278-83. [PMID: 19440083]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1097/JCP.0b013e3181a289cb', 'https://www.ncbi.nlm.nih.gov/pubmed/19440083', 'https://scholar.google.com/scholar_lookup?title=Olanzapine+plasma+concentrations+after+treatment+with+10,+20,+and+40+mg/d+in+patients+with+schizophrenia:+an+analysis+of+correlations+with+efficacy,+weight+gain,+and+prolactin+concentration+&author=L+Citrome&author=VL+Stauffer&author=L+Chen&author=BJ+Kinon&author=DL+Kurtz&author=JG+Jacobson&publication_year=2009&hl=en']",19440083,https://doi.org/10.1097/JCP.0b013e3181a289cb, Citrome 2009 ,additional,CD014384-bbs2-0110,,,19440083,19440083,87,,,19440083
CD014384-bib-0195,,Covidence,,,,". Version accessed 7 October 2022. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.   ",['citation-other']," Covidence. Version accessed 7 October 2022. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.    ",[],,, Covidence [Computer program] ,additional,CD014384-bbs2-0111,,41699724,,,,,,41699724
CD014384-bib-0196,David AS. ,Insight and psychosis, British Journal of Psychiatry ,1990,156,    ,['citation-journal'], David AS. Insight and psychosis.  British Journal of Psychiatry 1990;156(6):798-808.    Link to article     Google Scholar     ,"['https://doi.org/10.1192/bjp.156.6.798', 'https://scholar.google.com/scholar_lookup?title=Insight+and+psychosis&author=AS+David&publication_year=1990&hl=en']",,https://doi.org/10.1192/bjp.156.6.798, David 1990 ,additional,CD014384-bbs2-0112,,41579673,,2207510,1333,https://www.cambridge.org/core/services/aop-cambridge-core/content/view/5FA45CF19CBBE31F8547C13EE157ED76/S0955603600089492a.pdf/div-class-title-insight-and-psychosis-div.pdf,,2207510
CD014384-bib-0197,"Day JC, Wood G, Dewey M, Bentall RP. ",A self-rating scale for measuring neuroleptic side-effects: validation in a group of schizophrenic patients, British Journal of Psychiatry ,1995,166,    ,['citation-journal']," Day JC, Wood G, Dewey M, Bentall RP. A self-rating scale for measuring neuroleptic side-effects: validation in a group of schizophrenic patients.  British Journal of Psychiatry 1995;166(5):650-3.    Link to article     Google Scholar     ","['https://doi.org/10.1192/bjp.166.5.650', 'https://scholar.google.com/scholar_lookup?title=A+self-rating+scale+for+measuring+neuroleptic+side-effects:+validation+in+a+group+of+schizophrenic+patients+&author=JC+Day&author=G+Wood&author=M+Dewey&author=RP+Bentall&publication_year=1995&hl=en']",,https://doi.org/10.1192/bjp.166.5.650, Day 1995 ,additional,CD014384-bbs2-0113,,,,7620752,290,,,7620752
CD014384-bib-0198,Deeks J. ,Issues in the selection for meta-analyses of binary data,,2000,,    ,['citation-other']," Deeks J. Issues in the selection for meta-analyses of binary data. In: 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa. 2000.    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Issues+in+the+selection+for+meta-analyses+of+binary+data&author=J+Deeks&publication_year=2000&hl=en'],,, Deeks 2000 ,additional,CD014384-bbs2-0114,,12111921,,,,,,12111921
CD014384-bib-0199,"Deeks JJ, Higgins JPT, Altman DG, editor(s). ","Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022",,,,. Available from training.cochrane.org/handbook.   ,['citation-other']," Deeks JJ, Higgins JPT, Altman DG, editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.    ",[],,, Deeks 2022 ,additional,CD014384-bbs2-0115,,,,,,,,
CD014384-bib-0200,"Deragotis LR, Lipman RS, Covi MD. ","Symptom checklist-90 (SCL-90), an out-patient rating scale: preliminary report", Psychopharmacology Bulletin ,1973,9,    ,['citation-journal']," Deragotis LR, Lipman RS, Covi MD. Symptom checklist-90 (SCL-90), an out-patient rating scale: preliminary report.  Psychopharmacology Bulletin 1973;9:13-20.    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/4682398', 'https://scholar.google.com/scholar_lookup?title=Symptom+checklist-90+(SCL-90),+an+out-patient+rating+scale:+preliminary+report&author=LR+Deragotis&author=RS+Lipman&author=MD+Covi&publication_year=1973&hl=en']",4682398,, Deragotis 1973 ,additional,CD014384-bbs2-0116,,,,,,,,4682398
CD014384-bib-0201,DGPPN eV (ed) for the Guideline Group. ,,S3 Guideline for Schizophrenia. Abbreviated version,2019,,. [URL: www.awmf.org/leitlinien/detail/ll/038-009.html]   ,['citation-book']," DGPPN eV (ed) for the Guideline Group. S3 Guideline for Schizophrenia. Abbreviated version. Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), 2019. [URL: www.awmf.org/leitlinien/detail/ll/038-009.html]    ",[],,, DGPPN 2019 ,additional,CD014384-bbs2-0117,,,,,,,,
CD014384-bib-0202,"Divine GW, Brown JT, Frazier LM. ",The unit of analysis error in studies about physicians' patient care behavior, Journal of General Internal Medicine ,1992,7,    ,['citation-journal']," Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior.  Journal of General Internal Medicine 1992;7(6):623-9. [PMID: 1453246]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1007/BF02599201', 'https://www.ncbi.nlm.nih.gov/pubmed/1453246', ""https://scholar.google.com/scholar_lookup?title=The+unit+of+analysis+error+in+studies+about+physicians'+patient+care+behavior&author=GW+Divine&author=JT+Brown&author=LM+Frazier&publication_year=1992&hl=en""]",1453246,https://doi.org/10.1007/BF02599201, Divine 1992 ,additional,CD014384-bbs2-0118,,,,1453246,503,,,1453246
CD014384-bib-0203,"Donner A, Klar N. ",Issues in the meta-analysis of cluster randomized trials, Statistics in Medicine ,2002,21,    ,['citation-journal']," Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials.  Statistics in Medicine 2002;21(19):2971-80. [PMID: 12325113]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1002/sim.1301', 'https://www.ncbi.nlm.nih.gov/pubmed/12325113', 'https://scholar.google.com/scholar_lookup?title=Issues+in+the+meta-analysis+of+cluster+randomized+trials&author=A+Donner&author=N+Klar&publication_year=2002&hl=en']",12325113,https://doi.org/10.1002/sim.1301, Donner 2002 ,additional,CD014384-bbs2-0119,,12325113,,12325113,606,,,12325113
CD014384-bib-0204,"Egger M, Davey Smith G, Schneider M, Minder C. ","Bias in meta-analysis detected by a simple, graphical test", BMJ ,1997,315,    ,['citation-journal']," Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test.  BMJ 1997;315(7109):629-34. [PMID: 9310563]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.315.7109.629', 'https://www.ncbi.nlm.nih.gov/pubmed/9310563', 'https://scholar.google.com/scholar_lookup?title=Bias+in+meta-analysis+detected+by+a+simple,+graphical+test&author=M+Egger&author=G+DaveySmith&author=M+Schneider&author=C+Minder&publication_year=1997&hl=en']",9310563,https://doi.org/10.1136/bmj.315.7109.629, Egger 1997 ,additional,CD014384-bbs2-0120,,9310563,,9310563,49922,https://europepmc.org/articles/pmc2127453?pdf=render,,9310563
CD014384-bib-0205,"Elbourne D, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. ",Meta-analyses involving cross-over trials: methodological issues, International Journal of Epidemiology ,2002,31,    ,['citation-journal']," Elbourne D, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues.  International Journal of Epidemiology 2002;31(1):140-9. [PMID: 11914310]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1093/ije/31.1.140', 'https://www.ncbi.nlm.nih.gov/pubmed/11914310', 'https://scholar.google.com/scholar_lookup?title=Meta-analyses+involving+cross-over+trials:+methodological+issues&author=D+Elbourne&author=DG+Altman&author=JP+Higgins&author=F+Curtin&author=HV+Worthington&author=A+Vail&publication_year=2002&hl=en']",11914310,https://doi.org/10.1093/ije/31.1.140, Elbourne 2002 ,additional,CD014384-bbs2-0121,,11914310,,11914310,1541,https://academic.oup.com/ije/article-pdf/31/1/140/18525000/310140.pdf,,11914310
CD014384-bib-0206,"El Yazaji M, Battas O, Agoub M, Moussaoui D, Gutknecht C, Dalery J, et al. ",Validity of the depressive dimension extracted from principal component analysis of the PANSS in drug-free patients with schizophrenia, Schizophrenia Research ,2002,56,    ,['citation-journal']," El Yazaji M, Battas O, Agoub M, Moussaoui D, Gutknecht C, Dalery J, et al. Validity of the depressive dimension extracted from principal component analysis of the PANSS in drug-free patients with schizophrenia.  Schizophrenia Research 2002;56(1-2):121-7.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0920-9964(01)00247-X', 'https://www.ncbi.nlm.nih.gov/pubmed/12084426', 'https://scholar.google.com/scholar_lookup?title=Validity+of+the+depressive+dimension+extracted+from+principal+component+analysis+of+the+PANSS+in+drug-free+patients+with+schizophrenia+&author=M+ElYazaji&author=O+Battas&author=M+Agoub&author=D+Moussaoui&author=C+Gutknecht&author=J+Dalery&publication_year=2002&hl=en']",12084426,https://doi.org/10.1016/S0920-9964(01)00247-X, El Yazaji 2002 ,additional,CD014384-bbs2-0122,,,12084426,12084426,79,,,12084426
CD014384-bib-0207,"Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. ",Imputing missing standard deviations in meta-analyses can provide accurate results, Journal of Clinical Epidemiology ,2006,59,    ,['citation-journal']," Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results.  Journal of Clinical Epidemiology 2006;59(1):7-10. [PMID: 16360555]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.jclinepi.2005.06.006', 'https://www.ncbi.nlm.nih.gov/pubmed/16360555', 'https://scholar.google.com/scholar_lookup?title=Imputing+missing+standard+deviations+in+meta-analyses+can+provide+accurate+results&author=TA+Furukawa&author=C+Barbui&author=A+Cipriani&author=P+Brambilla&author=N+Watanabe&publication_year=2006&hl=en']",16360555,https://doi.org/10.1016/j.jclinepi.2005.06.006, Furukawa 2006 ,additional,CD014384-bbs2-0123,,16360555,,16360555,1339,,,16360555
CD014384-bib-0208,"Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. ",Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009, Schizophrenia Research ,2012,138,    ,['citation-journal']," Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.  Schizophrenia Research 2012;138:18-28. [PMID: 22534420]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.schres.2012.03.018', 'https://www.ncbi.nlm.nih.gov/pubmed/22534420', 'https://scholar.google.com/scholar_lookup?title=Prevalence+and+correlates+of+antipsychotic+polypharmacy:+a+systematic+review+and+meta-regression+of+global+and+regional+trends+from+the+1970s+to+2009+&author=JA+Gallego&author=J+Bonetti&author=J+Zhang&author=JM+Kane&author=CU+Correll&publication_year=2012&hl=en']",22534420,https://doi.org/10.1016/j.schres.2012.03.018, Gallego 2012 ,additional,CD014384-bbs2-0124,,22534420,22534420,,,,,22534420
CD014384-bib-0209,"Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. ",International consensus study of antipsychotic dosing, American Journal of Psychiatry ,2010,167,    ,['citation-journal']," Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing.  American Journal of Psychiatry 2010;167:686-93. [PMID: 20360319]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1176/appi.ajp.2009.09060802', 'https://www.ncbi.nlm.nih.gov/pubmed/20360319', ""https://scholar.google.com/scholar_lookup?title=International+consensus+study+of+antipsychotic+dosing&author=DM+Gardner&author=AL+Murphy&author=H+O'Donnell&author=F+Centorrino&author=RJ+Baldessarini&publication_year=2010&hl=en""]",20360319,https://doi.org/10.1176/appi.ajp.2009.09060802, Gardner 2010 ,additional,CD014384-bbs2-0125,,20360319,,,,,,20360319
CD014384-bib-0210,GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. ,"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017", Lancet ,2018,392,    ,['citation-journal']," GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017.  Lancet 2018;392:1789-858. [PMID: 30496104]    Link to article     PubMed     ","['https://doi.org/10.1016/S0140-6736(18)32279-7', 'https://www.ncbi.nlm.nih.gov/pubmed/30496104']",30496104,https://doi.org/10.1016/S0140-6736(18)32279-7, GBD 2018 ,additional,CD014384-bbs2-0126,,36240456,,,,,,30496104
CD014384-bib-0211,,GRADEpro GDT,,,,. Version accessed 6 August 2016. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.   ,['citation-other'], GRADEpro GDT. Version accessed 6 August 2016. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.    ,[],,, GRADEpro GDT [Computer program] ,additional,CD014384-bbs2-0127,,41626889,,,,,,41626889
CD014384-bib-0212,Gulliford MC. ,Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994, American Journal of Epidemiology ,1999,149,    ,['citation-journal'], Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.  American Journal of Epidemiology 1999;149(9):876-83. [PMID: 10221325]    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.1093/oxfordjournals.aje.a009904', 'https://www.ncbi.nlm.nih.gov/pubmed/10221325', 'https://scholar.google.com/scholar_lookup?title=Components+of+variance+and+intraclass+correlations+for+the+design+of+community-based+surveys+and+intervention+studies:+data+from+the+Health+Survey+for+England+1994+&author=MC+Gulliford&publication_year=1999&hl=en']",10221325,https://doi.org/10.1093/oxfordjournals.aje.a009904, Gulliford 1999 ,additional,CD014384-bbs2-0128,,10221325,10221325,10221325,711,https://academic.oup.com/aje/article-pdf/149/9/876/264847/149-9-876.pdf,,10221325
CD014384-bib-0213,Guy W. CGI Clinical Global Impressions. In: ,,ECDEU Assessment Manual for Psychopharmacology,1976,,:218-22.   ,['citation-book']," Guy W. CGI Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976:218-22.    ",[],,, Guy 1976 ,additional,CD014384-bbs2-0129,,,,,,,,
CD014384-bib-0214,"Haro JM, Kamath SA, Ochoa SO, Novick D, Rele K, Fargas A, et al. ",The Clinical Global Impression – Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia, Acta Psychiatrica Scandinavica ,2003,107,    ,['citation-journal']," Haro JM, Kamath SA, Ochoa SO, Novick D, Rele K, Fargas A, et al. The Clinical Global Impression – Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia.  Acta Psychiatrica Scandinavica 2003;107:16-23.    Link to article     Google Scholar     ","['https://doi.org/10.1034/j.1600-0447.107.s416.5.x', 'https://scholar.google.com/scholar_lookup?title=The+Clinical+Global+Impression+–+Schizophrenia+scale:+a+simple+instrument+to+measure+the+diversity+of+symptoms+present+in+schizophrenia+&author=JM+Haro&author=SA+Kamath&author=SO+Ochoa&author=D+Novick&author=K+Rele&author=A+Fargas&publication_year=2003&hl=en']",,https://doi.org/10.1034/j.1600-0447.107.s416.5.x, Haro 2003 ,additional,CD014384-bbs2-0130,,,,12755850,640,,,12755850
CD014384-bib-0215,"Harrow M, Jobe TH, Faull RN. ",Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study, Psychological Medicine ,2012,42,    ,['citation-journal']," Harrow M, Jobe TH, Faull RN. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study.  Psychological Medicine 2012;42:2145-55. [PMID: 22340278]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1017/S0033291712000220', 'https://www.ncbi.nlm.nih.gov/pubmed/22340278', 'https://scholar.google.com/scholar_lookup?title=Do+all+schizophrenia+patients+need+antipsychotic+treatment+continuously+throughout+their+lifetime?+A+20-year+longitudinal+study+&author=M+Harrow&author=TH+Jobe&author=RN+Faull&publication_year=2012&hl=en']",22340278,https://doi.org/10.1017/S0033291712000220, Harrow 2012 ,additional,CD014384-bbs2-0131,,,,22340278,160,https://figshare.com/articles/journal_contribution/Do_all_schizophrenia_patients_need_antipsychotic_treatment_continuously_throughout_their_lifetime_A_20-year_longitudinal_study/10757432/1/files/19269062.pdf,,22340278
CD014384-bib-0216,"Hawk AB, Carpenter WT, Strauss JS. ",Diagnostic criteria and five-year outcome in schizophrenia: a report from the International Pilot Study of Schizophrenia, Archives of General Psychiatry ,1975,32,    ,['citation-journal']," Hawk AB, Carpenter WT, Strauss JS. Diagnostic criteria and five-year outcome in schizophrenia: a report from the International Pilot Study of Schizophrenia.  Archives of General Psychiatry 1975;32(3):343-7.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/archpsyc.1975.01760210077005', 'https://www.ncbi.nlm.nih.gov/pubmed/1115575', 'https://scholar.google.com/scholar_lookup?title=Diagnostic+criteria+and+five-year+outcome+in+schizophrenia:+a+report+from+the+International+Pilot+Study+of+Schizophrenia+&author=AB+Hawk&author=WT+Carpenter&author=JS+Strauss&publication_year=1975&hl=en']",1115575,https://doi.org/10.1001/archpsyc.1975.01760210077005, Hawk 1975 ,additional,CD014384-bbs2-0132,,1115575,1115575,1115575,261,,,1115575
CD014384-bib-0217,"Heinrichs DW, Hanlon TE, Carpenter WT Jr. ",The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome, Schizophrenia Bulletin ,1984,10,    ,['citation-journal']," Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome.  Schizophrenia Bulletin 1984;10(3):388-98.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1093/schbul/10.3.388', 'https://www.ncbi.nlm.nih.gov/pubmed/6474101', 'https://scholar.google.com/scholar_lookup?title=The+Quality+of+Life+Scale:+an+instrument+for+rating+the+schizophrenic+deficit+syndrome&author=DW+Heinrichs&author=TE+Hanlon&publication_year=1984&hl=en']",6474101,https://doi.org/10.1093/schbul/10.3.388, Heinrichs 1984 ,additional,CD014384-bbs2-0133,,6474101,,6474101,1684,https://academic.oup.com/schizophreniabulletin/article-pdf/10/3/388/5229121/10-3-388.pdf,,6474101
CD014384-bib-0218,"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. ",Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017, Pharmacopsychiatry ,2018,51,    ,['citation-journal']," Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017.  Pharmacopsychiatry 2018;51(1-02):9-62. [DOI: 10.1055/s-0043-116492]    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/28910830', 'https://scholar.google.com/scholar_lookup?title=Consensus+guidelines+for+therapeutic+drug+monitoring+in+neuropsychopharmacology:+update+2017+&author=C+Hiemke&author=N+Bergemann&author=HW+Clement&author=A+Conca&author=J+Deckert&author=K+Domschke&publication_year=2018&hl=en']",28910830,, Hiemke 2018 ,additional,CD014384-bbs2-0134,,,,,,,,28910830
CD014384-bib-0219,"Higgins JP, Thompson SG, Deeks JJ, Altman DG. ",Measuring inconsistency in meta-analyses, BMJ ,2003,327,    ,['citation-journal']," Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses.  BMJ 2003;327(7414):557-60. [PMID: 12958120]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.327.7414.557', 'https://www.ncbi.nlm.nih.gov/pubmed/12958120', 'https://scholar.google.com/scholar_lookup?title=Measuring+inconsistency+in+meta-analyses&author=JP+Higgins&author=SG+Thompson&author=JJ+Deeks&author=DG+Altman&publication_year=2003&hl=en']",12958120,https://doi.org/10.1136/bmj.327.7414.557, Higgins 2003 ,additional,CD014384-bbs2-0135,,12958120,,12958120,55390,https://europepmc.org/articles/pmc192859?pdf=render,,12958120
CD014384-bib-0220,"Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). ","Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021",,,,. Available from training.cochrane.org/handbook/archive/v6.2.   ,['citation-other']," Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.    ",[],,, Higgins 2021a ,additional,CD014384-bbs2-0136,,,,,,,,
CD014384-bib-0221,"Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. ","Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021",,,,. Available from training.cochrane.org/handbook/archive/v6.2.   ,['citation-other']," Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.    ",[],,, Higgins 2021b ,additional,CD014384-bbs2-0137,,,,,,,,
CD014384-bib-0222,"Hill AL, Sun B, Karagianis JL, Watson SB, McDonnell DP. ",Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia, BMC Psychiatry ,2011,11,    ,['citation-journal']," Hill AL, Sun B, Karagianis JL, Watson SB, McDonnell DP. Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia.  BMC Psychiatry 2011;11:28. [DOI: 10.1186/1471-244X-11-28]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1186/1471-244X-11-28', 'https://www.ncbi.nlm.nih.gov/pubmed/21324135', 'https://scholar.google.com/scholar_lookup?title=Dose-associated+changes+in+safety+and+efficacy+parameters+observed+in+a+24-week+maintenance+trial+of+olanzapine+long-acting+injection+in+patients+with+schizophrenia+&author=AL+Hill&author=B+Sun&author=JL+Karagianis&author=SB+Watson&author=DP+McDonnell&publication_year=2011&hl=en']",21324135,https://doi.org/10.1186/1471-244X-11-28, Hill 2011 ,additional,CD014384-bbs2-0138,,,,,,,,21324135
CD014384-bib-0223,"Hjorthoj C, Sturup AE, McGrath JJ, Nordentoft M. ",Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis, Lancet Psychiatry ,2017,4,    ,['citation-journal']," Hjorthoj C, Sturup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis.  Lancet Psychiatry 2017;4(4):295-301. [PMID: 28237639]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S2215-0366(17)30078-0', 'https://www.ncbi.nlm.nih.gov/pubmed/28237639', 'https://scholar.google.com/scholar_lookup?title=Years+of+potential+life+lost+and+life+expectancy+in+schizophrenia:+a+systematic+review+and+meta-analysis+&author=C+Hjorthoj&author=AE+Sturup&author=JJ+McGrath&author=M+Nordentoft&publication_year=2017&hl=en']",28237639,https://doi.org/10.1016/S2215-0366(17)30078-0, Hjorthoj 2017 ,additional,CD014384-bbs2-0139,,28237639,,,,,,28237639
CD014384-bib-0224,"Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. ",Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia, Archives of General Psychiatry ,2011,68,    ,['citation-journal']," Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia.  Archives of General Psychiatry 2011;68:128-37. [PMID: 21300943]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/archgenpsychiatry.2010.199', 'https://www.ncbi.nlm.nih.gov/pubmed/21300943', 'https://scholar.google.com/scholar_lookup?title=Long-term+antipsychotic+treatment+and+brain+volumes:+a+longitudinal+study+of+first-episode+schizophrenia+&author=BC+Ho&author=NC+Andreasen&author=S+Ziebell&author=R+Pierson&author=V+Magnotta&publication_year=2011&hl=en']",21300943,https://doi.org/10.1001/archgenpsychiatry.2010.199, Ho 2011 ,additional,CD014384-bbs2-0140,,21300943,,,,,,21300943
CD014384-bib-0225,"Hogan TP, Awad AG, Eastwood R. ",A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity, Psychological Medicine ,1983,13,    ,['citation-journal']," Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity.  Psychological Medicine 1983;13(1):177-83.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1017/S0033291700050182', 'https://www.ncbi.nlm.nih.gov/pubmed/6133297', 'https://scholar.google.com/scholar_lookup?title=A+self-report+scale+predictive+of+drug+compliance+in+schizophrenics:+reliability+and+discriminative+validity+&author=TP+Hogan&author=AG+Awad&author=R+Eastwood&publication_year=1983&hl=en']",6133297,https://doi.org/10.1017/S0033291700050182, Hogan 1983 ,additional,CD014384-bbs2-0141,,6133297,,,,,,6133297
CD014384-bib-0226,"Horowitz MA, Jauhar S, Natesan S, Murray RM, Taylor D. ",A method for tapering antipsychotic treatment that may minimize the risk of relapse, Schizophrenia Bulletin ,2021,47,    ,['citation-journal']," Horowitz MA, Jauhar S, Natesan S, Murray RM, Taylor D. A method for tapering antipsychotic treatment that may minimize the risk of relapse.  Schizophrenia Bulletin 2021;47(4):1116-29. [DOI: 10.1093/schbul/sbab017]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1093/schbul/sbab017', 'https://www.ncbi.nlm.nih.gov/pubmed/33754644', 'https://scholar.google.com/scholar_lookup?title=A+method+for+tapering+antipsychotic+treatment+that+may+minimize+the+risk+of+relapse&author=MA+Horowitz&author=S+Jauhar&author=S+Natesan&author=RM+Murray&author=D+Taylor&publication_year=2021&hl=en']",33754644,https://doi.org/10.1093/schbul/sbab017, Horowitz 2021 ,additional,CD014384-bbs2-0142,,33754644,,,,,,33754644
CD014384-bib-0227,Hutton JL. ,Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials, British Journal of Haematology ,2009,146,    ,['citation-journal'], Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials.  British Journal of Haematology 2009;146(1):27-30. [PMID: 19438480]    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.1111/j.1365-2141.2009.07707.x', 'https://www.ncbi.nlm.nih.gov/pubmed/19438480', 'https://scholar.google.com/scholar_lookup?title=Number+needed+to+treat+and+number+needed+to+harm+are+not+the+best+way+to+report+and+assess+the+results+of+randomised+clinical+trials+&author=JL+Hutton&publication_year=2009&hl=en']",19438480,https://doi.org/10.1111/j.1365-2141.2009.07707.x, Hutton 2009 ,additional,CD014384-bbs2-0143,,,,,,,,19438480
CD014384-bib-0228,"Højlund M, Kemp AF, Haddad PM, Neill JC, Correll CU. ",Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials, Lancet Psychiatry ,2021,8,    ,['citation-journal']," Højlund M, Kemp AF, Haddad PM, Neill JC, Correll CU. Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials.  Lancet Psychiatry 2021;8(6):471-86. [DOI: 10.1016/S2215-0366(21)00078-X]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S2215-0366(21)00078-X', 'https://www.ncbi.nlm.nih.gov/pubmed/34023019', 'https://scholar.google.com/scholar_lookup?title=Standard+versus+reduced+dose+of+antipsychotics+for+relapse+prevention+in+multi-episode+schizophrenia:+a+systematic+review+and+meta-analysis+of+randomised+controlled+trials+&author=M+Højlund&author=AF+Kemp&author=PM+Haddad&author=JC+Neill&author=CU+Correll&publication_year=2021&hl=en']",34023019,https://doi.org/10.1016/S2215-0366(21)00078-X, Højlund 2021 ,additional,CD014384-bbs2-0144,,34023019,34023019,,,,,34023019
CD014384-bib-0229,Inada T. ,,DIEPSS: A Second-Generation Rating Scale for Antipsychotic-Induced Extrapyramidal Symptoms: Drug-Induced Extrapyramidal Symptoms Scale,2009,,.   ,['citation-book']," Inada T. DIEPSS: A Second-Generation Rating Scale for Antipsychotic-Induced Extrapyramidal Symptoms: Drug-Induced Extrapyramidal Symptoms Scale. Tokyo: Seiwa Shoten, 2009.    ",[],,, Inada 2009 ,additional,CD014384-bbs2-0145,,41697258,,,,,,41697258
CD014384-bib-0230,Japanese Society of Neuropsychopharmacology. ,Guideline for pharmacological therapy of schizophrenia, Neuropsychopharmacology Reports ,,41,    ,['citation-journal'], Japanese Society of Neuropsychopharmacology. Guideline for pharmacological therapy of schizophrenia.  Neuropsychopharmacology Reports   2021;41(3):266-324. [DOI: 10.1002/npr2.12193]    PubMed     ,['https://www.ncbi.nlm.nih.gov/pubmed/34390232'],34390232,, Japanese Society of Neuropsychopharmacology 2021 ,additional,CD014384-bbs2-0146,,37684711,,,,,,34390232
CD014384-bib-0231,"Kaar SJ, Natesan S, McCutcheon R, Howes D. ",Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology, Neuropharmacology ,2020,172,    ,['citation-journal']," Kaar SJ, Natesan S, McCutcheon R, Howes D. Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology.  Neuropharmacology 2020;172:107704. [PMID: 31299229]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.neuropharm.2019.107704', 'https://www.ncbi.nlm.nih.gov/pubmed/31299229', 'https://scholar.google.com/scholar_lookup?title=Antipsychotics:+mechanisms+underlying+clinical+response+and+side-effects+and+novel+treatment+approaches+based+on+pathophysiology+&author=SJ+Kaar&author=S+Natesan&author=R+McCutcheon&author=D+Howes&publication_year=2020&hl=en']",31299229,https://doi.org/10.1016/j.neuropharm.2019.107704, Kaar 2020 ,additional,CD014384-bbs2-0147,,,31299229,,,,,31299229
CD014384-bib-0232,Kalali A. ,"Patient satisfaction with, and acceptability of, atypical antipsychotics", Current Medical Research and Opinion ,1999,15,    ,['citation-journal']," Kalali A. Patient satisfaction with, and acceptability of, atypical antipsychotics.  Current Medical Research and Opinion 1999;15(2):135-7.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1185/03007999909113374', 'https://www.ncbi.nlm.nih.gov/pubmed/10494497', 'https://scholar.google.com/scholar_lookup?title=Patient+satisfaction+with,+and+acceptability+of,+atypical+antipsychotics&author=A+Kalali&publication_year=1999&hl=en']",10494497,https://doi.org/10.1185/03007999909113374, Kalali 1999 ,additional,CD014384-bbs2-0148,,10494497,,,,,,10494497
CD014384-bib-0233,"Kay SR, Opler LA, Fiszbein A. ",,Positive and Negative Syndrome Scale (PANSS) Manual,1986,,.   ,['citation-book']," Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi-Health Systems, 1986.    ",[],,, Kay 1986 ,additional,CD014384-bbs2-0149,,1935026,,,,,,1935026
CD014384-bib-0234,"Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. ",The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia, American Journal of Psychiatry ,2020,177,    ,['citation-journal']," Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia.  American Journal of Psychiatry 2020;177(9):868-72. [DOI: 10.1176/appi.ajp.2020.177901]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1176/appi.ajp.2020.177901', 'https://www.ncbi.nlm.nih.gov/pubmed/32867516', 'https://scholar.google.com/scholar_lookup?title=The+American+Psychiatric+Association+practice+guideline+for+the+treatment+of+patients+with+schizophrenia+&author=GA+Keepers&author=LJ+Fochtmann&author=JM+Anzia&author=S+Benjamin&author=JM+Lyness&author=R+Mojtabai&publication_year=2020&hl=en']",32867516,https://doi.org/10.1176/appi.ajp.2020.177901, Keepers 2020 ,additional,CD014384-bbs2-0150,,,,,,,,32867516
CD014384-bib-0235,"Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, et al. ","The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization", American Journal of Psychiatry ,2008,165,    ,['citation-journal']," Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, et al. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.  American Journal of Psychiatry 2008;165(2):214-20.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1176/appi.ajp.2007.07010043', 'https://www.ncbi.nlm.nih.gov/pubmed/18172018', 'https://scholar.google.com/scholar_lookup?title=The+MATRICS+Consensus+Cognitive+Battery,+part+2:+co-norming+and+standardization&author=RS+Kern&author=KH+Nuechterlein&author=MF+Green&author=LE+Baade&author=WS+Fenton&author=JM+Gold&publication_year=2008&hl=en']",18172018,https://doi.org/10.1176/appi.ajp.2007.07010043, Kern 2008 ,additional,CD014384-bbs2-0151,,,18172018,,,,,18172018
CD014384-bib-0236,"Knox ED, Stimmel GL. ","Clinical review of a long-acting, injectable formulation of risperidone", Clinical Therapy ,2004,26,    ,['citation-journal']," Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone.  Clinical Therapy 2004;26(12):1994-2002. [PMID: 15823763]    Link to article     Google Scholar     ","['https://doi.org/10.1016/j.clinthera.2004.12.009', 'https://scholar.google.com/scholar_lookup?title=Clinical+review+of+a+long-acting,+injectable+formulation+of+risperidone&author=ED+Knox&author=GL+Stimmel&publication_year=2004&hl=en']",,https://doi.org/10.1016/j.clinthera.2004.12.009, Knox 2004 ,additional,CD014384-bbs2-0152,,15823763,,,,,,15823763
CD014384-bib-0237,"Lako IM, van den Heuvel ER, Knegtering H, Bruggeman R, Taxis K. ",Estimating dopamine D 2 receptor occupancy for doses of 8 antipsychotics - a meta-analysis, Journal of Clinical Psychopharmacology ,2013,33,    ,['citation-journal']," Lako IM, van den Heuvel ER, Knegtering H, Bruggeman R, Taxis K. Estimating dopamine D 2 receptor occupancy for doses of 8 antipsychotics - a meta-analysis.  Journal of Clinical Psychopharmacology 2013;33:675-81. [PMID: 24949704]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1097/JCP.0b013e3182983ffa', 'https://www.ncbi.nlm.nih.gov/pubmed/23948784', 'https://scholar.google.com/scholar_lookup?title=Estimating+dopamine+D+2+receptor+occupancy+for+doses+of+8+antipsychotics+-+a+meta-analysis&author=IM+Lako&author=ER+denHeuvel&author=H+Knegtering&author=R+Bruggeman&author=K+Taxis&publication_year=2013&hl=en']",23948784,https://doi.org/10.1097/JCP.0b013e3182983ffa, Lako 2013 ,additional,CD014384-bbs2-0153,,24949704,,,,,,23948784
CD014384-bib-0238,"Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf M, et al. Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors(s). ",,Cochrane Handbook for Systematic Reviews of Interventions,2019,,    ,['citation-book']," Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf M, et al. Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors(s). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley & Sons, 2019:67-107. [DOI: 10.1002/9781119536604.ch4]    Link to article     ",['https://doi.org/10.1002/9781119536604.ch4'],,https://doi.org/10.1002/9781119536604.ch4, Lefebvre 2019 ,additional,CD014384-bbs2-0154,,,,,,,,
CD014384-bib-0239,"Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. ",Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology, Biological Psychiatry ,2006,59,    ,['citation-journal']," Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology.  Biological Psychiatry 2006;59(11):1001-5. [PMID: 16905632]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.biopsych.2005.10.020', 'https://www.ncbi.nlm.nih.gov/pubmed/16503329', 'https://scholar.google.com/scholar_lookup?title=Attrition+in+randomized+controlled+clinical+trials:+methodological+issues+in+psychopharmacology&author=AC+Leon&author=CH+Mallinckrodt&author=C+Chuang-Stein&author=DG+Archibald&author=GE+Archer&author=K+Chartier&publication_year=2006&hl=en']",16503329,https://doi.org/10.1016/j.biopsych.2005.10.020, Leon 2006 ,additional,CD014384-bbs2-0155,,16503329,16503329,,,,,16503329
CD014384-bib-0240,"Lesh TA, Tanase C, Geib BR, Niendam TA, Yoon JH, Minzenberg MJ, et al. ",A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia, JAMA Psychiatry ,2015,72,    ,['citation-journal']," Lesh TA, Tanase C, Geib BR, Niendam TA, Yoon JH, Minzenberg MJ, et al. A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia.  JAMA Psychiatry 2015;72:226-34. [PMID: 25588194]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/jamapsychiatry.2014.2178', 'https://www.ncbi.nlm.nih.gov/pubmed/25588194', 'https://scholar.google.com/scholar_lookup?title=A+multimodal+analysis+of+antipsychotic+effects+on+brain+structure+and+function+in+first-episode+schizophrenia+&author=TA+Lesh&author=C+Tanase&author=BR+Geib&author=TA+Niendam&author=JH+Yoon&author=MJ+Minzenberg&publication_year=2015&hl=en']",25588194,https://doi.org/10.1001/jamapsychiatry.2014.2178, Lesh 2015 ,additional,CD014384-bbs2-0156,,,25588194,,,,,25588194
CD014384-bib-0241,"Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. ",Clinical implications of Brief Psychiatric Rating Scale scores, British Journal of Psychiatry ,2005,187,    ,['citation-journal']," Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores.  British Journal of Psychiatry 2005;187:366-71. [PMID: 16199797]    Link to article     Google Scholar     ","['https://doi.org/10.1192/bjp.187.4.366', 'https://scholar.google.com/scholar_lookup?title=Clinical+implications+of+Brief+Psychiatric+Rating+Scale+scores&author=S+Leucht&author=JM+Kane&author=W+Kissling&author=J+Hamann&author=E+Etschel&author=R+Engel&publication_year=2005&hl=en']",,https://doi.org/10.1192/bjp.187.4.366, Leucht 2005a ,additional,CD014384-bbs2-0157,,16823384,,,,,,16823384
CD014384-bib-0242,"Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. ",What does the PANSS mean?, Schizophrenia Research ,2005,79,    ,['citation-journal']," Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophrenia Research 2005;79(2-3):231-8. [PMID: 15982856]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.schres.2005.04.008', 'https://www.ncbi.nlm.nih.gov/pubmed/15982856', 'https://scholar.google.com/scholar_lookup?title=What+does+the+PANSS+mean?&author=S+Leucht&author=JM+Kane&author=W+Kissling&author=J+Hamann&author=E+Etschel&author=RR+Engel&publication_year=2005&hl=en']",15982856,https://doi.org/10.1016/j.schres.2005.04.008, Leucht 2005b ,additional,CD014384-bbs2-0158,,16823384,,,,,,15982856
CD014384-bib-0243,"Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. ",Maintenance treatment with antipsychotic drugs for schizophrenia, Cochrane Database of Systematic Reviews ,2012,,    ,['citation-journal']," Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia.  Cochrane Database of Systematic Reviews 2012, Issue 5. Art. No: CD008016. [DOI: 10.1002/14651858.CD008016.pub2]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD008016.pub2', 'https://scholar.google.com/scholar_lookup?title=Maintenance+treatment+with+antipsychotic+drugs+for+schizophrenia&author=S+Leucht&author=M+Tardy&author=K+Komossa&author=S+Heres&author=W+Kissling&author=JM+Davis&publication_year=2012&hl=en']",,https://doi.org/10.1002/14651858.CD008016.pub2, Leucht 2012 ,additional,CD014384-bbs2-0159,,32840872,,,,,,32840872
CD014384-bib-0244,"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. ",Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis, Lancet ,2013,382,    ,['citation-journal']," Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.  Lancet 2013;382:951-62. [PMID: 23810019]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0140-6736(13)60733-3', 'https://www.ncbi.nlm.nih.gov/pubmed/23810019', 'https://scholar.google.com/scholar_lookup?title=Comparative+efficacy+and+tolerability+of+15+antipsychotic+drugs+in+schizophrenia:+a+multiple-treatments+meta-analysis+&author=S+Leucht&author=A+Cipriani&author=L+Spineli&author=D+Mavridis&author=D+Orey&author=F+Richter&publication_year=2013&hl=en']",23810019,https://doi.org/10.1016/S0140-6736(13)60733-3, Leucht 2013 ,additional,CD014384-bbs2-0160,,,,,,,,23810019
CD014384-bib-0245,"Leucht S, Samara M, Heres S, Davis JM. ",Dose equivalents for antipsychotic drugs: the DDD method, Schizophrenia Bulletin ,2016,42,    ,['citation-journal']," Leucht S, Samara M, Heres S, Davis JM. Dose equivalents for antipsychotic drugs: the DDD method.  Schizophrenia Bulletin 2016;42(Suppl 1):S90-4. [DOI: 10.1093/schbul/sbv167]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1093/schbul/sbv167', 'https://www.ncbi.nlm.nih.gov/pubmed/27460622', 'https://scholar.google.com/scholar_lookup?title=Dose+equivalents+for+antipsychotic+drugs:+the+DDD+method&author=S+Leucht&author=M+Samara&author=S+Heres&author=JM+Davis&publication_year=2016&hl=en']",27460622,https://doi.org/10.1093/schbul/sbv167, Leucht 2016 ,additional,CD014384-bbs2-0161,,27460622,,,,,,27460622
CD014384-bib-0246,"Leucht S, Bauer S, Siafis S, Hamza T, Wu H, Schneider-Thoma J, et al. ",Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia: a meta-analysis, JAMA Psychiatry ,2021,78,    ,['citation-journal']," Leucht S, Bauer S, Siafis S, Hamza T, Wu H, Schneider-Thoma J, et al. Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia: a meta-analysis.  JAMA Psychiatry 2021;78(11):1238-48. [DOI: 10.1001/jamapsychiatry.2021.2130]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/jamapsychiatry.2021.2130', 'https://www.ncbi.nlm.nih.gov/pubmed/34406325', 'https://scholar.google.com/scholar_lookup?title=Examination+of+dosing+of+antipsychotic+drugs+for+relapse+prevention+in+patients+with+stable+schizophrenia:+a+meta-analysis+&author=S+Leucht&author=S+Bauer&author=S+Siafis&author=T+Hamza&author=H+Wu&author=J+Schneider-Thoma&publication_year=2021&hl=en']",34406325,https://doi.org/10.1001/jamapsychiatry.2021.2130, Leucht 2021 ,additional,CD014384-bbs2-0162,,,34406325,,,,,34406325
CD014384-bib-0247,"Lindenmayer JP, Czobor P, Alphs L, Nathan AM, Anand R, Islam Z, et al. ",The InterSePT scale for suicidal thinking reliability and validity, Schizophrenia Research ,2003,63,    ,['citation-journal']," Lindenmayer JP, Czobor P, Alphs L, Nathan AM, Anand R, Islam Z, et al. The InterSePT scale for suicidal thinking reliability and validity.  Schizophrenia Research 2003;63(1-2):161-70.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0920-9964(02)00335-3', 'https://www.ncbi.nlm.nih.gov/pubmed/12892870', 'https://scholar.google.com/scholar_lookup?title=The+InterSePT+scale+for+suicidal+thinking+reliability+and+validity&author=JP+Lindenmayer&author=P+Czobor&author=L+Alphs&author=AM+Nathan&author=R+Anand&author=Z+Islam&publication_year=2003&hl=en']",12892870,https://doi.org/10.1016/S0920-9964(02)00335-3, Lindenmayer 2003 ,additional,CD014384-bbs2-0163,,,,,,,,12892870
CD014384-bib-0248,"Lindström E, Lewander T, Malm U, Malt Ulrik F, Lublin H, Ahlfors Ulf G. ",Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat), Nordic Journal of Psychiatry ,2001,55,    ,['citation-journal']," Lindström E, Lewander T, Malm U, Malt Ulrik F, Lublin H, Ahlfors Ulf G. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat).  Nordic Journal of Psychiatry 2001;55(Suppl 44):5-69.    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/11860666', 'https://scholar.google.com/scholar_lookup?title=Patient-rated+versus+clinician-rated+side+effects+of+drug+treatment+in+schizophrenia.+Clinical+validation+of+a+self-rating+version+of+the+UKU+Side+Effect+Rating+Scale+(UKU-SERS-Pat)+&author=E+Lindström&author=T+Lewander&author=U+Malm&author=F+MaltUlrik&author=H+Lublin&author=G+AhlforsUlf&publication_year=2001&hl=en']",11860666,, Lindström 2001 ,additional,CD014384-bbs2-0164,,,11860666,,,,,11860666
CD014384-bib-0249,"Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. ",The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients, Acta Psychiatrica Scandinavica ,1987,334,    ,['citation-journal']," Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.  Acta Psychiatrica Scandinavica 1987;334:1-100.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1111/j.1600-0447.1987.tb10566.x', 'https://www.ncbi.nlm.nih.gov/pubmed/2887090', 'https://scholar.google.com/scholar_lookup?title=The+UKU+side+effect+rating+scale:+a+new+comprehensive+rating+scale+for+psychotropic+drugs+and+a+cross-sectional+study+of+side+effects+in+neuroleptic-treated+patients+&author=O+Lingjaerde&author=UG+Ahlfors&author=P+Bech&author=SJ+Dencker&author=K+Elgen&publication_year=1987&hl=en']",2887090,https://doi.org/10.1111/j.1600-0447.1987.tb10566.x, Lingjaerde 1987 ,additional,CD014384-bbs2-0165,,,,,,,,2887090
CD014384-bib-0250,"Liu CC, Takeuchi H. ",Achieving the lowest effective antipsychotic dose for patients with remitted psychosis: a proposed guided dose-reduction algorithm, CNS Drugs ,2020,34,    ,['citation-journal']," Liu CC, Takeuchi H. Achieving the lowest effective antipsychotic dose for patients with remitted psychosis: a proposed guided dose-reduction algorithm.  CNS Drugs 2020;34(2):117-26. [DOI: 10.1007/s40263-019-00682-8]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1007/s40263-019-00682-8', 'https://www.ncbi.nlm.nih.gov/pubmed/31741178', 'https://scholar.google.com/scholar_lookup?title=Achieving+the+lowest+effective+antipsychotic+dose+for+patients+with+remitted+psychosis:+a+proposed+guided+dose-reduction+algorithm+&author=CC+Liu&author=H+Takeuchi&publication_year=2020&hl=en']",31741178,https://doi.org/10.1007/s40263-019-00682-8, Liu 2020 ,additional,CD014384-bbs2-0166,,31741178,,,,,,31741178
CD014384-bib-0251,"Marder SR, Chouinard G. ",The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials, Journal of Clinical Psychiatry ,1997,58,    ,['citation-journal']," Marder SR, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.  Journal of Clinical Psychiatry 1997;58(12):5887.    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=The+effects+of+risperidone+on+the+five+dimensions+of+schizophrenia+derived+by+factor+analysis:+combined+results+of+the+North+American+trials+&author=SR+Marder&author=G+Chouinard&publication_year=1997&hl=en'],,, Marder 1997 ,additional,CD014384-bbs2-0167,,9448657,9448657,,,,,9448657
CD014384-bib-0252,"Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. ",Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia, British Journal of Psychiatry ,2000,176,    ,['citation-journal']," Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia.  British Journal of Psychiatry 2000;176:249-52. [PMID: 10755072]    Link to article     Google Scholar     ","['https://doi.org/10.1192/bjp.176.3.249', 'https://scholar.google.com/scholar_lookup?title=Unpublished+rating+scales:+a+major+source+of+bias+in+randomised+controlled+trials+of+treatments+for+schizophrenia+&author=M+Marshall&author=A+Lockwood&author=C+Bradley&author=C+Adams&author=C+Joy&author=M+Fenton&publication_year=2000&hl=en']",,https://doi.org/10.1192/bjp.176.3.249, Marshall 2000 ,additional,CD014384-bbs2-0168,,,,,,,,
CD014384-bib-0253,"McGrath J, Saha S, Chant D, Welham J. ","Schizophrenia: a concise overview of incidence, prevalence, and mortality", Epidemiology Reviews ,2008,30,    ,['citation-journal']," McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality.  Epidemiology Reviews 2008;30:67-76. [PMID: 18480098]    Link to article     Google Scholar     ","['https://doi.org/10.1093/epirev/mxn001', 'https://scholar.google.com/scholar_lookup?title=Schizophrenia:+a+concise+overview+of+incidence,+prevalence,+and+mortality&author=J+McGrath&author=S+Saha&author=D+Chant&author=J+Welham&publication_year=2008&hl=en']",,https://doi.org/10.1093/epirev/mxn001, McGrath 2008 ,additional,CD014384-bbs2-0169,,18480098,18480098,,,,,18480098
CD014384-bib-0254,"Moreno-Küstner B, Martín C, Pastor L. ",Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses, PLOS ONE ,2018,13,    ,['citation-journal']," Moreno-Küstner B, Martín C, Pastor L. Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses.  PLOS ONE 2018;13:e0195687. [PMID: 29649252]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1371/journal.pone.0195687', 'https://www.ncbi.nlm.nih.gov/pubmed/29649252', 'https://scholar.google.com/scholar_lookup?title=Prevalence+of+psychotic+disorders+and+its+association+with+methodological+issues.+A+systematic+review+and+meta-analyses+&author=B+Moreno-Küstner&author=C+Martín&author=L+Pastor&publication_year=2018&hl=en']",29649252,https://doi.org/10.1371/journal.pone.0195687, Moreno‐Küstner 2018 ,additional,CD014384-bbs2-0170,,29649252,,,,,,29649252
CD014384-bib-0255,"Morisky DE, Green LW, Levine DM. ",Concurrent and predictive validity of a self-reported measure of medication adherence, Medical Care ,1986,24,    ,['citation-journal']," Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence.  Medical Care 1986;24:67-74.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1097/00005650-198601000-00007', 'https://www.ncbi.nlm.nih.gov/pubmed/3945130', 'https://scholar.google.com/scholar_lookup?title=Concurrent+and+predictive+validity+of+a+self-reported+measure+of+medication+adherence&author=DE+Morisky&author=LW+Green&author=DM+Levine&publication_year=1986&hl=en']",3945130,https://doi.org/10.1097/00005650-198601000-00007, Morisky 1986 ,additional,CD014384-bbs2-0171,,3945130,,,,,,3945130
CD014384-bib-0256,"Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. ","Development, reliability and acceptability of a new version of the DSM‐IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning", Acta Psychiatrica Scandinavica ,2000,101,    ,['citation-journal']," Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM‐IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning.  Acta Psychiatrica Scandinavica 2000;101(4):323-9.    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/10782554', 'https://scholar.google.com/scholar_lookup?title=Development,+reliability+and+acceptability+of+a+new+version+of+the+DSM‐IV+Social+and+Occupational+Functioning+Assessment+Scale+(SOFAS)+to+assess+routine+social+funtioning+&author=PL+Morosini&author=L+Magliano&author=L+Brambilla&author=S+Ugolini&author=R+Pioli&publication_year=2000&hl=en']",10782554,, Morosini 2000 ,additional,CD014384-bbs2-0172,,,,,,,,10782554
CD014384-bib-0257,Naber D. ,"A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables", International Clinical Psychopharmacology ,1995,10 Suppl 3,    ,['citation-journal']," Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables.  International Clinical Psychopharmacology 1995;10 Suppl 3:133-8.    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/8866775', 'https://scholar.google.com/scholar_lookup?title=A+self-rating+to+measure+subjective+effects+of+neuroleptic+drugs,+relationships+to+objective+psychopathology,+quality+of+life,+compliance+and+other+clinical+variables+&author=D+Naber&publication_year=1995&hl=en']",8866775,, Naber 1995 ,additional,CD014384-bbs2-0173,,8866775,8866775,,,,,8866775
CD014384-bib-0258,"Nielsen RE, Lindström E, Telléus GK, Levander S. ",Is the PANSS cognitive scale measuring cognition?, Nordic Journal of Psychiatry ,2014,68,    ,['citation-journal']," Nielsen RE, Lindström E, Telléus GK, Levander S. Is the PANSS cognitive scale measuring cognition? Nordic Journal of Psychiatry 2014;68(8):573-8.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.3109/08039488.2014.898790', 'https://www.ncbi.nlm.nih.gov/pubmed/24724929', 'https://scholar.google.com/scholar_lookup?title=Is+the+PANSS+cognitive+scale+measuring+cognition?&author=RE+Nielsen&author=E+Lindström&author=GK+Telléus&author=S+Levander&publication_year=2014&hl=en']",24724929,https://doi.org/10.3109/08039488.2014.898790, Nielsen 2014 ,additional,CD014384-bbs2-0174,,,,,,,,24724929
CD014384-bib-0259,"Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, et al. ","The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity", American Journal of Psychiatry ,2008,165,    ,['citation-journal']," Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.  American Journal of Psychiatry 2008;165(2):203-13.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1176/appi.ajp.2007.07010042', 'https://www.ncbi.nlm.nih.gov/pubmed/18172019', 'https://scholar.google.com/scholar_lookup?title=The+MATRICS+Consensus+Cognitive+Battery,+part+1:+test+selection,+reliability,+and+validity+&author=KH+Nuechterlein&author=MF+Green&author=RS+Kern&author=LE+Baade&author=DM+Barch&author=JD+Cohen&publication_year=2008&hl=en']",18172019,https://doi.org/10.1176/appi.ajp.2007.07010042, Nuechterlein 2008 ,additional,CD014384-bbs2-0175,,,18172019,,,,,18172019
CD014384-bib-0260,"O'Carroll RE, Smith K, Couston M, Cossar JA, Hayes PC. ",A comparison of the WHOQOL-100 and the WHOQOL-BREF in detecting change in quality of life following liver transplantation, Quality of Life Research ,2000,9,    ,['citation-journal']," O'Carroll RE, Smith K, Couston M, Cossar JA, Hayes PC. A comparison of the WHOQOL-100 and the WHOQOL-BREF in detecting change in quality of life following liver transplantation.  Quality of Life Research 2000;9(1):121-4.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1023/A:1008901320492', 'https://www.ncbi.nlm.nih.gov/pubmed/10981212', ""https://scholar.google.com/scholar_lookup?title=A+comparison+of+the+WHOQOL-100+and+the+WHOQOL-BREF+in+detecting+change+in+quality+of+life+following+liver+transplantation+&author=RE+O'Carroll&author=K+Smith&author=M+Couston&author=JA+Cossar&author=PC+Hayes&publication_year=2000&hl=en""]",10981212,https://doi.org/10.1023/A:1008901320492, O'Carroll 2000 ,additional,CD014384-bbs2-0176,,10981212,10981212,,,,,10981212
CD014384-bib-0261,"Overall JE, Gorham DR. ",The Brief Psychiatric Rating Scale, Psychological Reports ,1962,10,    ,['citation-journal']," Overall JE, Gorham DR. The Brief Psychiatric Rating Scale.  Psychological Reports 1962;10:799-812.    Link to article     Google Scholar     ","['https://doi.org/10.2466/pr0.1962.10.3.799', 'https://scholar.google.com/scholar_lookup?title=The+Brief+Psychiatric+Rating+Scale&author=JE+Overall&author=DR+Gorham&publication_year=1962&hl=en']",,https://doi.org/10.2466/pr0.1962.10.3.799, Overall 1962 ,additional,CD014384-bbs2-0177,,,,,,,,
CD014384-bib-0262,"Palmer BA, Pankratz VS, Bostwick J. ",The lifetime risk of suicide in schizophrenia: a re-examination, Archives of General Psychiatry ,2005,62,    ,['citation-journal']," Palmer BA, Pankratz VS, Bostwick J. The lifetime risk of suicide in schizophrenia: a re-examination.  Archives of General Psychiatry 2005;62:247-53. [PMID: 15753237]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/archpsyc.62.3.247', 'https://www.ncbi.nlm.nih.gov/pubmed/15753237', 'https://scholar.google.com/scholar_lookup?title=The+lifetime+risk+of+suicide+in+schizophrenia:+a+re-examination&author=BA+Palmer&author=VS+Pankratz&author=J+Bostwick&publication_year=2005&hl=en']",15753237,https://doi.org/10.1001/archpsyc.62.3.247, Palmer 2005 ,additional,CD014384-bbs2-0178,,,,,,,,15753237
CD014384-bib-0263,"Patel MX, Bishara D, Jayakumar S, Zalewska K, Shiers D, Crawford MJ, et al. ",Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales, European Neuropsychopharmacology ,2014,24,    ,['citation-journal']," Patel MX, Bishara D, Jayakumar S, Zalewska K, Shiers D, Crawford MJ, et al. Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales.  European Neuropsychopharmacology 2014;24:499-509. [PMID: 24491953]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.euroneuro.2014.01.014', 'https://www.ncbi.nlm.nih.gov/pubmed/24491953', 'https://scholar.google.com/scholar_lookup?title=Quality+of+prescribing+for+schizophrenia:+evidence+from+a+national+audit+in+England+and+Wales+&author=MX+Patel&author=D+Bishara&author=S+Jayakumar&author=K+Zalewska&author=D+Shiers&author=MJ+Crawford&publication_year=2014&hl=en']",24491953,https://doi.org/10.1016/j.euroneuro.2014.01.014, Patel 2014 ,additional,CD014384-bbs2-0179,,,,,,,,24491953
CD014384-bib-0264,"Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. ",Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry, Journal of Clinical Epidemiology ,2008,61,    ,['citation-journal']," Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry.  Journal of Clinical Epidemiology 2008;61(10):991-6. [PMID: 18538991]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.jclinepi.2007.11.010', 'https://www.ncbi.nlm.nih.gov/pubmed/18538991', 'https://scholar.google.com/scholar_lookup?title=Contour-enhanced+meta-analysis+funnel+plots+help+distinguish+publication+bias+from+other+causes+of+asymmetry+&author=JL+Peters&author=AJ+Sutton&author=DR+Jones&author=KR+Abrams&author=L+Rushton&publication_year=2008&hl=en']",18538991,https://doi.org/10.1016/j.jclinepi.2007.11.010, Peters 2008 ,additional,CD014384-bbs2-0180,,18538991,18538991,,,,,18538991
CD014384-bib-0265,"Popovic D, Benabarre A, Crespo JM, Goikolea JM, González-Pinto A, Gutiérrez-Rojas L, et al. ",Risk factors for suicide in schizophrenia: systematic review and clinical recommendations, Acta Psychiatrica Scandinavica ,2014,130,    ,['citation-journal']," Popovic D, Benabarre A, Crespo JM, Goikolea JM, González-Pinto A, Gutiérrez-Rojas L, et al. Risk factors for suicide in schizophrenia: systematic review and clinical recommendations.  Acta Psychiatrica Scandinavica 2014;130(6):418-26. [PMID: 25230813]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1111/acps.12332', 'https://www.ncbi.nlm.nih.gov/pubmed/25230813', 'https://scholar.google.com/scholar_lookup?title=Risk+factors+for+suicide+in+schizophrenia:+systematic+review+and+clinical+recommendations&author=D+Popovic&author=A+Benabarre&author=JM+Crespo&author=JM+Goikolea&author=A+González-Pinto&author=L+Gutiérrez-Rojas&publication_year=2014&hl=en']",25230813,https://doi.org/10.1111/acps.12332, Popovic 2014 ,additional,CD014384-bbs2-0181,,,,,,,,25230813
CD014384-bib-0266,"Posner K, Brent D, Lucas C, Gould M, Stanley B, Brown G, et al. ",Columbia-suicide severity rating scale (C-SSRS),,,,. cssrs.columbia.edu/wp-content/uploads/C-SSRS_Pediatric-SLC_11.14.16.pdf (accessed prior to 29 October 2022).   ,['citation-other']," Posner K, Brent D, Lucas C, Gould M, Stanley B, Brown G, et al. Columbia-suicide severity rating scale (C-SSRS). cssrs.columbia.edu/wp-content/uploads/C-SSRS_Pediatric-SLC_11.14.16.pdf (accessed prior to 29 October 2022).    ",[],,, Posner 2008 ,additional,CD014384-bbs2-0182,,,,,,,,
CD014384-bib-0267,,R: a language and environment for statistical computing,,2017,,. Available at www.R-project.org.   ,['citation-other']," R: a language and environment for statistical computing. Version 3.4.2. Vienna, Austria: R Foundation for Statistical Computing, 2017. Available at www.R-project.org.    ",[],,, R 2017 [Computer program] ,additional,CD014384-bbs2-0183,,,,,,,,
CD014384-bib-0268,"Ran MS, Weng X, Chan CL, Chen EY, Tang CP, Lin FR, et al. ",Different outcomes of never-treated and treated patients with schizophrenia: 14-year follow-up study in rural China, British Journal of Psychiatry ,2015,207,    ,['citation-journal']," Ran MS, Weng X, Chan CL, Chen EY, Tang CP, Lin FR, et al. Different outcomes of never-treated and treated patients with schizophrenia: 14-year follow-up study in rural China.  British Journal of Psychiatry 2015;207:495-500. [PMID: 26382951]    Link to article     Google Scholar     ","['https://doi.org/10.1192/bjp.bp.114.157685', 'https://scholar.google.com/scholar_lookup?title=Different+outcomes+of+never-treated+and+treated+patients+with+schizophrenia:+14-year+follow-up+study+in+rural+China+&author=MS+Ran&author=X+Weng&author=CL+Chan&author=EY+Chen&author=CP+Tang&author=FR+Lin&publication_year=2015&hl=en']",,https://doi.org/10.1192/bjp.bp.114.157685, Ran 2015 ,additional,CD014384-bbs2-0184,,,26382951,,,,,26382951
CD014384-bib-0269,"Randolph C, Tierney MC, Mohr E, Chase TN. ",The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity, Journal of Clinical and Experimental Neuropsychology ,1998,20,    ,['citation-journal']," Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity.  Journal of Clinical and Experimental Neuropsychology 1998;20(3):310-9.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1076/jcen.20.3.310.823', 'https://www.ncbi.nlm.nih.gov/pubmed/9845158', 'https://scholar.google.com/scholar_lookup?title=The+Repeatable+Battery+for+the+Assessment+of+Neuropsychological+Status+(RBANS):+preliminary+clinical+validity+&author=C+Randolph&author=MC+Tierney&author=E+Mohr&author=TN+Chase&publication_year=1998&hl=en']",9845158,https://doi.org/10.1076/jcen.20.3.310.823, Randolph 1998 ,additional,CD014384-bbs2-0185,,9845158,,,,,,9845158
CD014384-bib-0270,,Review Manager Web (RevMan Web),,2022,,. Available at revman.cochrane.org.   ,['citation-other']," Review Manager Web (RevMan Web). Version 4.15.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.    ",[],,, RevMan Web 2022 [Computer program] ,additional,CD014384-bbs2-0186,,41695702,,,,,,41695702
CD014384-bib-0271,Cochrane Review Group. ,Risk of Bias 2 Starter Pack,,,,. methods.cochrane.org/file/rob-2-starter-pack-cochrane-reviews.pdf (accessed prior to 29 October 2022).   ,['citation-other'], Cochrane Review Group. Risk of Bias 2 Starter Pack. methods.cochrane.org/file/rob-2-starter-pack-cochrane-reviews.pdf (accessed prior to 29 October 2022).    ,[],,, Risk of Bias 2 Starter Pack ,additional,CD014384-bbs2-0187,,,,,,,,
CD014384-bib-0272,"Roberts MT, Shokraneh F, Sun Y, Groom M, Adams CE. ",Classification of psychotherapy interventions for people with schizophrenia: development of the Nottingham Classification of Psychotherapies, Evidence-Based Mental Health ,2021,24,    ,['citation-journal']," Roberts MT, Shokraneh F, Sun Y, Groom M, Adams CE. Classification of psychotherapy interventions for people with schizophrenia: development of the Nottingham Classification of Psychotherapies.  Evidence-Based Mental Health 2021;24:62-9. [DOI: 10.1136/ebmental-2020-300151]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/ebmental-2020-300151', 'https://www.ncbi.nlm.nih.gov/pubmed/33355248', 'https://scholar.google.com/scholar_lookup?title=Classification+of+psychotherapy+interventions+for+people+with+schizophrenia:+development+of+the+Nottingham+Classification+of+Psychotherapies+&author=MT+Roberts&author=F+Shokraneh&author=Y+Sun&author=M+Groom&author=CE+Adams&publication_year=2021&hl=en']",33355248,https://doi.org/10.1136/ebmental-2020-300151, Roberts 2021 ,additional,CD014384-bbs2-0188,,33355248,33355248,,,,,33355248
CD014384-bib-0273,"Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. ",Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder, Archives of General Psychiatry ,1999,56,    ,['citation-journal']," Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.  Archives of General Psychiatry 1999;56:241-7. [PMID: 10078501]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/archpsyc.56.3.241', 'https://www.ncbi.nlm.nih.gov/pubmed/10078501', 'https://scholar.google.com/scholar_lookup?title=Predictors+of+relapse+following+response+from+a+first+episode+of+schizophrenia+or+schizoaffective+disorder+&author=D+Robinson&author=MG+Woerner&author=JM+Alvir&author=R+Bilder&author=R+Goldman&author=S+Geisler&publication_year=1999&hl=en']",10078501,https://doi.org/10.1001/archpsyc.56.3.241, Robinson 1999 ,additional,CD014384-bbs2-0189,,,,,,,,10078501
CD014384-bib-0274,Sağlam Aykut D. ,"Comparison of paliperidone palmitate and second-generation oral antipsychotics in terms of medication adherence, side effects, and quality of life", Journal of Clinical Psychopharmacology ,2019,39,    ,['citation-journal']," Sağlam Aykut D. Comparison of paliperidone palmitate and second-generation oral antipsychotics in terms of medication adherence, side effects, and quality of life.  Journal of Clinical Psychopharmacology 2019;39(1):57-62. [PMID: 30566417]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1097/JCP.0000000000000993', 'https://www.ncbi.nlm.nih.gov/pubmed/30566417', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+paliperidone+palmitate+and+second-generation+oral+antipsychotics+in+terms+of+medication+adherence,+side+effects,+and+quality+of+life+&author=D+SağlamAykut&publication_year=2019&hl=en']",30566417,https://doi.org/10.1097/JCP.0000000000000993, Sağlam Aykut 2019 ,additional,CD014384-bbs2-0190,,30566417,30566417,,,,,30566417
CD014384-bib-0275,"Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, et al. ","Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis", JAMA Psychiatry ,2016,73,    ,['citation-journal']," Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis.  JAMA Psychiatry 2016;73(3):199-210. [PMID: 26842482]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/jamapsychiatry.2015.2955', 'https://www.ncbi.nlm.nih.gov/pubmed/26842482', 'https://scholar.google.com/scholar_lookup?title=Efficacy,+acceptability,+and+tolerability+of+antipsychotics+in+treatment-resistant+schizophrenia:+a+network+meta-analysis+&author=MT+Samara&author=M+Dold&author=M+Gianatsi&author=A+Nikolakopoulou&author=B+Helfer&author=G+Salanti&publication_year=2016&hl=en']",26842482,https://doi.org/10.1001/jamapsychiatry.2015.2955, Samara 2016 ,additional,CD014384-bbs2-0191,,,,,,,,26842482
CD014384-bib-0276,"Samara MT, Nikolakopoulou A, Salanti G, Leucht S. ",How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An analysis based on individual patient data from randomized controlled trials, Schizophrenia Bulletin ,2019,45,    ,['citation-journal']," Samara MT, Nikolakopoulou A, Salanti G, Leucht S. How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An analysis based on individual patient data from randomized controlled trials.  Schizophrenia Bulletin 2019;45(3):639-46. [PMID: 29982701]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1093/schbul/sby095', 'https://www.ncbi.nlm.nih.gov/pubmed/29982701', 'https://scholar.google.com/scholar_lookup?title=How+many+patients+with+schizophrenia+do+not+respond+to+antipsychotic+drugs+in+the+short+term?+An+analysis+based+on+individual+patient+data+from+randomized+controlled+trials+&author=MT+Samara&author=A+Nikolakopoulou&author=G+Salanti&author=S+Leucht&publication_year=2019&hl=en']",29982701,https://doi.org/10.1093/schbul/sby095, Samara 2019 ,additional,CD014384-bbs2-0192,,26842482,,,,,,29982701
CD014384-bib-0277,"Schennach-Wolff R, Jäger M, Seemüller F, Obermeier M, Messer T, Laux G, et al. ",Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders, Schizophrenia Research ,2009,113,    ,['citation-journal']," Schennach-Wolff R, Jäger M, Seemüller F, Obermeier M, Messer T, Laux G, et al. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders.  Schizophrenia Research 2009;113(2-3):210-7.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.schres.2009.05.032', 'https://www.ncbi.nlm.nih.gov/pubmed/19560901', 'https://scholar.google.com/scholar_lookup?title=Defining+and+predicting+functional+outcome+in+schizophrenia+and+schizophrenia+spectrum+disorders+&author=R+Schennach-Wolff&author=M+Jäger&author=F+Seemüller&author=M+Obermeier&author=T+Messer&author=G+Laux&publication_year=2009&hl=en']",19560901,https://doi.org/10.1016/j.schres.2009.05.032, Schennach‐Wolff 2009 ,additional,CD014384-bbs2-0193,,,,,,,,19560901
CD014384-bib-0278,"Schneider-Thoma J, Efthimiou O, Bighelli I, Dörries C, Huhn M, Krause M, et al. ",Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis, Lancet Psychiatry ,2019,6,    ,['citation-journal']," Schneider-Thoma J, Efthimiou O, Bighelli I, Dörries C, Huhn M, Krause M, et al. Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis.  Lancet Psychiatry 2019;6:753-65. [PMID: 31320283]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S2215-0366(19)30223-8', 'https://www.ncbi.nlm.nih.gov/pubmed/31320283', 'https://scholar.google.com/scholar_lookup?title=Second-generation+antipsychotic+drugs+and+short-term+somatic+serious+adverse+events:+a+systematic+review+and+meta-analysis+&author=J+Schneider-Thoma&author=O+Efthimiou&author=I+Bighelli&author=C+Dörries&author=M+Huhn&author=M+Krause&publication_year=2019&hl=en']",31320283,https://doi.org/10.1016/S2215-0366(19)30223-8, Schneider‐Thoma 2019 ,additional,CD014384-bbs2-0194,,,31320283,,,,,31320283
CD014384-bib-0279,"Schünemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ, Glasziou P, et al. ","Chapter 12: Interpreting results and drawing conclusions. In Higgins JP, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011",,,,. Available from training.cochrane.org/handbook/archive/v5.1/.   ,['citation-other']," Schünemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JP, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.    ",[],,, Schünemann 2011 ,additional,CD014384-bbs2-0195,,,,,,,,
CD014384-bib-0280,Shacham S. ,A shortened version of the Profile of Mood States, Journal of Personality Assessment ,1983,47,    ,['citation-journal'], Shacham S. A shortened version of the Profile of Mood States.  Journal of Personality Assessment 1983;47:305-6.    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.1207/s15327752jpa4703_14', 'https://www.ncbi.nlm.nih.gov/pubmed/6886962', 'https://scholar.google.com/scholar_lookup?title=A+shortened+version+of+the+Profile+of+Mood+States&author=S+Shacham&publication_year=1983&hl=en']",6886962,https://doi.org/10.1207/s15327752jpa4703_14, Shacham 1983 ,additional,CD014384-bbs2-0196,,6886962,,,,,,6886962
CD014384-bib-0281,"Shepherd M, Watt D, Falloon I, Smeeton N. ",The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics, Psychological Medicine Supplement ,1989,15,    ,['citation-journal']," Shepherd M, Watt D, Falloon I, Smeeton N. The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics.  Psychological Medicine Supplement 1989;15:1-46. [PMID: 2798648]    Link to article     Google Scholar     ","['https://doi.org/10.1017/S026418010000059X', 'https://scholar.google.com/scholar_lookup?title=The+natural+history+of+schizophrenia:+a+five-year+follow-up+study+of+outcome+and+prediction+in+a+representative+sample+of+schizophrenics+&author=M+Shepherd&author=D+Watt&author=I+Falloon&author=N+Smeeton&publication_year=1989&hl=en']",,https://doi.org/10.1017/S026418010000059X, Shepherd 1989 ,additional,CD014384-bbs2-0197,,,,,,,,
CD014384-bib-0282,"Shokraneh F, Adams CE. ",Study-based registers of randomized controlled trials: starting a systematic review with data extraction or meta-analysis, BioImpacts ,2017,7,    ,['citation-journal']," Shokraneh F, Adams CE. Study-based registers of randomized controlled trials: starting a systematic review with data extraction or meta-analysis.  BioImpacts 2017;7(4):209-17. [DOI: 10.15171/bi.2017.25]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.15171/bi.2017.25', 'https://www.ncbi.nlm.nih.gov/pubmed/29435428', 'https://scholar.google.com/scholar_lookup?title=Study-based+registers+of+randomized+controlled+trials:+starting+a+systematic+review+with+data+extraction+or+meta-analysis+&author=F+Shokraneh&author=CE+Adams&publication_year=2017&hl=en']",29435428,https://doi.org/10.15171/bi.2017.25, Shokraneh 2017 ,additional,CD014384-bbs2-0198,,30863537,,,,,,29435428
CD014384-bib-0283,"Shokraneh F, Adams CE. ",Study-based registers reduce waste in systematic reviewing: discussion and case report, Systematic Reviews ,2019,8,    ,['citation-journal']," Shokraneh F, Adams CE. Study-based registers reduce waste in systematic reviewing: discussion and case report.  Systematic Reviews 2019;8:129. [DOI: 10.1186/s13643-019-1035-3]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1186/s13643-019-1035-3', 'https://www.ncbi.nlm.nih.gov/pubmed/31146776', 'https://scholar.google.com/scholar_lookup?title=Study-based+registers+reduce+waste+in+systematic+reviewing:+discussion+and+case+report&author=F+Shokraneh&author=CE+Adams&publication_year=2019&hl=en']",31146776,https://doi.org/10.1186/s13643-019-1035-3, Shokraneh 2019 ,additional,CD014384-bbs2-0199,,31146776,31146776,,,,,31146776
CD014384-bib-0284,"Shokraneh F, Adams CE. ",Cochrane Schizophrenia Group’s study-based register of randomized controlled trials: development and content analysis, Schizophrenia Bulletin Open ,2020,1,    ,['citation-journal']," Shokraneh F, Adams CE. Cochrane Schizophrenia Group’s study-based register of randomized controlled trials: development and content analysis.  Schizophrenia Bulletin Open 2020;1:sgaa061. [DOI: 10.1093/schizbullopen/sgaa061]    Link to article     Google Scholar     ","['https://doi.org/10.1093/schizbullopen/sgaa061', 'https://scholar.google.com/scholar_lookup?title=Cochrane+Schizophrenia+Group’s+study-based+register+of+randomized+controlled+trials:+development+and+content+analysis+&author=F+Shokraneh&author=CE+Adams&publication_year=2020&hl=en']",,https://doi.org/10.1093/schizbullopen/sgaa061, Shokraneh 2020 ,additional,CD014384-bbs2-0200,,29435428,,,,,,29435428
CD014384-bib-0285,"Shokraneh F, Adams CE. ",Classification of all pharmacological interventions tested in trials relevant to people with schizophrenia: a study-based analysis,,,,]   ,['citation-other']," Shokraneh F, Adams CE. Classification of all pharmacological interventions tested in trials relevant to people with schizophrenia: a study-based analysis. Health Information and Libraries Journal 2021 Feb 18 [Epub ahead of print]:1-16. [DOI: 10.1111/hir.12366]    ",[],,, Shokraneh 2021 ,additional,CD014384-bbs2-0201,,33615663,33615663,,,,,33615663
CD014384-bib-0286,"Simon V, van Winkel R, De Hert M. ",Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review, Journal of Clinical Psychiatry ,2009,70,    ,['citation-journal']," Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review.  Journal of Clinical Psychiatry 2009;70(7):1041-50. [PMID: 19653979]    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/19653979', 'https://scholar.google.com/scholar_lookup?title=Are+weight+gain+and+metabolic+side+effects+of+atypical+antipsychotics+dose+dependent?+A+literature+review+&author=V+Simon&author=R+Winkel&author=M+DeHert&publication_year=2009&hl=en']",19653979,, Simon 2009 ,additional,CD014384-bbs2-0202,,19653979,,,,,,19653979
CD014384-bib-0287,"Simpson GM, Angus JWS. ",A rating scale for extrapyramidal side effects, Acta Psychiatrica Scandinavica ,1970,45,    ,['citation-journal']," Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects.  Acta Psychiatrica Scandinavica 1970;45(S212):11-9.    Link to article     Google Scholar     ","['https://doi.org/10.1111/j.1600-0447.1970.tb02066.x', 'https://scholar.google.com/scholar_lookup?title=A+rating+scale+for+extrapyramidal+side+effects&author=GM+Simpson&author=JWS+Angus&publication_year=1970&hl=en']",,https://doi.org/10.1111/j.1600-0447.1970.tb02066.x, Simpson 1970 ,additional,CD014384-bbs2-0203,,,,,,,,
CD014384-bib-0288,"Simpson GM, Lee JH, Zoubok B, Gardos G. ",A rating scale for tardive dyskinesia, Psychopharmacology ,1979,64,    ,['citation-journal']," Simpson GM, Lee JH, Zoubok B, Gardos G. A rating scale for tardive dyskinesia.  Psychopharmacology 1979;64(2):171-9.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1007/BF00496058', 'https://www.ncbi.nlm.nih.gov/pubmed/115037', 'https://scholar.google.com/scholar_lookup?title=A+rating+scale+for+tardive+dyskinesia&author=GM+Simpson&author=JH+Lee&author=B+Zoubok&author=G+Gardos&publication_year=1979&hl=en']",115037,https://doi.org/10.1007/BF00496058, Simpson 1979 ,additional,CD014384-bbs2-0204,,115037,,,,,,115037
CD014384-bib-0289,"Spertus J, Horvitz-Lennon M, Abing H, Normand SL. ",Risk of weight gain for specific antipsychotic drugs: a meta-analysis, NPJ Schizophrenia ,2018,4,    ,['citation-journal']," Spertus J, Horvitz-Lennon M, Abing H, Normand SL. Risk of weight gain for specific antipsychotic drugs: a meta-analysis.  NPJ Schizophrenia 2018;4(1):12. [PMID: 29950586]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1038/s41537-018-0053-9', 'https://www.ncbi.nlm.nih.gov/pubmed/29950586', 'https://scholar.google.com/scholar_lookup?title=Risk+of+weight+gain+for+specific+antipsychotic+drugs:+a+meta-analysis&author=J+Spertus&author=M+Horvitz-Lennon&author=H+Abing&author=SL+Normand&publication_year=2018&hl=en']",29950586,https://doi.org/10.1038/s41537-018-0053-9, Spertus 2018 ,additional,CD014384-bbs2-0205,,29950586,,,,,,29950586
CD014384-bib-0290,"Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. ",RoB 2: a revised tool for assessing risk of bias in randomised trials, BMJ ,2019,366,    ,['citation-journal']," Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials.  BMJ 2019;366:l4898. [DOI: 10.1136/bmj.l4898]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.l4898', 'https://www.ncbi.nlm.nih.gov/pubmed/31462531', 'https://scholar.google.com/scholar_lookup?title=RoB+2:+a+revised+tool+for+assessing+risk+of+bias+in+randomised+trials&author=JA+Sterne&author=J+Savović&author=MJ+Page&author=RG+Elbers&author=NS+Blencowe&author=I+Boutron&publication_year=2019&hl=en']",31462531,https://doi.org/10.1136/bmj.l4898, Sterne 2019 ,additional,CD014384-bbs2-0206,,,,,,,,31462531
CD014384-bib-0291,"Strauss JS, Carpenter WT Jr. ",The prediction of outcome in schizophrenia. II. Relationships between predictor and outcome variables: a report from the WHO international pilot study of schizophrenia, Archives of General Psychiatry ,1974,31,    ,['citation-journal']," Strauss JS, Carpenter WT Jr. The prediction of outcome in schizophrenia. II. Relationships between predictor and outcome variables: a report from the WHO international pilot study of schizophrenia.  Archives of General Psychiatry 1974;31(1):37-42. [DOI: 10.1001/archpsyc.1974.01760130021003]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/archpsyc.1974.01760130021003', 'https://www.ncbi.nlm.nih.gov/pubmed/4835985', 'https://scholar.google.com/scholar_lookup?title=The+prediction+of+outcome+in+schizophrenia.+II.+Relationships+between+predictor+and+outcome+variables:+a+report+from+the+WHO+international+pilot+study+of+schizophrenia+&author=JS+Strauss&publication_year=1974&hl=en']",4835985,https://doi.org/10.1001/archpsyc.1974.01760130021003, Strauss 1974 ,additional,CD014384-bbs2-0207,,4835985,4835985,,,,,4835985
CD014384-bib-0292,"Strauss JS, Carpenter WT. ",Prediction of outcome in schizophrenia: III. Five-yearn outcome and its predictors, Archives of General Psychiatry ,1977,34,    ,['citation-journal']," Strauss JS, Carpenter WT. Prediction of outcome in schizophrenia: III. Five-yearn outcome and its predictors.  Archives of General Psychiatry 1977;34(2):159-63.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/archpsyc.1977.01770140049005', 'https://www.ncbi.nlm.nih.gov/pubmed/843175', 'https://scholar.google.com/scholar_lookup?title=Prediction+of+outcome+in+schizophrenia:+III.+Five-yearn+outcome+and+its+predictors&author=JS+Strauss&author=WT+Carpenter&publication_year=1977&hl=en']",843175,https://doi.org/10.1001/archpsyc.1977.01770140049005, Strauss 1977 ,additional,CD014384-bbs2-0208,,843175,,,,,,843175
CD014384-bib-0293,"Suzuki T, Uchida H, Tanaka KF, Tomita M, Tsunoda K, Nomura K, et al. ",Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia, International Clinical Psychopharmacology ,2003,18,    ,['citation-journal']," Suzuki T, Uchida H, Tanaka KF, Tomita M, Tsunoda K, Nomura K, et al. Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia.  International Clinical Psychopharmacology 2003;18(6):323-9. [PMID: 14571152]    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/14571152', 'https://scholar.google.com/scholar_lookup?title=Reducing+the+dose+of+antipsychotic+medications+for+those+who+had+been+treated+with+high-dose+antipsychotic+polypharmacy:+an+open+study+of+dose+reduction+for+chronic+schizophrenia+&author=T+Suzuki&author=H+Uchida&author=KF+Tanaka&author=M+Tomita&author=K+Tsunoda&author=K+Nomura&publication_year=2003&hl=en']",14571152,, Suzuki 2003 ,additional,CD014384-bbs2-0209,,,14571152,,,,,14571152
CD014384-bib-0294,"Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M. ",Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms, Schizophrenia Research ,2012,134,    ,['citation-journal']," Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms.  Schizophrenia Research 2012;134:219-25. [PMID: 31784340]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.schres.2011.11.021', 'https://www.ncbi.nlm.nih.gov/pubmed/22154594', 'https://scholar.google.com/scholar_lookup?title=Antipsychotic+treatment+for+schizophrenia+in+the+maintenance+phase:+a+systematic+review+of+the+guidelines+and+algorithms+&author=H+Takeuchi&author=T+Suzuki&author=H+Uchida&author=K+Watanabe&author=M+Mimura&publication_year=2012&hl=en']",22154594,https://doi.org/10.1016/j.schres.2011.11.021, Takeuchi 2012 ,additional,CD014384-bbs2-0210,,22154594,,,,,,22154594
CD014384-bib-0295,"Takeuchi H, Remington G. ",Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction, Evidence-Based Mental Health ,2015,18,    ,['citation-journal']," Takeuchi H, Remington G. Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction.  Evidence-Based Mental Health 2015;18(4):117. [PMID: 26459470]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/eb-2015-102209', 'https://www.ncbi.nlm.nih.gov/pubmed/26459470', 'https://scholar.google.com/scholar_lookup?title=Improving+symptoms+and+side+effects+in+older+patients+with+schizophrenia+with+decreasing+dopamine+D2/3+receptor+occupancy+following+risperidone+and+olanzapine+dose+reduction+&author=H+Takeuchi&author=G+Remington&publication_year=2015&hl=en']",26459470,https://doi.org/10.1136/eb-2015-102209, Takeuchi 2015 ,additional,CD014384-bbs2-0211,,26459470,26459470,,,,,26459470
CD014384-bib-0296,"Tandon R, DeVellis RF, Han J, Li H, Frangou S, Dursun S, et al. ","Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder", Psychiatry Research ,2005,136,    ,['citation-journal']," Tandon R, DeVellis RF, Han J, Li H, Frangou S, Dursun S, et al. Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder.  Psychiatry Research 2005;136(2-3):211-21.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.psychres.2005.05.006', 'https://www.ncbi.nlm.nih.gov/pubmed/16115690', ""https://scholar.google.com/scholar_lookup?title=Validation+of+the+Investigator's+Assessment+Questionnaire,+a+new+clinical+tool+for+relative+assessment+of+response+to+antipsychotics+in+patients+with+schizophrenia+and+schizoaffective+disorder+&author=R+Tandon&author=RF+DeVellis&author=J+Han&author=H+Li&author=S+Frangou&author=S+Dursun&publication_year=2005&hl=en""]",16115690,https://doi.org/10.1016/j.psychres.2005.05.006, Tandon 2005 ,additional,CD014384-bbs2-0212,,,16115690,,,,,16115690
CD014384-bib-0297,"Tani H, Takasu S, Uchida H, Suzuki T, Mimura M, Takeuchi H. ",Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials, Neuropsychopharmacology ,2020,45,    ,['citation-journal']," Tani H, Takasu S, Uchida H, Suzuki T, Mimura M, Takeuchi H. Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials.  Neuropsychopharmacology 2020;45(5):887-901.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1038/s41386-019-0573-7', 'https://www.ncbi.nlm.nih.gov/pubmed/31770770', 'https://scholar.google.com/scholar_lookup?title=Factors+associated+with+successful+antipsychotic+dose+reduction+in+schizophrenia:+a+systematic+review+of+prospective+clinical+trials+and+meta-analysis+of+randomized+controlled+trials+&author=H+Tani&author=S+Takasu&author=H+Uchida&author=T+Suzuki&author=M+Mimura&author=H+Takeuchi&publication_year=2020&hl=en']",31770770,https://doi.org/10.1038/s41386-019-0573-7, Tani 2020 ,additional,CD014384-bbs2-0213,,31974442,,,,,,31770770
CD014384-bib-0298,"Tanskanen A, Tiihonen J, Taipale H. ",Mortality in schizophrenia: 30-year nationwide follow-up study, Acta Psychiatrica Scandinavica ,2018,138,    ,['citation-journal']," Tanskanen A, Tiihonen J, Taipale H. Mortality in schizophrenia: 30-year nationwide follow-up study.  Acta Psychiatrica Scandinavica 2018;138:492-9. [PMID: 29900527]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1111/acps.12913', 'https://www.ncbi.nlm.nih.gov/pubmed/29900527', 'https://scholar.google.com/scholar_lookup?title=Mortality+in+schizophrenia:+30-year+nationwide+follow-up+study&author=A+Tanskanen&author=J+Tiihonen&author=H+Taipale&publication_year=2018&hl=en']",29900527,https://doi.org/10.1111/acps.12913, Tanskanen 2018 ,additional,CD014384-bbs2-0214,,29900527,29900527,,,,,29900527
CD014384-bib-0299,The EuroQol Group . ,EuroQol - a new facility for the measurement of health-related quality of life, Health Policy ,1990,16,    ,['citation-journal'], The EuroQol Group . EuroQol - a new facility for the measurement of health-related quality of life.  Health Policy 1990;16(3):199-208.    Link to article     PubMed     ,"['https://doi.org/10.1016/0168-8510(90)90421-9', 'https://www.ncbi.nlm.nih.gov/pubmed/10109801']",10109801,https://doi.org/10.1016/0168-8510(90)90421-9, The EuroQol Group 1990 ,additional,CD014384-bbs2-0215,,41661214,,,,,,10109801
CD014384-bib-0300,"Thompson K, Kulkarni J, Sergejew AA. ",Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses, Schizophrenia Research ,2000,42,    ,['citation-journal']," Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses.  Schizophrenia Research 2000;42(3):241-7.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0920-9964(99)00130-9', 'https://www.ncbi.nlm.nih.gov/pubmed/10785582', 'https://scholar.google.com/scholar_lookup?title=Reliability+and+validity+of+a+new+Medication+Adherence+Rating+Scale+(MARS)+for+the+psychoses+&author=K+Thompson&author=J+Kulkarni&author=AA+Sergejew&publication_year=2000&hl=en']",10785582,https://doi.org/10.1016/S0920-9964(99)00130-9, Thompson 2000 ,additional,CD014384-bbs2-0216,,10785582,,,,,,10785582
CD014384-bib-0301,"Uchida H, Suzuki T, Takeuchi H, Arenovich T, Mamo DC. ",Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis, Schizophrenia Bulletin ,2011,37,    ,['citation-journal']," Uchida H, Suzuki T, Takeuchi H, Arenovich T, Mamo DC. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis.  Schizophrenia Bulletin 2011;37(4):788-99. [DOI: 10.1093/schbul/sbp149]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1093/schbul/sbp149', 'https://www.ncbi.nlm.nih.gov/pubmed/19946012', 'https://scholar.google.com/scholar_lookup?title=Low+dose+vs+standard+dose+of+antipsychotics+for+relapse+prevention+in+schizophrenia:+meta-analysis+&author=H+Uchida&author=T+Suzuki&author=H+Takeuchi&author=T+Arenovich&author=DC+Mamo&publication_year=2011&hl=en']",19946012,https://doi.org/10.1093/schbul/sbp149, Uchida 2011 ,additional,CD014384-bbs2-0217,,19946012,19946012,,,,,19946012
CD014384-bib-0302,"Ukoumunne OC, Gulliford MC, Chinn S, Sterne JA, Burney PG. ",Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review, Health Technology Assessment ,1999,3,    ,['citation-journal']," Ukoumunne OC, Gulliford MC, Chinn S, Sterne JA, Burney PG. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review.  Health Technology Assessment 1999;3(5):iii-92. [PMID: 10982317]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.3310/hta3050', 'https://www.ncbi.nlm.nih.gov/pubmed/10982317', 'https://scholar.google.com/scholar_lookup?title=Methods+for+evaluating+area-wide+and+organisation-based+intervention+in+health+and+health+care:+a+systematic+review+&author=OC+Ukoumunne&author=MC+Gulliford&author=S+Chinn&author=JA+Sterne&author=PG+Burney&publication_year=1999&hl=en']",10982317,https://doi.org/10.3310/hta3050, Ukoumunne 1999 ,additional,CD014384-bbs2-0218,,10982317,,,,,,10982317
CD014384-bib-0303,"Van Haren NE, Cahn W, Hulshoff Pol HE, Kahn RS. ",Confounders of excessive brain volume loss in schizophrenia, Neuroscience and Biobehavioral Reviews ,2013,37,    ,['citation-journal']," Van Haren NE, Cahn W, Hulshoff Pol HE, Kahn RS. Confounders of excessive brain volume loss in schizophrenia.  Neuroscience and Biobehavioral Reviews 2013;37(10 Pt 1):2418-23. [PMID: 23000300]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.neubiorev.2012.09.006', 'https://www.ncbi.nlm.nih.gov/pubmed/23000300', 'https://scholar.google.com/scholar_lookup?title=Confounders+of+excessive+brain+volume+loss+in+schizophrenia&author=NE+VanHaren&author=W+Cahn&author=HE+HulshoffPol&author=RS+Kahn&publication_year=2013&hl=en']",23000300,https://doi.org/10.1016/j.neubiorev.2012.09.006, Van Haren 2013 ,additional,CD014384-bbs2-0219,,23000300,,,,,,23000300
CD014384-bib-0304,"Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. ",Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010, Lancet ,2012,380,    ,['citation-journal']," Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010.  Lancet 2012;380:2163-96. [PMID: 23245607]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0140-6736(12)61729-2', 'https://www.ncbi.nlm.nih.gov/pubmed/23245607', 'https://scholar.google.com/scholar_lookup?title=Years+lived+with+disability+(YLDs)+for+1160+sequelae+of+289+diseases+and+injuries+1990–2010:+a+systematic+analysis+for+the+Global+Burden+of+Disease+Study+2010+&author=T+Vos&author=AD+Flaxman&author=M+Naghavi&author=R+Lozano&author=C+Michaud&author=M+Ezzati&publication_year=2012&hl=en']",23245607,https://doi.org/10.1016/S0140-6736(12)61729-2, Vos 2012 ,additional,CD014384-bbs2-0220,,,23245607,,,,,23245607
CD014384-bib-0305,"Ware JE Jr, Sherbourne CD. ",The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection, Medical Care ,1992,30,    ,['citation-journal']," Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection.  Medical Care 1992;30:473-83.    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/1593914', 'https://scholar.google.com/scholar_lookup?title=The+MOS+36-item+short-form+health+survey+(SF-36):+I.+Conceptual+framework+and+item+selection+&author=CD+Sherbourne&publication_year=1992&hl=en']",1593914,, Ware 1992 ,additional,CD014384-bbs2-0221,,1593914,,,,,,1593914
CD014384-bib-0306,"Wiersma D, DeJong A, Ormel J. ","The Groningen Social Disabilities Schedule: development, relationship with ICIDH, and psychometric properties", International Journal of Rehabilitation Research ,1988,11,    ,['citation-journal']," Wiersma D, DeJong A, Ormel J. The Groningen Social Disabilities Schedule: development, relationship with ICIDH, and psychometric properties.  International Journal of Rehabilitation Research 1988;11(3):213-24.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1097/00004356-198809000-00001', 'https://www.ncbi.nlm.nih.gov/pubmed/2978514', 'https://scholar.google.com/scholar_lookup?title=The+Groningen+Social+Disabilities+Schedule:+development,+relationship+with+ICIDH,+and+psychometric+properties+&author=D+Wiersma&author=A+DeJong&author=J+Ormel&publication_year=1988&hl=en']",2978514,https://doi.org/10.1097/00004356-198809000-00001, Wiersma 1988 ,additional,CD014384-bbs2-0222,,2978514,,,,,,2978514
CD014384-bib-0307,Woodhead M. ,"80% of China's clinical trial data are fraudulent, investigation finds", BMJ ,2016,355,    ,['citation-journal']," Woodhead M. 80% of China's clinical trial data are fraudulent, investigation finds.  BMJ 2016;355:i5396. [PMID: 27707716]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.i5396', 'https://www.ncbi.nlm.nih.gov/pubmed/27707716', ""https://scholar.google.com/scholar_lookup?title=80%+of+China's+clinical+trial+data+are+fraudulent,+investigation+finds&author=M+Woodhead&publication_year=2016&hl=en""]",27707716,https://doi.org/10.1136/bmj.i5396, Woodhead 2016 ,additional,CD014384-bbs2-0223,,27707716,27707716,,,,,27707716
CD014384-bib-0308,"Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. ",Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial, JAMA Psychiatry ,2013,70,    ,['citation-journal']," Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial.  JAMA Psychiatry 2013;70:913-20. [PMID: 23824214]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/jamapsychiatry.2013.19', 'https://www.ncbi.nlm.nih.gov/pubmed/23824214', 'https://scholar.google.com/scholar_lookup?title=Recovery+in+remitted+first-episode+psychosis+at+7+years+of+follow-up+of+an+early+dose+reduction/discontinuation+or+maintenance+treatment+strategy:+long-term+follow-up+of+a+2-year+randomized+clinical+trial+&author=L+Wunderink&author=RM+Nieboer&author=D+Wiersma&author=S+Sytema&author=FJ+Nienhuis&publication_year=2013&hl=en']",23824214,https://doi.org/10.1001/jamapsychiatry.2013.19, Wunderink 2013 ,additional,CD014384-bbs2-0224,,23824214,,,,,,23824214
CD014384-bib-0309,"Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. ",Loss to outcomes stakeholder survey: the LOSS study, Psychiatric Bulletin ,2009,33,    ,['citation-journal']," Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study.  Psychiatric Bulletin 2009;33(7):254-7.    Link to article     Google Scholar     ","['https://doi.org/10.1192/pb.bp.108.021949', 'https://scholar.google.com/scholar_lookup?title=Loss+to+outcomes+stakeholder+survey:+the+LOSS+study&author=J+Xia&author=CE+Adams&author=N+Bhagat&author=V+Bhagat&author=P+Bhoopathi&author=H+El-Sayeh&publication_year=2009&hl=en']",,https://doi.org/10.1192/pb.bp.108.021949, Xia 2009 ,additional,CD014384-bbs2-0225,,,,,,,,
CD014384-bib-0310,"Bighelli I, Samara MT, Rodolico A, Hansen WP, Leucht S. ",Antipsychotic dose reduction compared to dose continuation for people with schizophrenia, Cochrane Database of Systematic Reviews ,2021,,    ,['citation-journal']," Bighelli I, Samara MT, Rodolico A, Hansen WP, Leucht S. Antipsychotic dose reduction compared to dose continuation for people with schizophrenia.  Cochrane Database of Systematic Reviews 2021, Issue 4. Art. No: CD014384. [DOI: 10.1002/14651858.CD014384]    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Antipsychotic+dose+reduction+compared+to+dose+continuation+for+people+with+schizophrenia&author=I+Bighelli&author=MT+Samara&author=A+Rodolico&author=WP+Hansen&author=S+Leucht&publication_year=2021&hl=en'],,, Bighelli 2021 ,other_versions,CD014384-bbs2-0226,,36420692,,,,,,36420692
